

Annual Report

08




09037188

Received SEC
MAR 13 2009
Washington, DC 20549

PROCESSED
MAR 27 2009
THOMSON REUTERS



 **IntriCon**
The Body-Worn Device Company

IntriCon is the Body-Worn Device Company

About IntriCon

We design, develop and manufacture miniature and micro-miniature body-worn medical and electronics products based on our proprietary technology.

We meet the rising demand for smaller, portable and more advanced devices.

Our mission is clear: to enhance the mobility and effectiveness of these body-worn products that connect people to people and to the devices around them.

Our expertise is focused on three main markets: medical, hearing health and professional audio communications. Within these chosen markets, we combine ultra-miniature mechanical and electronics capabilities with proprietary technology – including ultra-low-power (ULP) wireless and digital signal processing (DSP) capabilities – to enhance the performance of body-worn devices, ultimately improving peoples' quality of life. This builds lasting customer relationships with leaders in medical, hearing health and professional audio communications, and allows us to leverage our technology development over all three markets.

IntriCon is headquartered in Arden Hills, Minn., a suburb of Minneapolis/St. Paul. We employ more than 600 people at facilities in the United States, Europe and Asia. IntriCon common stock is traded on the NASDAQ Stock Market under the symbol "IIN."

Our Markets

Medical

From life-critical diagnostic monitoring devices to drug-delivery solutions, we design, develop and manufacture injection-molded plastics, microelectronics, micro-mechanical assemblies and complete bio-telemetry devices based on our proprietary ULP nanoDSP™ and ULP nanoLink™ technology for emerging companies, as well as leading medical device manufacturers. Our products shift the point of care by connecting patients and caregivers, providing vital information and feedback while improving productivity and lowering the cost of quality health care.

Hearing Health

IntriCon provides customers with advanced hearing products ranging from ultra-miniature volume controls and trimmers to custom amplifiers and complete hearing instruments based on proprietary ULP nanoDSP and ULP nanoLink wireless technology. IntriCon's nanoDSP amplifier line includes our newly released Ethos™ amplifier with an advanced adaptive feedback canceller (AFC) and noise reduction (NR) algorithms. Our BodyNet™ line features a series of wirelessly enabled products, including wireless programming adapters, remote microphones and wireless earpieces, which improve the performance of hearing instruments in difficult listening situations.

Professional Audio Communications

For customers focusing on security and emergency response needs, and hearing protection, IntriCon offers body-worn devices that are extremely portable and perform well in noisy or hazardous environments – making them well-suited for applications in the aviation, fire, law enforcement, safety and military markets. We also provide products for technical surveillance by law enforcement and security agencies. Additionally, we support performers and production staff in the music and stage performance markets with proven ear- and head-worn devices. Increasingly, these products will include our proprietary ULP nanoDSP and ULP nanoLink wireless technology to improve performance in difficult listening environments and wireless operation.

Electronics

IntriCon is a leader in the field of miniaturized electronics. Used in a broad range of industries, we believe our products enable manufacturers to produce smaller, more reliable devices that effectively meet the needs of their customers.

Financial Highlights


(dollars in thousands, except per share data)

Fiscal Year Ended December 31,

	2008	2007	2006
Net sales	\$ 65,555	\$ 68,983	\$ 51,726
Gross profit	16,046	17,245	12,422
% of net sales	24.5%	25.0%	24.0%
Research and development expense	3,248	3,089	2,123
Income from continuing operations	1,038	1,867	1,241
Net earnings	1,038	1,867	1,163
% of net sales	1.6%	2.7%	2.2%
Diluted net earnings per share	0.19	0.34	0.22


At December 31,

	2008	2007	2006
Cash	\$ 249	\$ 381	\$ 160
Working capital	10,602	9,365	8,445
Total current liabilities	9,421	10,536	10,203
Shareholders' equity	20,312	18,597	15,607




Net Sales

(dollars in thousands)




Investment in Research And Development

(dollars in thousands)



Earnings Per Share From Continuing Operations



Shareholders' Equity

(dollars in thousands)

We're excited for the future of IntriCon

To Our Shareholders

Though challenging, the past year is one we're proud of at IntriCon. Facing an uncertain economy, we steadied our sights on the company's future and over the course of 12 months, further positioned ourselves as the body-worn device company.

Our medical and professional audio communications businesses posted gains for the year, and we continued to enhance our foundation for long-term success in core markets with strong fundamentals. Importantly, IntriCon remained profitable, generating strong cash flow from operations and improving liquidity. This gives us the financial flexibility to weather the conditions in 2009 and emerge even stronger when an economic rebound occurs.

We're excited for the future of IntriCon. We continue to invest heavily in research and development (R&D) to design new proprietary technologies to be used in our core markets. Our R&D focus is on improving the mobility and effectiveness of body-worn devices by incorporating ultra-low-power (ULP) wireless and digital signal processing (DSP) capabilities. This better connects people to devices and, we feel, will allow us to ultimately gain market share and further grow our business.

IntriCon made significant and tangible strides in 2008 that enhanced our body-worn device capabilities. Our ULP BodyNet product family, that offers customers wireless connectivity for the entire body based on our ULP nanoLink technology, gained momentum in the marketplace. As did IntriCon's nanoDSP technology, which provides ULP DSP-based products that can be customized for a range of applications.

We also introduced our new wireless nanoLink product family. Part of IntriCon's BodyNet wireless portfolio, nanoLink is a family of products based on proprietary new radio technology and circuitry we developed. nanoLink's advanced capabilities and micro-miniature footprint enable wireless transmission and intra-device communication that's ideally suited for both the hearing health and medical markets. We're pleased to announce that our nanoLink radio technology has received regulatory approval in 13 European countries, paving the way for commercialization of a product family we see as a key to our company's future.

Additionally, we're particularly excited about the bio-telemetry projects with our strategic partner, Advanced Medical Electronics (AME). We continue to seek out additional opportunities to expand our presence in bio-telemetry, which encompasses wirelessly transmitting critical diagnostic and therapeutic information. We also intend to leverage this technology, integrating both BodyNet and nanoDSP, for our professional audio communications business.

At IntriCon, we strive for efficiency and solutions that save customers time and money, while improving quality. This was exemplified by our integration of Tibbetts Industries, which we acquired in 2007. During 2008 we successfully transferred much of Tibbetts' manufacturing to our low-cost facility in Singapore while restructuring our Maine facility to better serve the needs of our U.S. Government customers.

We also implemented Six Sigma in key medical product lines and plan to roll the process out to our other businesses in 2009.



Members of IntriCon's management team in New York City to ring NASDAQ's closing bell on July 17, 2008.

Left to Right:

Greg Gruenhagen, VP Quality & Regulatory Affairs; Dennis Gonsior, VP Global Operations; Chris Conger, VP Research & Development; Mark Gorder, President & CEO; Michael Geraci, VP Sales & Marketing; and Scott Longval, CFO, Secretary & Treasurer.

2008 Results

For the year, IntriCon reported net sales of \$65.6 million and net income of \$1.0 million, or \$0.19 per diluted share. This compares to 2007 net sales of \$69.0 million and net income of \$1.9 million, or \$0.34 per diluted share.

Core business net income for 2008 was \$1.3 million, or \$0.24 per diluted share, partially offset by a net loss in the non-core business of \$277,000, or \$0.05 per diluted share. For 2007, core business net income was \$1.7 million, or \$0.31 per diluted share; non-core business net income was \$155,000, or \$0.03 per diluted share. The 2008 results include non-cash FAS 123(R) stock-based compensation expense of \$526,000, or \$0.09 per diluted share, compared to \$280,000, or \$0.05 per diluted share, for 2007.

In 2008 we also continued to make significant investments in our proprietary intellectual property (IP), specifically in the development of ULP wireless and DSP capabilities on body-worn platforms. As a percent of 2008 sales, research and development was 5.0 percent, up from 4.5 percent in 2007. In addition, we had a significant amount of customer-funded R&D and technology licensed from AME as a result of customer-funded grants, which greatly increased our IP portfolio. We plan to continue to invest heavily in targeted R&D areas that will drive future sales growth.

Medical

Industry-wide, the trend toward further miniaturization in medical products continues. Device sizes are shrinking and moving to body-worn platforms—many incorporating ULP wireless capabilities to transmit critical data. The market also views the emergence of wireless-based bio-telemetry applications as paradigm shifting. IntriCon is one of the few companies with the capabilities to design, manufacture and bring these products to market, incorporating our own proprietary technology.

IntriCon's strong relationships with leading OEMs and our device expertise helped grow medical sales more than 7 percent in 2008. Moreover, we invested time and energy during the year laying the groundwork for new medical work we anticipate will launch later in 2009.

The medical market continues to be IntriCon's core strength and focus. Our expertise in the robotic manufacture of miniature and micro-miniature electronic products is well-suited to address the needs of the aging population demanding these devices. Moreover, the medical market has rigorous demands for high-tech,

miniature, portable devices; and we are able to deliver those benefits to our customers both directly and via key partnerships. A key medical initiative for us is our bio-telemetry initiative, and projects are under way with our strategic partner AME. Through these efforts, the company is working to develop devices that wirelessly transmit critical diagnostic and therapeutic information.

Examples of development projects include: a miniature wearable electroencephalograph (EEG) transmitter that will digitize EEG signals and transmit them in neuroscience research; and a wearable electromyography (EMG) and inertial limb tracking system for bio-mechanical research and clinical studies.

The bio-telemetry opportunity will allow us to leverage both our BodyNet and nanoDSP devices across our medical business. We're focused on creating new devices that shift the point of care, better connecting patients and caregivers, providing critical information and feedback—improving both the quality and the cost of care.

Hearing Health

Overall, IntriCon's hearing-health business decreased in 2008. The biggest factor impacting us was an industry-wide pause in hearing-health spending by our manufacturer customers and their end consumers. While the hearing-health market is by no means shrinking, customers are delaying hearing aid purchases.

We feel that this is chiefly due to adverse economic conditions and the overall pullback in consumer spending. Additionally, the completion of a one-time hearing-health program in early 2008 drove a \$2.7 million reduction in revenue compared to 2007.

That said, the hearing-health market holds tremendous opportunities for IntriCon. Here's why: the over-65 age demographic is the fastest growing segment of the population in the United States, Europe and Japan. The over-65 group is very important to us, as many of them at some point could benefit from a proprietary IntriCon hearing device that offers advanced technology and superior performance. When the pullback in consumer spending ends, we are confident that we will be ready to take advantage of this opportunity.

Today, we can service the hearing-health segment better than ever, due to the introduction of Ethos™, our new high-performance adaptive DSP hearing aid amplifier. With advanced capabilities ideally suited for the hearing-health market, we feel Ethos will greatly improve hearing performance for customers. DSP devices have greater clarity and more efficiently filter background noise and feedback. By offering both assemblies, as well as complete devices, we've established ourselves as a leading supplier of high-quality DSP amplifier devices.

During the year we also entered into a strategic alliance with Australia-based Dynamic Hearing, a designer of proprietary DSP firmware used in hardware platforms for the hearing health and professional audio communications markets. We will use the license from Dynamic Hearing to develop new body-worn applications and expand our hearing health and professional audio communications product portfolio. During the fourth quarter, we completed the development of a custom high-performance DSP amplifier for a large customer using technology and resources available through our strategic alliance with Dynamic Hearing.

We're also working on other hearing-health projects with our strategic partner AME. Through these efforts, the company is working to develop wireless technologies that enhance the performance and capabilities of hearing devices. One example of a development project is the Hearing Aid Companion Microphone that will provide for wireless broadcast to a hearing device.

Professional Audio Communications

IntriCon's sales in the professional audio communications market grew more than 20 percent in 2008—an achievement we're very excited by. A mere eight years after we entered the market, ongoing relationships with, and dedication to major audio players continue to drive this opportunity.

We provide products for military, aerospace, police, fire and emergency response needs, as well as for music and stage performance, including boom microphones, ear-worn microphones, headsets and accessories. In 2008, we launched a number of professional audio communications products. These include our SK series ear-worn headset line and our wireless Push-to-Talk (PTT) line.

Our acquisition of Tibbetts in 2007, and successful integration in 2008, affords us new opportunities through access to key technologies, as well as entry into the law enforcement and security agency markets. By shifting Tibbetts' production to our cost-effective locations, we're helping customers lower costs while maintaining quality. In addition, we have restructured our Maine facility to better serve the needs of our U.S. Government customers.

Moreover, the same proprietary technology that we use in hearing health, including ULP wireless and DSP, holds tremendous potential for professional audio communications and we're beginning to leverage that on several fronts. As the demand for smaller and smaller ear- and body-worn devices continues to rise, we have both the capabilities and product offering to meet customer needs.

Looking Ahead

At IntriCon, our goal in 2009 is to further our position as the body-worn medical device company – creating products that improve quality of life. To do so, we will invest strategically, manage prudently and listen to our customers.

Our commitment to R&D is expected to drive new product development—now and in the future. And we have partnered with leaders in the body-worn device space and will continue to forge new relationships.

Despite challenging economic conditions, over the next 12 months we intend to: develop new bio-telemetry medical applications; gain additional traction and market share in hearing health; and further advance our professional audio communications product offering. We will do so with an added emphasis on fiscal prudence while still investing in growth initiatives.

On behalf of IntriCon's management and the board of directors, I would like to thank our customers for their loyalty, our team of employees for their contributions and our shareholders for their support.

I look forward to updating you on our progress during the year.

Sincerely,



Mark S. Gorder
President and Chief Executive Officer
IntriCon Corporation

March 13, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

(Mark one)

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2008

or

TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____.

Commission File Number 1-5005

INTRICON CORPORATION

(Exact name of registrant as specified in its charter)

Pennsylvania 23-1069060
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)

1260 Red Fox Road
Arden Hills, Minnesota 55112
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (651) 636-9770

Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on
Title of each class which registered
Common Shares, \$1 par value per share The NASDAQ Global Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (Section 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined by rule 12b-2 of the Act). Yes No

The aggregate market value of the voting common shares held by non-affiliates of the registrant on June 30, 2008 was \$40,267,744. Common shares held by each officer and director and by each person who owns 10% or more of the outstanding common shares have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

The number of outstanding shares of the registrant's common shares on February 27, 2009 was 5,343,079.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Company's definitive proxy statement for the 2009 annual meeting of shareholders are incorporated by reference into Part III of this report; provided, however, that the Audit Committee Report and any other information in such Proxy Statement that is not required to be included in this Annual Report on Form 10-K, shall not be deemed to be incorporated herein or filed for the purposes of the Securities Act of 1933 or the Securities Exchange Act of 1934.

Table of Contents

	Page No.
PART I	
Item 1. Business	4
Item 1A. Risk Factors	12
Item 1B. Unresolved Staff Comments	17
Item 2. Properties	17
Item 3. Legal Proceedings	17
Item 4. Submission of Matters to a Vote of Security Holders	18
Item 4A. Executive Officers of the Registrant	18
PART II	
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	20
Item 6. Selected Financial Data	22
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations	24
Item 7A. Quantitative and Qualitative Disclosures About Market Risk	35
Item 8. Financial Statements and Supplementary Data	37
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	69
Item 9A(T). Controls and Procedures	69
Item 9B. Other Information	69
PART III	
Item 10. Directors, Executive Officers and Corporate Governance	70
Item 11. Executive Compensation	70
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	70
Item 13. Certain Relationships and Related Transactions, and Director Independence	71
Item 14. Principal Accountant Fees and Services	71
PART IV	
Item 15. Exhibits, Financial Statement Schedules	71
SIGNATURES	77
EXHIBIT INDEX	78

PART I

ITEM 1. Business

Company Overview

IntriCon Corporation, formerly Selas Corporation of America (together with its subsidiaries referred herein as the “Company”, or “IntriCon”, “we”, “us” or “our”) is an international firm engaged in the designing, developing, engineering and manufacturing of body-worn devices and electronic products. The Company serves the body-worn device market by designing, developing, engineering and manufacturing micro-miniature injection-molded plastics, microelectronics, micro-mechanical assemblies and complete assemblies, primarily for bio-telemetry devices, medical equipment, hearing instruments, electronics, professional audio and telecommunications devices and computers. The Company, headquartered in Arden Hills, Minnesota has facilities in Minnesota, California, Maine, Singapore and Germany, and operates through subsidiaries. The Company is a Pennsylvania corporation. The Company has gone through several transformations since its formation. The Company’s core business of body-worn devices was established in 1993 through the acquisition of Resistance Technologies Inc., now known as IntriCon, Inc. The majority of IntriCon’s current management came to the Company with the Resistance Technologies Inc. acquisition, including IntriCon’s President and CEO, who was a co-founder of Resistance Technologies Inc.

In the past, the Company operated in three segments: the precision miniature medical and electronics products segment, the heat technology segment, and the tire holders, lifts and related products segment. In 2001, the Company began focusing on its precision miniature medical and electronics products segment and developing plans to exit the businesses that comprised the heat technology segment and the tire holders, lifts and related products segment. The Company exited the tire holders, lifts and related products business in 2003 and the heat technology segment in the first quarter of 2005. For all periods presented, the Company classified its heat technology segment as discontinued operations.

Currently, the Company has two operating segments: its body worn device segment and electronics products segment. Prior to 2008, the Company’s body-worn device and electronics products segments were combined in the Company’s precision miniature medical and electronics products segment. The Company determined these segments no longer meet the criteria for aggregation. The nature of the products and services has been deemed separately identifiable, as the Company has further developed technologies and products included in the body-worn device segment. Furthermore, as the underlying products and technology have changed, the economic characteristics of each business segment are not expected to be similar. Our electronics products segment margin is subject to more variability due to material pricing and we believe our future revenue growth and margin will be different for each segment as a result of the proprietary technology included in our body-worn device products.

Business Highlights

Major Events in 2008

On July 20, 2008, the Company entered into a strategic alliance agreement with Australia-based Dynamic Hearing Pty Ltd (“Dynamic Hearing”), a designer of proprietary digital signal processing (“DSP”) firmware used in ultra-low power (“ULP”) DSP hardware platforms for the hearing health and professional audio market. Effective October 1, 2008, Dynamic Hearing granted a license to the Company to use certain of Dynamic Hearing’s technology, including ULP-DSP technology. IntriCon intends to use the license from Dynamic Hearing to develop new body-worn ULP-DSP applications and expand its hearing health and professional audio product portfolio.

The initial term of the agreement is five years from the date of execution and may be extended upon agreement of the parties within two months of the expiration of the initial term; however, either party may terminate the agreement after the second year of the term upon three months notice. The Company agreed to pay Dynamic Hearing: (i) an annual fee for access to the technology licensed pursuant to the agreement and (ii) an additional “second component” fee to maintain exclusive rights granted to the Company with respect to hearing health products. Additionally, IntriCon agreed to make royalty payments on products that incorporate Dynamic Hearing’s technology and Dynamic Hearing has also agreed to provide the Company with engineering and other services in connection with the licensed technology.

Major Events in 2007

On May 22, 2007, the Company completed the acquisition of substantially all of the assets of Tibbetts Industries, Inc., other than real estate. Pursuant to an Asset Purchase Agreement, dated as of April 19, 2007, by and among the Company and Tibbetts and certain of the principal shareholders of Tibbetts, the Company purchased substantially all of the assets of Tibbetts, other than real estate, for cash of \$4,500,000, subject to a closing adjustment, and the assumption of certain liabilities (total purchase price of \$5,569,000 including acquisition costs of \$228,000). The acquisition was financed with borrowings under the Company's \$14.5 million in senior secured credit facilities, which the Company closed on May 22, 2007. Terms of the credit facilities included:

- a \$10.0 million revolving credit facility, with a subfacility for letters of credit, to mature in five years, and
- a \$4.5 million term loan facility, amortized in increasing quarterly principal installments based on a five-year repayment schedule.

The credit facilities are further described in Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations".

In October 2007, the Company entered into a strategic alliance with Advanced Medical Electronics Corp. ("AME") to develop and manufacture new miniature, wireless, ultra-low-power bio-telemetry instruments. Through this partnership, AME and IntriCon intend to develop and manufacture wireless instruments including a:

- binaural hearing aid which will use wireless technology to enhance hearing by allowing hearing aids on both ears to coordinate their operations;
- hearing aid companion microphone that will transmit companion voice signals to the wearer of a hearing aid, allowing vast improvement in speech intelligibility in noisy environments;
- miniature wearable electroencephalograph (EEG) transmitter that will digitize EEG signals and transmit them for neuroscience research; and
- wearable electromyograph (EMG) and inertial limb tracking systems for bio-mechanical research and clinical studies.

AME receives support from the federal Small Business Innovation Research program and will develop the bio-telemetry instruments. IntriCon will manufacture these devices and supply them to third-party distributors. IntriCon also gains exclusive access to key AME technology and will be able to use this technology to develop additional bio-telemetry applications. In 2009, there was an amendment to the strategic alliance to include four additional funded projects, related to the development of advanced biotelemetry technologies.

Forward-Looking Statements

Certain statements included or incorporated by reference in this Annual Report on Form 10-K or the Company's other public filings and releases, which are not historical facts, or that include forward-looking terminology such as "may", "will", "believe", "expect", "should", "optimistic" or "continue" or the negative thereof or other variations thereof, are forward-looking statements (as such term is defined in Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, and the regulations thereunder), which are intended to be covered by the safe harbors created thereby. These statements may include, but are not limited to:

- statements in "Business," "Legal Proceedings" and "Risk Factors", such as the Company's ability to focus on the precision miniature medical and electronics products markets, the ability to compete, statements concerning the Tibbetts acquisition, strategic alliances and their benefits, the adequacy of insurance coverage, and potential increase in demand for the Company's products; and
- statements in "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Notes to the Consolidated Financial Statements," such as the net operating loss carryforwards, the ability to meet cash requirements for operating needs, the ability to meet liquidity needs, assumptions used to calculate future level of funding of employee benefit plans, the adequacy of insurance coverage, the impact of new accounting pronouncements and litigation.

Forward-looking statements also include, without limitation, statements as to the Company's expected future results of operations and growth, the Company's ability to meet working capital requirements, the Company's business strategy, the expected increases in operating efficiencies, anticipated trends in the Company's body-worn device and electronic products markets, estimates of goodwill impairments and amortization expense of other intangible assets, the effects of changes in accounting pronouncements, the effects of litigation and the amount of insurance coverage, and statements as to trends or the Company's or management's beliefs, expectations and opinions. Forward-looking statements are subject to risks and uncertainties and may be affected by various risks, uncertainties and other factors that can cause actual results and developments to be materially different from those expressed or implied by such forward-looking statements, including, without limitation, the risk factors discussed in Item 1A of this Annual Report on Form 10-K.

The Company does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the Company.

Market Overview: Body-Worn Devices

IntriCon, Inc. (formerly known as Resistance Technology, Inc.), IntriCon PTE LTD ("PTE"), and IntriCon Tibbetts, Inc. ("ITC") are wholly-owned subsidiaries of the Company, that design, develop, engineer and manufacture micro-miniature injection-molded plastics, microelectronics, micro-mechanical assemblies and complete assemblies, primarily for bio-telemetry devices, medical equipment, hearing instruments, professional audio and telecommunications devices and computers.

Products and Industries Served. IntriCon designs, develops and manufactures miniature and micro-miniature body-worn products based on its proprietary technology to meet the rising demand for smaller, portable and more advanced devices. Our expertise is focused on three main markets: medical, hearing health and professional audio. Within these chosen markets, we combine ultra-miniature mechanical and electronics capabilities with proprietary technology – including ULP wireless and DSP capabilities - that enhances the performance of body-worn devices.

Medical

In the medical market, the Company is focused on sales of multiple biotelemetry devices from life-critical diagnostic monitoring devices to drug-delivery systems. Using our nanoDSP™ and ULP nanoLink™ technology, the Company manufactures microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components and complete bio-telemetry devices for emerging and leading medical device manufacturers. Targeted customers include medical product manufacturers of portable and lightweight battery powered devices, as well as a variety of sensors designed to connect a patient to an electronic device.

The medical industry is faced with pressures to reduce the costs of healthcare. IntriCon currently serves this market by offering medical manufacturers the capabilities to design, develop and manufacture components for medical devices that are easier to use, measure with greater accuracy and provide more functions while reducing the costs to manufacture these devices. IntriCon manufactures and supplies bubble sensors and flow restrictors that monitor and control the flow of fluid in an intravenous infusion system. IntriCon also manufactures a family of safety needle products for an OEM customer that utilizes IntriCon's insert and straight molding capabilities. These products are assembled using full automation including built-in quality checks within the production lines. Other examples include sensors used to detect pathologies in specific organs of the body and monitoring devices to detect cardiac, respiratory functions, and blood glucose levels. The early and accurate detection of pathologies allows for increased likelihood for successful treatment of chronic diseases and cancers. Accurate monitoring of multiple functions of the body, such as heart rate, breathing and blood glucose levels, aids in generating more accurate diagnosis and treatments for patients.

In addition, there has been an industry-wide trend toward further miniaturization and ambulatory operation enabled by wireless connectivity, which is also referred to as bio-telemetry. Through the further development of our ULP BodyNet™ family, a series of wirelessly enabled products including our new wireless nanoLink™ family, we believe the bio-telemetry offers a significant future opportunity. Increasingly, the medical industry is looking for wireless, low-power capabilities in their devices. We believe our strategic partnership with AME will allow us to develop new bio-telemetry devices that better connect patients and care givers, providing critical information and

feedback. Current examples of IntriCon biotelemetry products used by medical device manufacturers include components found in wireless glucose sensor pumps that introduce drugs into the bloodstream.

Hearing Health

IntriCon manufactures hybrid amplifiers and integrated circuit components ("hybrid amplifiers"), along with faceplates for in-the-ear and in-the-canal hearing instruments. IntriCon is a leading manufacturer and supplier of microminiature electromechanical components to hearing instrument manufacturers. These components consist of volume controls, microphones, receivers, trimmer potentiometers and switches. Components are offered in a variety of sizes, colors and capacities in order to accommodate a hearing manufacturer's individualized specifications.

Hearing instruments, which fit behind or in a person's ear to amplify and process sound for a hearing impaired person, generally are composed of four basic parts and several supplemental components for control or fitting purposes. The four basic parts are microphones, amplifier circuits, miniature receivers/speakers and batteries, all of which IntriCon manufactures, with the exception of the battery. IntriCon's hybrid amplifiers are a type of amplifier circuit. Supplemental components include volume controls, trimmer potentiometers, which shape sound frequencies to respond to the particular nature of a person's hearing loss, and switches used to turn the instrument on and off and to go from telephone to normal speech modes. Faceplates and an ear shell, molded to fit the user's ear, often serve as housing for hearing instruments. IntriCon manufactures its components on a short lead-time basis in order to supply "just-in-time" delivery to its customers and, consequently, order backlog amounts are not meaningful.

Using our ULP BodyNet™ family technology, specifically nanoDSP™ and our new wireless nanoLink™ product family, IntriCon is building a new generation of affordable, high-quality hearing aids and similar amplifier devices under contracts for OEM's. DSP devices have better clarity, attractive pricing points and an improved ability to filter out background noise. During 2008, we introduced Ethos, our new high-performance adaptive DSP hearing instrument amplifier. In our view, Ethos' advanced capabilities are ideally suited for the hearing health market. We believe the introduction of Ethos solidifies our position as a leader of high-performance adaptive DSP hearing instrument amplifiers. Furthermore, we believe our strategic alliance with Dynamic Hearing will allow us to develop new body-worn applications and further expand both our hearing health and professional audio product portfolio.

Overall, we believe the hearing health market holds significant opportunities for the Company. In the United States, Europe and Japan, the 65-year-old-plus age demographic is the fastest growing segment of the population, and many of those individuals could, at some point, benefit from a hearing device that uses IntriCon's proprietary technology.

While it harbors great potential, the hearing health market is experiencing slowness due to macroeconomic conditions. In general, the U.S. market does not provide insurance reimbursement for hearing aid purchases. People can defer their hearing aid purchase. We believe the softness in the market will continue into 2009. Reimbursement trends in Europe are more favorable, with insurers and the governments covering more devices.

Professional Audio Communications

IntriCon entered the high-quality audio communication device market in 2001, and now has a line of miniature, professional audio headset products used by customers focusing on homeland security and emergency response needs. The line includes several communication devices that are extremely portable and perform well in noisy or hazardous environments. These products are well suited for applications in the fire, law enforcement, safety, aviation and military markets. In addition, the company has a line of miniature ear- and head-worn devices used by performers and support staff in the music and stage performance markets. Our May 2007 acquisition of Tibbett's Industries provided the Company access to homeland security agencies in this market. We believe performance in difficult listening environments and wireless operations will continue to improve as these products increasingly include our proprietary nanoDSP™, wireless nanoLink™ and ULP nanoLink™ technology.

For information concerning our net sales, net income and assets, see the consolidated financial statements in Item 8 of this Annual Report on Form 10-K.

Marketing and Competition. IntriCon sells its hearing instrument components directly to domestic hearing instrument manufacturers through an internal sales force. Sales of medical and professional audio communications products are also made mainly through an internal sales force. In recent years, five companies have accounted for a substantial portion of the Company's sales in this segment.

In 2008, one customer accounted for 15 percent of the Company's body-worn device net sales. During 2008, the top five customers accounted for approximately \$22.6 million or 39 percent of the Company's body-worn device net sales. See note 4 to the consolidated financial statements for a discussion of net sales and long-lived assets by geographic area and segment.

Internationally, sales representatives employed by IntriCon GmbH ("GmbH"), a German company 90% of whose capital stock is owned by IntriCon, solicit sales from European hearing instrument manufacturers on behalf of IntriCon.

IntriCon believes that it is the largest supplier worldwide of micro-miniature electromechanical components to hearing instrument manufacturers and that its full product line and automated manufacturing process allow it to compete effectively with other manufacturers within this market. In the market of hybrid amplifiers and molded plastic faceplates, IntriCon's primary competition is from the hearing instrument manufacturers themselves. The hearing instrument manufacturers produce a substantial portion of their internal needs for these components.

IntriCon markets its high performance microphone products to the radio communication and professional audio industries and has several larger competitors who have greater financial resources. IntriCon holds a small market share in the global market for microphone capsules and other related products.

Employees. As of January 31, 2009, our body-worn device segment had a total of 523 full time equivalent employees, of whom 33 are executive and administrative personnel, 16 are sales personnel and 474 are engineering and operations personnel. The Company considers its relations with its employees to be satisfactory. None of the Company's employees are represented by a union.

As a supplier of parts for consumer and medical products, IntriCon is subject to claims for personal injuries allegedly caused by its products. The Company maintains what it believes to be adequate insurance coverage.

Research and Development. IntriCon conducts research and development activities primarily to improve its existing products and proprietary technology. The Company is committed to increasing its investment in the research and development of proprietary technologies, such as the ULP nanoDSP and Bodynet technologies. The Company believes the continued development of key proprietary technologies will be the catalyst for long-term revenues and margin growth. Research and development expenditures were \$3,248,000, \$3,089,000, and \$2,123,000 in 2008, 2007 and 2006, respectively. These amounts are net of customer reimbursed research and development. See note 1 to the consolidated financial statements for information regarding customer funded research and development projects.

IntriCon owns a number of United States patents which cover a number of product designs and processes. The Company believes that, although these patents collectively add some value to the Company, no one patent or group of patents is of material importance to its business as a whole.

Market Overview: Electronic Products

Our electronic products segment business is conducted by RTI Electronics, Inc. ("RTIE"), a wholly owned subsidiary of the Company. RTIE designs and manufactures thermistor, film capacitor and magnetic products to industrial, commercial and military customers.

Products and Industries Served. RTIE manufactures and sells thermistors and thermistor assemblies, which are solid state devices that produce precise changes in electrical resistance as a function of any change in absolute body temperature. RTIE sells through its Surge-Gard™ product line, an inrush current limiting device used primarily in computer power supplies. The balance of sales represents various industrial, commercial and military sales for other thermistor, film capacitor and magnetic products to domestic and international markets. RTIE's principal raw materials are plastics, polymers, metals, various metal oxide powders and silver paste, for which it believes there are multiple sources of supply.

For information concerning net sales, net income and assets, see the consolidated financial statements in Item 8.

Marketing and Competition. RTIE sells its thermistors, film capacitors and magnetic products through a combination of independent sales representatives and internal sales force. This business has many competitors, both domestic and foreign, that sell various thermistors, film capacitors and magnetics and some of these competitors are larger and have greater financial resources. In addition, RTIE holds a relatively small market share in the world-market of thermistor and film capacitor products.

In 2008, one customer accounted for 11 percent of the RTIE's electronic products net sales. During 2008, the top five customers accounted for approximately \$2.4 million or 31 percent of RTIE's electronic products net sales. See note 4 to the consolidated financial statements for a discussion of net sales and long-lived assets by geographic area and segment.

Employees. As of January 31, 2009, RTIE had a total of 82 full time equivalent employees, of whom 6 are executive and administrative personnel, 3 are sales personnel and 73 are operations personnel. RTIE considers its relations with its employees to be satisfactory. None of the RTIE's employees are represented by a union.

As a supplier of parts for consumer products, RTIE is subject to claims for personal injuries allegedly caused by its products. The Company maintains what it believes to be adequate insurance coverage.

Discontinued Operations – Heat Technology

The Company specialized in the controlled application of heat to achieve precise process and temperature control. The Company's principal heat technology equipment and systems were smaller standard-engineered systems, burners and combustion control equipment. The Company sold this business in the first quarter of 2005 and has accounted for it as discontinued operations as further described in note 2 in the accompanying consolidated financial statements in Item 8.

Standard Engineered Systems. The Company engineered and fabricated a variety of small heat treating furnaces and heat processing equipment. This standard equipment and small-furnace business was conducted principally by its then subsidiaries, Nippon Selas (Tokyo, Japan) and Selas Waermettechnik (Ratingen, Germany).

Burners and Combustion Control Equipment. At its Dresher, Pennsylvania facility and through its then subsidiaries in Japan, Nippon Selas (Tokyo), and Germany, Selas Waermettechnik, (Ratingen), the Company designed, manufactured and sold an array of original equipment and replacement gas-fired industrial burners for many applications.

The Company was a producer of burners used in fluid processing furnaces serving the petrochemical industry. The Company also produced burners suitable for creating a high temperature furnace environment desirable in steel and glass heat treating furnaces. The Company's burners accommodated a wide variety of fuel types, environmental constraints and customer production requirements.

The Company furnished many industries with gas combustion control equipment sold both as component parts and as systems that were engineered to meet a particular customer's needs. This equipment was provided with the Company's original custom-engineered and standard heat treating equipment, as replacement or additional components for existing furnaces being refurbished or upgraded, and as original components for heat treating equipment manufactured by others.

Marketing and Competition. The Company marketed its standard-engineered systems products on a global basis through its sales and marketing personnel located in Dresher, Pennsylvania, and also sold these products through licensees and agents located in various parts of the world.

Operations. As of December 31, 2004, the heat technology segment had a total of 48 employees. At its Dresher facility, the Company had 32 employees; 6 were executive and administrative personnel, 10 were sales and engineering personnel and 16 were personnel engaged in manufacturing. The hourly personnel were represented by

a union. Selas Waermetchnik had 6 employees; 1 was an administrative personnel, 3 were sales and engineering personnel and 2 were personnel engaged in manufacturing.

In April 2001, the Company sold a minority interest of Nippon Selas to three directors of Nippon Selas. This minority interest was reacquired by the Company in the first quarter of 2005 in contemplation of the sale of this business, which was completed in the first quarter of 2005. Its Tokyo facility employed 10 people; 3 administrative and 7 sales and engineering.

Research and Development. The Company conducted limited research and development activities at its Dresher facility to support its heat processing services and products. Research and development expenditures for heat processing aggregated \$4,000 in 2005.

Available Information

The Company files or furnishes its annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and other information with the SEC. You may read and copy any reports, statements and other information that the Company files with the SEC at the SEC's Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The Company's filings are also available on the SEC's Internet site as part of the EDGAR database (<http://www.sec.gov>).

The Company maintains an internet web site at www.IntriCon.com. The Company maintains a link to the SEC's website by which you may review its annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act.

The information on the website listed above, is not and should not be considered part of this annual report on Form 10-K and is not incorporated by reference in this document. This website is and is only intended to be an inactive textual reference.

In addition, we will provide, at no cost (other than for exhibits), paper or electronic copies of our reports and other filings made with the SEC. Requests should be directed to:

Corporate Secretary
IntriCon Corporation
1260 Red Fox Road
Arden Hills, MN 55112

ITEM 1A. Risk Factors

You should carefully consider the risks described below. If any of the risks actually occur, our business, financial condition or results of future operations could be materially adversely affected. This Annual Report on Form 10-K contains forward-looking statements that involve risk and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of many factors, including the risks faced by us described below and elsewhere in this Annual Report on Form 10-K.

We have experienced and expect to continue to experience fluctuations in our results of operations, which could adversely affect us.

Factors that affect our results of operations include, but are not limited to, the volume and timing of orders received, changes in the global economy and financial markets, changes in the mix of products sold, market acceptance of our products and our customer's products, competitive pricing pressures, global currency valuations, the availability of electronic components that we purchase from suppliers, our ability to meet demand, our ability to introduce new products on a timely basis, the timing of new product announcements and introductions by our or our competitors, changing customer requirements, delays in new product qualifications, and the timing and extent of research and development expenses. These factors have caused and may continue to cause us to experience fluctuations in operating results on a quarterly and/or annual basis. These fluctuations could materially adversely affect our business, financial condition and results of operations, which in turn, could adversely affect the price of our common stock.

The loss of one or more of our major customers could adversely affect our results of operations.

We are dependent on a small number of customers for a large portion of our revenues. In fiscal year 2008, our largest customer accounted for 13% of our net sales and our five largest customers accounted for 35% of our net sales. A significant decrease in the sales to or loss of any of our major customers could have a material adverse effect on our business and results of operations. Our revenues are largely dependent upon the ability of customers to develop and sell products that incorporate our products. No assurance can be given that our major customers will not experience financial, technical or other difficulties that could adversely affect their operations and, in turn, our results of operations.

We may not be able to collect outstanding accounts receivable from our customers.

Some of our customers purchase our products on credit, which may cause a concentration of accounts receivable among some of our customers. As of December 31, 2008, we had accounts receivable, less allowance for doubtful accounts, of \$9,525,000, which represented approximately 46.9 percent of our shareholders' equity as of that date. As of that date, two customers accounted for approximately 11 and 10 percent of our accounts receivable, respectively. Our financial condition and profitability may be harmed if one or more of our customers are unable or unwilling to pay these accounts receivable when due.

If we are unable to continue to develop new products that are inexpensive to manufacture, our results of operations could be adversely affected.

We may not be able to continue to achieve our historical profit margins in our body-worn device and electronic products segments due to advancements in technology. The ability to continue our profit margins is dependent upon our ability to stay competitive by developing products that are technologically advanced and inexpensive to manufacture.

Our need for continued investment in research and development may increase expenses and reduce our profitability.

Our industry is characterized by the need for continued investment in research and development. If we fail to invest sufficiently in research and development, our products could become less attractive to potential customers and our business and financial condition could be materially and adversely affected. As a result of the need to maintain or increase spending levels in this area and the difficulty in reducing costs associated with research and development,

our operating results could be materially harmed if our research and development efforts fail to result in new products or if revenues fall below expectations. In addition, as a result of our commitment to invest in research and development, management expects that research and development expenses as a percentage of revenues could increase in the future.

We operate in a highly competitive business and if we are unable to be competitive, our financial condition could be adversely affected.

Several of our competitors have been able to offer more standardized and less technologically advanced hearing products at lower prices. Price competition has had an adverse effect on our sales and margins. There can be no assurance that we will be able to maintain or enhance our technical capabilities or compete successfully with our existing and future competitors.

Merger and acquisition activity in our hearing health market has resulted in a smaller customer base. Reliance on fewer customers may have an adverse effect on us.

Several of our customers in the hearing health market have undergone mergers or acquisitions, resulting in a smaller customer base with larger customers. If we are unable to maintain satisfactory relationships with the reduced customer base, it may adversely affect our operating profits and revenue.

Unfavorable legislation in the hearing health market may decrease the demand for our products, and may negatively impact our financial condition.

In some of our foreign markets, government subsidies cover a portion of the cost of hearing aids. A change in legislation that would reduce or eliminate these subsidies could decrease the demand for our hearing health products. This could result in an adverse effect on our operating results. We are unable to predict the likelihood of any such legislation.

Implementation of our growth strategy may not be successful, which could affect our ability to increase revenues.

Our growth strategy includes developing new products and entering new markets, as well as identifying and integrating acquisitions. Our ability to compete in new markets will depend upon a number of factors including, among others:

- our ability to create demand for products in new markets;
- our ability to manage growth effectively;
- our ability to successfully identify, complete and integrate acquisitions;
- our ability to respond to changes in our customers' businesses by updating existing products and introducing, in a timely fashion, new products which meet the needs of our customers;
- the quality of our new products; and
- our ability to respond rapidly to technological change.

The failure to do any of the foregoing could have a material adverse effect on our business, financial condition and results of operations. In addition, we may face competition in these new markets from various companies that may have substantially greater research and development resources, marketing and financial resources, manufacturing capability and customer support organizations.

We operate in Singapore and Germany, and various factors relating to our international operations could affect our results of operations.

In 2008, we operated in Singapore and Germany. Approximately 17 percent of our revenues were derived from our facilities in these countries in 2008. As of December 31, 2008 approximately 7 percent of our long-lived assets are located in these countries. Political or economic instability in these countries could have an adverse impact on our results of operations due to diminished revenues in these countries. Our future revenues, costs of operations and

profit results could be affected by a number of factors related to our international operations, including changes in foreign currency exchange rates, changes in economic conditions from country to country, changes in a country's political condition, trade protection measures, licensing and other legal requirements and local tax issues. Unanticipated currency fluctuations in the Euro could lead to lower reported consolidated revenues due to the translation of these currencies into U.S. dollars when we consolidate our revenues.

We may explore acquisitions that complement or expand our business. We may not be able to complete these transactions and these transactions, if executed, pose significant risks and may materially adversely affect our business, financial condition and operating results.

We intend to explore opportunities to buy other businesses or technologies that could complement, enhance or expand our current business or product lines or that might otherwise offer us growth opportunities. We may have difficulty finding these opportunities or, if we do identify these opportunities, we may not be able to complete the transactions for various reasons, including a failure to secure financing. Any transactions that we are able to identify and complete may involve a number of risks, including: the diversion of our management's attention from our existing business to integrate the operations and personnel of the acquired or combined business or joint venture; possible adverse effects on our operating results during the integration process; unanticipated liabilities; and our possible inability to achieve the intended objectives of the transaction. In addition, we may not be able to successfully or profitably integrate, operate, maintain and manage our newly acquired operations or employees. In addition, future acquisitions may result in dilutive issuances of equity securities or the incurrence of additional debt.

We may experience difficulty in paying our debt when it comes due, which could limit our ability to obtain financing.

As of December 31, 2008, we had bank indebtedness of \$7,692,000 and additional indebtedness of \$1,279,000, consisting of \$1,020,000 payable to HIMPP and \$259,000 payable to Amecon. Our ability to pay the principal and interest on our indebtedness as it comes due will depend upon our current and future performance. Our performance is affected by general economic conditions and by financial, competitive, political, business and other factors. Many of these factors are beyond our control. We believe that availability under our existing credit facility combined with funds expected to be generated from operations and control of capital spending will be sufficient to meet our anticipated cash requirements for operating needs for at least the next 12 months. If, however, we are unable to renew these facilities in the future or do not generate sufficient cash or complete such financings on a timely basis, we may be required to seek additional financing or sell equity on terms which may not be as favorable as we could have otherwise obtained. No assurance can be given that any refinancing, additional borrowing or sale of equity will be possible when needed or that we will be able to negotiate acceptable terms. In addition, our access to capital is affected by prevailing conditions in the financial and equity capital markets, as well as our own financial condition.

Our success depends on our senior management team and if we are not able to retain them, it could have a materially adverse effect on us.

We are highly dependent upon the continued services and experience of our senior management team, including Mark S. Gorder, our President, Chief Executive Officer and director. We depend on the services of Mr. Gorder and the other members of our senior management team to, among other things, continue the development and implementation of our business strategies and maintain and develop our client relationships.

Our future success depends in part on the continued service of our engineering and technical personnel and our ability to identify, hire and retain additional personnel.

There is intense competition for qualified personnel in our markets. We may not be able to continue to attract and retain engineers or other qualified personnel necessary for the development and growth of our business or to replace engineers or other qualified personnel who may leave our employ in the future. The failure to retain and recruit key technical personnel could cause additional expense, potentially reduce the efficiency of our operations and could harm our business.

We and/or our customers may be unable to protect our and their proprietary technology and intellectual

property rights or keep up with that of competitors.

Our ability to compete effectively against other companies in our markets depends, in part, on our ability and the ability of our customers to protect our and their current and future proprietary technology under patent, copyright, trademark, trade secret and unfair competition laws. We cannot assure that our means of protecting our proprietary rights in the United States or abroad will be adequate, or that others will not develop technologies similar or superior to our technology or design around the proprietary rights we own or license. In addition, we may incur substantial costs in attempting to protect our proprietary rights.

Also, despite the steps taken by us to protect our proprietary rights, it may be possible for unauthorized third parties to copy or reverse-engineer aspects of our and our customers' products, develop similar technology independently or otherwise obtain and use information that we or our customers regard as proprietary. We and our customers may be unable to successfully identify or prosecute unauthorized uses of our or our customers' technology.

If we become subject to material intellectual property infringement claims, we could incur significant expenses and could be prevented from selling specific products.

We may become subject to material claims that we infringe the intellectual property rights of others in the future. We cannot assure that, if made, these claims will not be successful. Any claim of infringement could cause us to incur substantial costs defending against the claim even if the claim is invalid, and could distract management from other business. Any judgment against us could require substantial payment in damages and could also include an injunction or other court order that could prevent us from offering certain products.

Environmental liability and compliance obligations may affect our operations and results.

Our manufacturing operations are subject to a variety of environmental laws and regulations as well as internal programs and policies governing:

- air emissions;
- wastewater discharges;
- the storage, use, handling, disposal and remediation of hazardous substances, wastes and chemicals; and
- employee health and safety.

If violations of environmental laws occur, we could be held liable for damages, penalties, fines and remedial actions. Our operations and results could be adversely affected by any material obligations arising from existing laws, as well as any required material modifications arising from new regulations that may be enacted in the future. We may also be held liable for past disposal of hazardous substances generated by our business or former businesses or businesses we acquire. In addition, it is possible that we may be held liable for contamination discovered at our present or former facilities.

We are subject to numerous asbestos-related lawsuits, which could adversely affect our financial position, results of operations or liquidity.

We are a defendant along with a number of other parties in approximately 122 lawsuits as of December 31, 2008, (approximately 122 lawsuits as of December 31, 2007) alleging that plaintiffs have or may have contracted asbestos-related diseases as a result of exposure to asbestos products or equipment containing asbestos sold by one or more named defendants. These lawsuits relate to the discontinued Heat Technologies segment which was sold in March 2005. Due to the noninformative nature of the complaints, we do not know whether any of the complaints state valid claims against us. Certain insurance carriers have informed us that the primary policies for the period August 1, 1970-1973, have been exhausted and that the carriers will no longer provide a defense under those policies. We have requested that the carriers substantiate this situation. We believe we have additional policies available for other years which have been ignored by the carriers. Because settlement payments are applied to all years a litigant was deemed to have been exposed to asbestos, we believe when settlement payments are applied to these additional policies, we will have availability under the years deemed exhausted. If our insurance policies do not cover the costs and any awards for the asbestos-related lawsuits, we will have to use our cash or obtain additional financing to pay the asbestos-related obligations and settlement costs. There is no assurance that we will have the cash or be able to

obtain additional financings on favorable terms to pay asbestos related obligations or settlements should they occur. The ultimate outcome of any legal matter cannot be predicted with certainty. In light of the significant uncertainty associated with asbestos lawsuits, there is no guarantee that these lawsuits will not materially adversely affect our financial position, results of operations or liquidity.

The market price of our common stock has been and is likely to continue to be volatile, which may make it difficult for shareholders to resell common stock when they want to and at prices they find attractive.

The market price of our common stock has been and is likely to be highly volatile, and there has been limited trading volume in the common stock. The common stock market price could be subject to wide fluctuations in response to a variety of factors, including the following:

- announcements of fluctuations in our or our competitors' operating results;
- the timing and announcement of sales or acquisitions of assets by us or our competitors;
- changes in estimates or recommendations by securities analysts;
- adverse or unfavorable publicity about our services or us;
- the commencement of material litigation, or an unfavorable verdict, against us;
- terrorist attacks, war and threats of attacks and war;
- additions or departures of key personnel; and
- sales of common stock.

In addition, the stock market in recent years has experienced significant price and volume fluctuations. Such volatility and decline has affected many companies irrespective of, or disproportionately to, the operating performance of these companies. These broad fluctuations and limited trading volume may materially adversely affect the market price of our common stock, and your ability to sell our common stock.

Most of our outstanding shares are available for resale in the public market without restriction. The sale of a large number of these shares could adversely affect the share price and could impair our ability to raise capital through the sale of equity securities or make acquisitions for common stock.

“Anti-takeover” provisions may make it more difficult for a third party to acquire control of us, even if the change in control would be beneficial to shareholders.

We are a Pennsylvania corporation. Anti-takeover provisions in Pennsylvania law and our charter and bylaws could make it more difficult for a third party to acquire control of us. These provisions could adversely affect the market price of the common stock and could reduce the amount that shareholders might receive if we are sold. For example, our charter provides that the board of directors may issue preferred stock without shareholder approval. In addition, our bylaws provide for a classified board, with each board member serving a staggered three-year term. Directors may be removed by shareholders only with the approval of the holders of at least two-thirds of all of the shares outstanding and entitled to vote.

If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud. As a result, current and potential shareholders and customers could lose confidence in our financial reporting, which could harm our business, the trading price of our stock and our ability to retain our current customers or obtain new customers.

Beginning in fiscal 2004, we began a process to document and evaluate our internal controls over financial reporting in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act, which requires annual management assessments of the effectiveness of our internal controls over financial reporting and a report by our independent auditors addressing these assessments. In this regard, management has been dedicating internal resources, has engaged outside consultants and has adopted a detailed work plan to (i) assess and document the adequacy of internal controls over financial reporting, (ii) take steps to improve control processes, where appropriate, (iii) validate through testing that controls are functioning as documented and (iv) implement a continuous reporting and improvement process for internal control over financial reporting. At this time, we are not aware, and our outside auditors have not advised us, of any “material weaknesses” or “significant deficiencies” in our internal controls, as

defined in the relevant literature. If we fail to identify and correct any issues in the design or operating effectiveness of internal controls over financial reporting or fail to prevent fraud, current and potential shareholders and customers could lose confidence in our financial reporting, which could harm our business, the trading price of our stock and our ability to retain our current customers and obtain new customers.

The global financial crisis may have an impact on our business and financial condition in ways that we currently cannot predict.

The continued credit crisis, reduction in confidence and related turmoil in the global financial system may have an impact on our business and our financial condition. Due to the recent tightening of credit markets and concerns regarding the availability of credit, our customers may not have access to sufficient cash or short-term credit to obtain IntriCon product or other services provided by the Company.

ITEM 1B. Unresolved Staff Comments.

Not Applicable.

ITEM 2. Properties

The Company leases seven facilities, five domestically and two internationally, as follows:

- a 47,000 sq. ft. manufacturing facility in Arden Hills, Minnesota, which also serves as the Company's headquarters, from a partnership consisting of two former officers of IntriCon Inc. and Mark S. Gorder who serves as the president and CEO of the Company and IntriCon Inc. and on the Company's Board of Directors. At this facility, the Company manufactures body-worn devices, other than plastic component parts. Annual base rent expense, including real estate taxes and other charges, is approximately \$477,000. The Company believes the terms of the lease agreement are comparable to those which could be obtained from unaffiliated third parties. The lease expires in October 2011.
- a 46,000 sq. ft. building in Vadnais Heights, Minnesota at which IntriCon produces plastic component parts for body-worn devices. Annual base rent expense, including real estate taxes and other charges, is approximately \$382,000. The lease expires in June 2016.
- a building in Anaheim, California, which contains RTIE's electronics products manufacturing facilities and offices and consists of a total of 50,000 square feet. Annual base rent expense, including real estate taxes and other charges, is approximately \$404,000. The lease expires in September 2009.
- two buildings in Camden, Maine, which contain Tibbetts manufacturing facilities and offices and consist of a total of 32,000 square feet. Annual base rent expense on the 25,000 square foot facility, including real estate taxes and other charges, is approximately \$104,000. This lease expires in June 2012. Annual base rent expense on the 7,000 square foot facility, including real estate taxes and other charges, is approximately \$62,000. This lease expires in June 2017.
- a 21,000 square foot building in Singapore which houses production facilities and administrative offices. Annual base rent expense, including real estate taxes and other charges, is approximately \$208,000. This lease expires in May 2010.
- a 2,000 square foot facility in Germany which houses sales and administrative offices. Annual base rent expense, including real estate taxes and other charges, is approximately \$48,000. This lease expires in June 2012.

All of the foregoing facilities are used in the Company's body-worn device segment, other than the Anaheim, California facility which is used in the electronic products segment. See notes 15 and 16 to the Company's consolidated financial statements in Item 8 of the Annual Report on Form 10-K.

ITEM 3. Legal Proceedings

The Company is a defendant along with a number of other parties in approximately 122 lawsuits as of December 31, 2008, (approximately 122 lawsuits as of December 31, 2007) alleging that plaintiffs have or may have contracted

asbestos-related diseases as a result of exposure to asbestos products or equipment containing asbestos sold by one or more named defendants. These lawsuits relate to the discontinued Heat Technologies segment which was sold in March 2005. Due to the noninformative nature of the complaints, the Company does not know whether any of the complaints state valid claims against the Company. Certain insurance carriers have informed the Company that the primary policies for the period August 1, 1970-1973, have been exhausted and that the carriers will no longer provide a defense under those policies. The Company has requested that the carriers substantiate this situation. The Company believes it has additional policies available for other years which have been ignored by the carriers. Because settlement payments are applied to all years a litigant was deemed to have been exposed to asbestos, the Company believes when settlement payments are applied to these additional policies, the Company will have availability under the years deemed exhausted. The Company does not believe that the asserted exhaustion of the primary insurance coverage for this period will have a material adverse effect on its financial condition, liquidity, or results of operations. Management believes that the number of insurance carriers involved in the defense of the suits and the significant number of policy years and policy limits, to which these insurance carriers are insuring the Company, make the ultimate disposition of these lawsuits not material to the Company's consolidated financial position or results of operations.

The Company's wholly owned French subsidiary, Selas SAS, filed for insolvency in France and is being managed by a court appointed judiciary administrator. The Company may be subject to additional litigation or liabilities as a result of the French insolvency proceeding.

The Company is also involved in other lawsuits arising in the normal course of business, as further described in note 15 to the consolidated financial statements in Item 8. While it is not possible to predict with certainty the outcome of these matters, management is of the opinion that the disposition of these lawsuits and claims will not materially affect the Company's consolidated financial position, liquidity, or results of operations.

ITEM 4. Submission of Matters to a Vote of Security Holders

None.

ITEM 4A. Executive Officers of the Registrant

The names, ages and offices (as of February 28, 2009) of the Company's executive officers were as follows:

<u>Name</u>	<u>Age</u>	<u>Position</u>
Mark S. Gorder	62	President, Chief Executive Officer and Director of the Company; President of IntriCon, Inc.
Scott Longval	32	Chief Financial Officer and Treasurer of the Company
Christopher D. Conger	48	Vice President, Research and Development
Michael P. Geraci	50	Vice President, Sales and Marketing
Dennis L. Gonsior	50	Vice President, Operations
Steve M. Binnix	59	Vice President and General Manager, RTI Electronics, Inc.
Greg Gruenhagen	55	Vice President, Corporate Quality and Regulatory Affairs

Mr. Gorder joined the Company in October 1993 when IntriCon Inc. was acquired by the Company. Mr. Gorder received a Bachelor of Arts degree in Mathematics from the St. Olaf College, a Bachelor of Science degree in Electrical Engineering from the University of Minnesota and a Master of Business Administration from the University of Minnesota. Prior to the acquisition, Mr. Gorder was President and one of the founders of IntriCon Inc., which began operations in 1977. Mr. Gorder was promoted to Vice President of the Company and elected to the Board of Directors in April 1996. In December 2000, he was elected President and Chief Operating Officer and in April 2001, Mr. Gorder assumed the role of Chief Executive Officer.

Mr. Longval has served as the Company's Chief Financial Officer since July 2006. Mr. Longval received a Bachelor

of Science degree in Accounting from the University of St. Thomas. Prior to being appointed as CFO, Mr. Longval served as the Company's Corporate Controller since September 2005. Prior to joining the Company, Mr. Longval was Principal Project Analyst at ADC Telecommunications, Inc., a provider of innovative network infrastructure products and services, from March 2005 until September 2005. From May 2002 until March 2005 he was employed by Accellent, Inc., formerly MedSource Technologies, a provider of outsourcing solutions to the medical device industry, most recently as Manager of Financial Planning and Analysis. From September 1998 until April 2002, he was employed by Arthur Andersen, most recently as experienced audit senior.

Mr. Conger joined the Company in September 1997. Mr. Conger received a Bachelor of Science degree in Electrical Engineering from the University of Missouri and a Master of Science degree in Electrical Engineering from the University of Minnesota. He has served as the Company's Vice President of Research and Development since February 2005. Prior to that, Mr. Conger served as Director of Research and Development since 1997.

Mr. Geraci joined the Company in October 1983. Mr. Geraci received a Bachelor of Science degree from Bradley University. He has served as the Company's Vice President of Sales and Marketing since January 1995.

Mr. Gonsior joined the Company in February 1982. Mr. Gonsior received a Bachelor of Science degree from Saint Cloud State University. He has served as the Company's Vice President of Operations since January 1996.

Mr. Binnix joined the Company in January 1989. Mr. Binnix is a Certified Manufacturing Engineer and received his Bachelor of Science degree from the University of LaVerne, California. He has served as the Company's Vice President of RTI Electronics, Inc. since April 2006 and as General Manager since 1993.

Mr. Gruenhagen joined the Company in November 1984. Mr. Gruenhagen received a Bachelor of Science degree from Iowa State University. He has served as the Company's Vice President of Corporate Quality and Regulatory Affairs since December 2007. Prior to that, Mr. Gruenhagen served as Director of Corporate Quality since 2004 and Director of Project Management since 2000.

PART II

ITEM 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Since January 2, 2008, the Company's common shares have been listed on the NASDAQ Global Market under the ticker symbol "IIN". From April 4, 2005 through January 1, 2008 the Company's common shares were listed on the American Stock Exchange under the ticker symbol "IIN".

Market and Dividend Information

The high and low sale prices of the Company's common stock during each quarterly period during the past two years were as follows:

	2008		2007	
	Market		Market	
	Price Range		Price Range	
Quarter	High	Low	High	Low
First	\$ 13.30	\$ 5.71	\$ 6.40	\$ 4.80
Second	10.07	7.10	7.89	5.75
Third	9.00	3.01	11.50	6.87
Fourth	6.50	3.12	15.54	9.20

The closing sale price of the Company's common stock on February 27, 2009, was \$4.10 per share.


At February 28, 2009 the Company had 336 shareholders of record of common stock. Such number of records does not reflect shareholders who beneficially own common stock in nominee or street name.

The Company ceased paying quarterly cash dividends in the fourth quarter of 2001 and has no intention of paying cash dividends in the foreseeable future. Any payment of future dividends will be at the discretion of the Board of Directors and will depend upon, among other things, the Company's earnings, financial condition, capital requirements, level of indebtedness, contractual restrictions with respect to the payment of dividends, and other factors that the Board of Directors deems relevant. Terms of the Company's banking agreements prohibit the payment of cash dividends without prior bank approval.

See "ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters — Equity Compensation Plans" of this Annual Report on Form 10-K for disclosure regarding our equity compensation plans.

Stock Performance Graph

The following graph shows the cumulative total return for the last five years, calculated as of December 31 of each such year, for the Common Shares, the Standard & Poor's 500 Index, and the Russell 2000 Index ("RUT"). The graph assumes that the value of the investment in each of three was \$100 at December 31, 2003 and that all dividends were reinvested.



Source: Yahoo Finance

Note: Stock price performance shown in this Performance Graph for our common stock is historical and not necessarily indicative of future price performance. The information contained in this Performance Graph is not “soliciting material” and has not been “filed” with the Securities and Exchange Commission. This Performance Graph will not be incorporated by reference into any of our future filings under the Securities Act of 1933 or the Securities Exchange Act of 1934.

ITEM 6. Selected Financial Data

Five-Year Summary of Operations*
(In thousands, except for per share and share data)

Years ended December 31,	<u>2008</u>	<u>2007 (a)</u>	<u>2006</u>	<u>2005</u>	<u>2004(b)</u> <u>Restated</u>
Sales, net	\$ 65,555	\$ 68,983	\$ 51,726	\$ 44,455	\$ 35,183
Cost of sales	49,509	51,739	39,304	32,853	27,121
Operating expenses	14,002	13,981	10,455	10,181	11,535
Interest expense	702	978	499	409	465
Interest income	(20)	(85)	(48)	(52)	(2)
Equity in earnings of partnerships	4	158	--	--	--
Gain on sale of asset	--	--	--	--	3,110
Other (income) expense, net	<u>56</u>	<u>164</u>	<u>102</u>	<u>(106)</u>	<u>(61)</u>
Income (loss) from continuing operations before income taxes and discontinued ops	1,302	2,048	1,415	1,171	(765)
Income tax expense	<u>264</u>	<u>181</u>	<u>174</u>	<u>409</u>	<u>1,140</u>
Income (loss) from continuing operations before discontinued operations	1,038	1,867	1,241	762	(1,905)
Income (loss) from discontinued operations, net of income taxes (Note 2)	--	--	(78)	767	1,369
Extraordinary gain from discontinued ops	<u>--</u>	<u>--</u>	<u>--</u>	<u>--</u>	<u>684</u>
Net income	<u>\$ 1,038</u>	<u>\$ 1,867</u>	<u>\$ 1,163</u>	<u>\$ 1,529</u>	<u>\$ 148</u>
Basic income (loss) per share:					
Continuing operations	\$.20	\$.36	\$.24	\$.15	\$(.37)
Discontinued operations	--	--	(.01)	.15	.27
Extraordinary gain discontinued operations	<u>--</u>	<u>--</u>	<u>--</u>	<u>--</u>	<u>.13</u>
Net income	<u>\$.20</u>	<u>\$.36</u>	<u>\$.23</u>	<u>\$.30</u>	<u>\$.03</u>
Diluted income (loss) per share:					
Continuing operations	\$.19	\$.34	\$.23	\$.14	\$(.37)
Discontinued operations	--	--	(.01)	.15	.27
Extraordinary gain discontinued operations	<u>--</u>	<u>--</u>	<u>--</u>	<u>--</u>	<u>.13</u>
Net income	<u>\$.19</u>	<u>\$.34</u>	<u>\$.22</u>	<u>\$.29</u>	<u>\$.03</u>
Weighted average number of Shares outstanding during year:					
Basic	5,314,387	5,209,567	5,159,216	5,135,348	5,129,214
Diluted	5,539,456	5,519,780	5,319,802	5,261,491	5,131,841

Other Financial Highlights*
(In thousands, except for per share data)

Years ended December 31,

	<u>2008</u>	<u>2007(a)</u>	<u>2006</u>	<u>2005</u>	<u>2004(b)</u> <u>Restated</u>
Working capital (c)	\$ 10,602	\$ 9,365	\$ 8,445	\$ 8,185	\$ 2,183
Total assets	\$ 39,462	\$ 39,732	\$ 34,143	\$ 29,237	\$ 30,939
Long-term debt	\$ 6,188	\$ 6,963	\$ 3,830	\$ 5,319	\$ --
Shareholders' equity:					
Capital stock and additional paid-in capital	\$ 19,980	\$ 19,205	\$ 18,046	\$ 17,719	\$ 17,670
Retained earnings (accumulated deficit)	1,915	878	(990)	(2,152)	(3,680)
Accumulated other comprehensive loss	(318)	(220)	(185)	(213)	(597)
Treasury stock	<u>(1,265)</u>	<u>(1,265)</u>	<u>(1,265)</u>	<u>(1,265)</u>	<u>(1,265)</u>
Total shareholders' equity	\$ 20,312	\$ 18,597	\$ 15,607	\$ 14,089	\$ 12,128
Depreciation and amortization	\$ 2,297	\$ 2,128	\$ 1,849	\$ 2,069	\$ 2,289

* See Note 1 and Note 13 to the Company's consolidated financial statements included herein for reclassifications and quarterly results of operations, respectively.

- (a) Included in the 2007 results and balances at December 31, 2007, are net sales of \$4.5 million, total assets of \$6.4 million, long-term debt of \$4.3 million, and depreciation and amortization of \$100,000 from the acquisition of Tibbetts Industries. Because the 2007 results and balances at December 31, 2007 include amounts from the acquisition of Tibbetts Industries, the financial statements for 2007 may not be comparable to our prior historical results.
- (b) For 2003, the Company reclassified the remaining portion of its Heat Technology business, which consisted of the burners and components portion of that business, as discontinued operations. The Company sold this portion of the business in the first quarter of 2005. For 2004 the Heat Technology business had revenues of \$9.7 million, with net income of \$2.1 million.
- (c) Working capital is equal to current assets less current liabilities.

ITEM 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

Company Overview

IntriCon Corporation, (the "Company" or "IntriCon", "we", "us" or "our") is an international firm engaged in the designing, developing, engineering and manufacturing of body-worn devices and electronic products. The Company serves the body-worn device market by designing, developing, engineering and manufacturing micro-miniature injection-molded plastics, microelectronics, micro-mechanical assemblies and complete assemblies, primarily for bio-telemetry devices, medical equipment, hearing instruments, electronics, professional audio and telecommunications devices and computers.

Currently, the Company has two operating segments, its body-worn device segment and electronics products segment. Our expertise in body-worn devices is focused on three main markets within this segment: medical, hearing health, and professional audio. Within these chosen markets, we combine ultra-miniature mechanical and electronics capabilities with proprietary technology that enhances the performance of body-worn devices.

Business Highlights

On July 20, 2008, the Company entered into a strategic alliance with Dynamic Hearing, a designer of proprietary DSP firmware used in ULP DSP hardware platforms for the hearing health and professional audio market. Dynamic Hearing granted a license to the Company to use certain of Dynamic Hearing's technology, including DSP and ULP technology. IntriCon intends to use the license from Dynamic Hearing to develop new body-worn ULP-DSP applications and expand its hearing health and professional audio product portfolio.

Forward-Looking Statements

The following discussion and analysis of our financial condition and results of operations should be read together with the selected consolidated financial data and our financial statements and the related notes appearing in Item 6. and Item 8. of this report. This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those under the heading "Risk Factors" in Item 1A of this Annual Report on Form 10-K.

Results of Operations: 2008 Compared with 2007

Consolidated Net Sales

Consolidated net sales for 2008 and 2007 were as follows (dollars in thousands):

	<u>2008</u>	<u>2007</u>	<u>Change</u>	
			<u>Dollars</u>	<u>Percent</u>
Consolidated net sales	\$65,555	\$68,983	\$3,428	(5.0%)

Our net sales are comprised of four main markets: hearing health, medical, and professional audio (collectively our body-worn device segment) and electronics (our electronics products segment).

We experienced an increase of 7 percent in net sales in the medical equipment market in 2008 as a direct result of increased sales to existing original equipment manufacturer, or OEM, customers. We believe there is an industry-wide trend toward further miniaturization and ambulatory operation enabled by wireless connectivity, referred to as bio-telemetry, which resulted in further growth in our medical business. We have experienced solid growth in our most advanced biotelemetry device, a continuous wireless glucose monitor, which we manufacture for a major medical OEM. We are also working with our strategic partner, Advanced Medical Electronics, on proprietary biotelemetry technologies that will enable us to develop new devices that connect patients and care givers, providing critical information and feedback.

Net sales in our hearing health business declined 19 percent from 2007 primarily due to lower demand from our customers in this market and the completion of a one-time hearing health project in the 2007 third and fourth quarters, which the customer took in-house in 2008. We expect the softness in the market will continue into 2009. Despite the anticipated short-term softness, we believe our longer term prospects in our hearing health business remain strong as we continue to develop advanced technologies, such as our nanoDSP™, which will enhance the performance of hearing devices. In addition, we believe the market indicators in the hearing health industry, including the aging world population, suggest long-term industry growth.

Net sales to the professional audio communications market grew 21 percent over the prior year fueled by a full year of revenue from our May 2007 acquisition of ITC and higher demand for communication devices from new and existing customers. Our professional audio communication business serves customers in need of high-performance portable communication devices. For customers focusing on homeland security needs, the line includes several communication devices that are more portable and perform well in noisy or hazardous environments. These products are also well suited for applications in the fire, law enforcement, safety, aviation and military markets.

Net sales to the electronics product sector decreased 18 percent from prior year, primarily due to lower demand from one customer. In addition, management made an effort to eliminate lower margin revenue from non-strategic customers and reduce the electronics business' cost structure in attempt to maximize profit from this segment.

Gross Profit

Gross profit, both in dollars and as a percent of sales, for 2008 and 2007, were as follows (dollars in thousands):

	<u>2008</u>		<u>2007</u>		<u>Change</u>	
	<u>Dollars</u>	<u>Percent</u>	<u>Dollars</u>	<u>Percent</u>	<u>Dollars</u>	<u>Percent</u>
Gross profit	\$16,046	24.5%	\$17,245	25.0%	(\$1,199)	(7.0%)

In 2008, gross profit dollars decreased primarily due to lower sales volume; gross profit as a percentage of sales decreased primarily as a result of the conclusion of the one-time hearing health program in 2007, general softness in hearing health and the decline in our electronics product segment. We have various activities underway to increase our gross margins, such as transferring our microphone and receiver production from our Maine operation to our lower cost Singapore facility, increasing the percentage of IntriCon proprietary content in the devices we manufacture and significant investments to introduce Six Sigma lean manufacturing methods into key medical device product lines.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the years ended December 31, 2008 and 2007 were (dollars in thousands):

	<u>2008</u>		<u>2007</u>		<u>Change</u>	
	<u>Dollars</u>	<u>Percent of Sales</u>	<u>Dollars</u>	<u>Percent of Sales</u>	<u>Dollars</u>	<u>Percent</u>
Selling	\$3,959	6.0%	\$4,034	5.8%	(\$ 75)	(1.9%)
Research and development	3,248	5.0%	3,089	4.5%	\$ 159	5.1%
General and administrative	6,796	10.4%	6,859	9.9%	(\$ 63)	(0.9%)

The decreased selling expenses for 2008 as compared to the prior year were primarily driven by decreases in royalties and commissions as a result of lower revenues. The decrease in general and administrative expenses were driven by cost control measures taken by the Company in conjunction with the revenue decreases, as well as lower professional and legal fees compared to the prior year offset, in part by a \$246,000 increase in stock based compensation expense. The 2007 expenses included significant costs related to the Energy Transportation Group, Inc. litigation and our acquisition of ITC. The increased research and development expenses as compared to the

prior year were due to our continued emphasis on investing in research and development projects to develop new products and technology to further enhance our product portfolio.

Net Interest Expense

Net interest expense for 2008 was \$682,000, a decrease of \$211,000 from \$893,000 in 2007. The decrease in net interest expense was due primarily to charges related to the refinancing of the credit facility that were incurred in 2007 in connection with the ITC acquisition and lower interest rates in effect on lower outstanding debt in 2008, offset in part by decreased interest income as a result of the lower balance of the note receivable.

Equity in Earnings of Partnerships

The equity in earnings of partnerships for 2008 was \$4,000 compared to \$158,000 in 2007.

The Company recorded a \$145,000 decrease in the carrying amount of its investment in the Hearing Instrument Manufacturers Patent Partnership (“HIMPP”) for 2008, reflecting amortization of the patents and other intangibles and the Company’s portion of the partnership’s operating results for the year ended December 31, 2008, compared to a \$333,000 decrease in the carrying amount of the investment in 2007 for the amortization of the patents and other intangibles and the Company’s portion of the partnership’s operating results for the year ended December 31, 2007.

The Company recorded a \$141,000 and \$175,000 increase in the carrying amount of ITC’s investment in a joint venture, reflecting the Company’s portion of the joint venture’s operating results for year ended December 31, 2008 and 2007, respectively.

Other

In 2008, other expense was \$56,000 compared to \$164,000 in 2007. The other expense for 2008 and 2007 primarily related to the losses on foreign currency exchange as a result of the exchange rate changes in the Singapore dollar and Euro.

Income Taxes

Income taxes were as follows (dollars in thousands):

	<u>2008</u>	<u>2007</u>
Income tax expense	\$ 264	\$ 181
Percentage of pre-tax income	20.3%	8.8%

The expense in 2008 and 2007 was primarily due to foreign taxes on German and Singapore operations. The Company is in a net operating loss position (“NOL”) for federal income tax purposes and, consequently, minimal income tax expense from the current period domestic operations was recognized. Our deferred tax asset related to the NOL carryforwards has been offset by a full valuation allowance. We estimate we have approximately \$13.5 million of NOL carryforwards available to offset future federal income taxes that begin to expire in 2022.

Results of Operations: 2007 Compared with 2006

Consolidated Net Sales

Consolidated net sales for 2007 and 2006 were as follows (dollars in thousands):

	<u>2007</u>	<u>2006</u>	<u>Change</u>	
			<u>Dollars</u>	<u>Percent</u>
Consolidated net sales	\$68,983	\$51,726	\$17,257	33.4%

Net sales in our hearing health business grew 17 percent from 2006 fueled by increased demand for the latest technology advancements in hearing devices, including our advanced line of amplifier assemblies and systems based on our proprietary nanoDSP technology.

We experienced an increase of 122 percent in net sales in the medical equipment market in 2007 as a direct result of increased sales to existing OEM customers. Exclusive of net sales resulting from the ITC acquisition, medical net sales increased 101 percent from 2006.

Net sales to the professional audio device product sector grew 44 percent over the prior year due to additional sales of microphones to a specific customer and additional sales resulting from the acquisition of ITC. Excluding the results from ITC, professional audio device sales grew 11 percent from 2006.

Net sales to the electronics product sector decreased 10 percent from prior year, primarily due to lower demand from one customer.

Gross Profit

Gross profit, both in dollars and as a percent of sales, for 2007 and 2006, were as follows (dollars in thousands):

	<u>2007</u>		<u>2006</u>		<u>Change</u>	
	<u>Dollars</u>	<u>Percent</u>	<u>Dollars</u>	<u>Percent</u>	<u>Dollars</u>	<u>Percent</u>
Gross profit	\$17,245	25.0%	\$12,422	24.0%	\$4,823	38.8%

In 2007, gross margin dollars increased due to the higher overall sales volume. Additionally, gross profit margin as a percentage of sales increased to 25 percent. Gross margin increase from 2006 was primarily due to increased IntriCon product content, proprietary technology and leverage gained on increased volume.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the years ended December 31, 2007 and 2006 were (dollars in thousands):

	<u>2007</u>		<u>2006</u>		<u>Change</u>	
	<u>Dollars</u>	<u>Percent of Sales</u>	<u>Dollars</u>	<u>Percent of Sales</u>	<u>Dollars</u>	<u>Yr-over-yr Incr.</u>
Selling	\$4,034	5.8%	\$3,410	6.6%	\$ 624	18.3%
Research and development	3,089	4.5%	2,123	4.1%	\$ 966	45.5%
General and administrative	6,859	9.9%	4,922	9.5%	\$1,937	39.4%

The increased selling, research and development and general and administrative expenses in 2007 as compared to the prior year were primarily driven by the expenses incurred to adequately support our growth and the May 22, 2007 acquisition of ITC. ITC operating expenses for the year were \$1.0M. The Company made continued efforts to invest in strategic research and development opportunities in 2007.

Net Interest Expense

Net interest expense for 2007 was \$893,000, an increase of \$442,000 from \$451,000 in 2006. The increase from the prior year's expense was primarily due to the higher outstanding debt balance, a prepayment penalty of \$110,000 related to debt which was paid off early as a result of refinancing our debt at the time we acquired ITC, partly offset by a decrease in the average interest rate compared to the prior year. The higher outstanding debt balance was primarily driven by the debt related to the purchase of ITC.

Equity in Earnings of Partnerships

Equity in earnings of partnerships for 2007 resulted in a net loss of \$158,000. This represents the Company's portion of the operating results of equity method investments, as well as amortization of the excess of the HIMPP investment over the underlying partnership assets.

Other

In 2007, other expense was \$164,000 compared to \$102,000 in 2006. The other expense for 2007 and 2006 primarily related to the loss on foreign currency exchange.

Income Taxes

Income taxes were as follows (dollars in thousands):

	<u>2007</u>	<u>2006</u>
Income tax expense	\$ 181	\$ 174
Percentage of pre-tax income	8.8%	12.3%

The expense in 2007 and 2006 was primarily due to foreign taxes on German and Singapore operations. On February 22, 2006, the Company received approval from the Singapore Ministry of Trade and Industry to lower the effective tax rate in Singapore from 20% to 13%. This change was retroactive to September 2003. As such a \$106,000 benefit was recognized in the first quarter of 2006.

Discontinued Operations

We recorded a loss from discontinued operations as follows (dollars in thousands):

	2007	2006
Loss from discontinued Heat Technology Business	\$ --	\$ (78)

Heat Technology Segment

The 2006 net loss of \$(78,000), or \$(0.01) per diluted share, was primarily due to a write-off of a portion of the note receivable recorded upon sale of the assets.

Liquidity and Capital Resources

Our primary sources of cash have been cash flows from operations, bank borrowings, and other financing transactions such as sale-leaseback transactions and capital leases. For the last three years, cash has been used for repayments of bank borrowings, the ITC acquisition, purchases of equipment, and working capital to support research and development.

As of December 31, 2008, we had approximately \$0.2 million of cash on hand. Sources of our cash for the year ended December 31, 2008 have been from our operations, as described below.

Consolidated net working capital increased to \$10.6 million at December 31, 2008 from \$9.4 million at December 31, 2007. Our cash flows from operating, investing and financing activities, as reflected in the statement of cash flows at December 31, are summarized as follows (dollars in thousands):

	<u>2008</u>	<u>2007</u>	<u>2006</u>
Cash provided (used) by:			
Continuing operations	\$ 2,452	\$ 3,534	\$ 1,656
Discontinued operations	--	--	(78)
Investing activities	(98)	(7,060)	(565)
Financing activities	(2,480)	3,740	(1,308)
Effect of exchange rate changes on cash	<u>(6)</u>	<u>8</u>	<u>14</u>
Increase (decrease) in cash	<u>\$ (132)</u>	<u>\$ 221</u>	<u>\$ (281)</u>

Operating Activities. The most significant items that contributed to the \$2.5 million of cash provided by continuing operations were net income of \$1.0 million, depreciation of \$2.4 million and changes in operating assets and liabilities of \$(1.2) million. The change in operating assets and liabilities was primarily due to increases in accounts receivable and decreases in accounts payable and accrued expenses, partially offset by decreases in inventory and other assets. The change in accounts receivable and accounts payable are primarily due to the timing of sales, payments received from customers and payments made to vendors.

Investing Activities. The most significant items that contributed to the \$0.1 million of cash used by investing activities were purchases of property, plant and equipment of \$1.5 million partially offset by \$1.1 million of net cash received from equipment sales and \$0.2 million of dividends received.

Financing Activities. Net cash used by financing activities of \$2.5 million was comprised primarily of net payments of debt of \$2.3 million.

Cash generated from operations may be affected by a number of factors. See “Forward Looking Statements” and “Item 1A: Risk Factors” contained herein for a discussion of some of the factors that can negatively impact the amount of cash we generate from our operations.

We had the following bank arrangements at December 31, (dollars in thousands):

	<u>2008</u>	<u>2007</u>
Total availability under existing facilities	<u>\$13,243</u>	<u>\$13,623</u>
Borrowings and commitments:		
Domestic credit facility	3,000	3,000
Domestic term loans	2,756	4,275
Foreign overdraft and letter of credit facility	605	1,071
Capital leases	<u>1,330</u>	<u>94</u>
Total borrowings and commitments	7,691	8,440
Remaining availability under existing facilities	<u>\$ 5,552</u>	<u>\$ 5,183</u>

The Company and its subsidiaries, IntriCon, Inc., RTI Electronics, Inc. and IntriCon Tibbetts Corporation, referred to as the borrowers, entered into a credit facility with LaSalle Bank, National Association (now Bank of America), referred to as the lender, on May 22, 2007 replacing the prior credit facilities with M & I Business Credit (formerly known as Diversified Business Credit, Inc.). The credit facility provides for:

- a \$10,000,000 revolving credit facility, with a \$200,000 subfacility for letters of credit. Under the revolving credit facility, the availability of funds depends on a borrowing base composed of stated percentages of our eligible trade receivables and eligible inventory, less a reserve.
- a \$4,500,000 term loan, which was used to fund the Tibbetts acquisition.

Loans under the new credit facility are secured by a security interest in substantially all of the assets of the borrowers including a pledge of the stock of the subsidiaries. All of the borrowers are jointly and severally liable for all borrowings under the new credit facility.

Proceeds from the new facility were used to repay amounts owed under the prior credit facilities of approximately \$5.0 million and the \$4.5 million purchase price to complete the Tibbetts asset acquisition.

Loans under the new credit facility bear interest, at the option of the Company, at:

- the London InterBank Offered Rate (“LIBOR”) plus 1.90%, in the case of revolving line of credit loans, or LIBOR plus 2.15%, in the case of the term loan, or
- the base rate, which is the higher of (a) the rate publicly announced from time to time by the lender as its “prime rate” and (b) the Federal Funds Rate plus 0.5%.

Interest is payable monthly in arrears, except that interest on LIBOR based loans is payable at the end of the one, two or three month interest periods applicable to LIBOR based loans, or every three months in the case of LIBOR based loans with a six month interest period.

Weighted average interest on the domestic asset-based revolving credit facilities (including the prior credit facility) was 5.51% and 7.82% for 2008 and 2007, respectively.

The new credit facility will expire and all outstanding loans will become due and payable on June 30, 2012. The term loan requires quarterly principal payments, commencing on September 30, 2007, based on an increasing installment schedule, with any balance due on June 30, 2012. The principal balance of the term loan was \$2,756,250 and \$4,275,000 at December 31, 2008 and 2007, respectively. In 2008, we used proceeds of \$1,013,000 from the equipment sale-leaseback described below to pay down the term loan.

The outstanding balance of the revolving credit facility was \$3,000,000 at December 31, 2008 and 2007, respectively. The total remaining availability on the revolving credit facility was approximately \$4,349,000 and \$4,443,000 at December 31, 2008 and 2007, respectively.

The revolving facility carries a non-use fee equal to 0.25% per year of the unused portion of the revolving line of credit facility, payable quarterly in arrears.

The Company is subject to various covenants under the credit facility, including financial covenants relating to tangible net worth, funded debt to Earnings Before Interest, Taxes, Depreciation and Amortization, fixed charge coverage ratio and capital expenditures. Under the credit facility, except as otherwise permitted, the borrowers may not, among other things, incur or permit to exist any indebtedness; grant or permit to exist any liens or security interests on their assets or pledge the stock of any subsidiary; make investments; be a party to any merger or consolidation, or purchase of all or substantially all of the assets or equity of any other entity; sell, transfer, convey or lease all or any substantial part of its assets or capital securities; sell or assign, with or without recourse, any receivables; issue any capital securities; make any distribution or dividend (other than stock dividends), whether in cash or otherwise, to any of its equityholders; purchase or redeem any of its equity interests or any warrants, options or other rights in respect thereof; enter into any transaction with any of its affiliates or with any director, officer or employee of any borrower; be a party to any unconditional purchase obligations; cancel any claim or debt owing to it; enter into any agreement inconsistent with the provisions of the credit facility or other agreements and documents entered into in connection with the credit facility; engage in any line of business other than the businesses engaged in on the date of the credit facility and businesses reasonably related thereto; or permit its charter, bylaws or other organizational documents to be amended or modified in any way which could reasonably be expected to materially adversely affect the interests of the lender. Effective as of September 30, 2007, the credit facility was amended to change the tangible net worth covenant. Effective as of June 30, 2008, the credit facility was amended to correct an error in the amortization table set forth in the loan agreement. Effective as of December 31, 2008, the credit facility was amended to change the fixed charge coverage covenant to exclude payments made in connection with the June 2008 sale leaseback described below. As of December 31, 2008, the Company was in compliance with all financial covenants under the credit facility, as amended.

Upon the occurrence and during the continuance of an event of default (as defined in the credit facility), the lender may, among other things: terminate its commitments to the borrowers (including terminating or suspending its obligation to make loans and advances); declare all outstanding loans, interest and fees to be immediately due and payable; take possession of and sell any pledged assets and other collateral; and exercise any and all rights and

remedies available to it under the Uniform Commercial Code or other applicable law. In the event of the insolvency or bankruptcy of any borrower, all commitments of the lender will automatically terminate and all outstanding loans, interest and fees will be immediately due and payable. Events of default include, among other things: failure to pay any amounts when due; material misrepresentation; default in the performance of any covenant, condition or agreement to be performed that is not cured within 20 days after notice from the lender; default in the payment of other indebtedness or other obligation with an outstanding principal balance of more than \$50,000, or of any other term, condition or covenant contained in the agreement under which such obligation is created, the effect of which is to allow the other party to accelerate such payment or to terminate the agreements; the insolvency or bankruptcy of any borrower; the entrance of any judgment against any borrower in excess of \$50,000, which is not fully covered by insurance; the occurrence of a change in control (as defined in the credit facility); certain collateral impairments; and a contribution failure with respect to any employee benefit plan that gives rise to a lien under ERISA.

The prior credit facility provided for:

- a \$5,500,000 domestic revolving credit facility, bearing interest at an annual rate equal to the greater of 5.25%, or 0.5% over prime. Under the revolving credit facility, the availability of funds depended on a borrowing base composed of stated percentages of our eligible trade receivables and eligible inventory, less a reserve.
- a \$1,000,000 domestic equipment term loan, bearing interest at an annual rate equal to the greater of 5.25%, or 0.75% over the prime rate.

The revolving facility carried a commitment fee of 0.25% per year, payable on the unborrowed portion of the line. Additionally, the credit facility required an annual fee of \$27,500 due on August 31, 2007, and 2008. Upon termination of the credit facility by us prior to maturity, the Company was required to pay a termination fee equal to 2% of the total of the maximum amount available under the revolving credit facility, equal to \$110,000, which is included in interest expense, plus the amounts then outstanding under the term loan.

The credit facility originally included a real estate loan with an original principal balance of \$1,500,000, which was associated with our Vadnais Heights manufacturing facility. In June 2006, the Company completed a sale-leaseback of the Vadnais Heights manufacturing facility. The transaction generated proceeds of \$2,650,000, of which \$1,388,000 was used to repay the associated real estate loan and the remainder to pay down our domestic revolver. The remaining gain on the sale of \$825,631 is being recognized over the initial 10-year lease term as the renewal options in the lease are not assured and a penalty does not exist if we do not exercise the renewal options.

In addition to its domestic credit facilities, the Company's wholly-owned subsidiary, IntriCon, PTE LTD., entered into an international senior secured credit agreement with Oversea-Chinese Banking Corporation Ltd. that provides for a \$1.8 million line of credit. Borrowings bear interest at a rate of .75% to 2.5% over the lender's prevailing prime lending rate. Weighted average interest on the international credit facilities was 5.84% and 6.36% for 2008 and 2007, respectively. The outstanding balance was \$605,000 and \$1,071,000 at December 31, 2008 and 2007, respectively. The total remaining availability on the international senior secured credit agreement was approximately \$1,203,000 and \$740,000 at December 31, 2008 and 2007, respectively.

In June 2008, the Company completed a sale-leaseback of machinery and equipment with Bank of America. The transaction generated proceeds of \$1,098,000, of which \$1,013,000 was used to pay down the domestic term loan. The capital lease agreement expires in June 2014, requires monthly payments of \$15,800 and has a present value of future minimum lease payments of \$1,098,000 with an effective interest rate of 5.14%. The transaction resulted in a gain of \$62,000 which is being recognized over the initial 6-year lease term.

The Company also has entered into several other capital lease agreements to fund the acquisition of machinery and equipment. The total principal amount of all capital leases (including the equipment sale-leaseback described above) was \$1,661,000 with effective interest rates ranging from 5.1% to 8.0%. These agreements range from 3 to 6 years. The outstanding balance under these capital lease agreements at December 31, 2008 and December 31, 2007 was \$1,330,000 and \$94,000, respectively. The accumulated amortization on leased equipment was \$257,000 and \$119,000 at December 31, 2008 and 2007, respectively. The amortization of capital leases is included in depreciation expense for 2008 and 2007.

We believe that funds expected to be generated from operations, the available borrowing capacity through our revolving credit loan facilities and the control of capital spending will be sufficient to meet our anticipated cash requirements for operating needs for at least the next 12 months. If, however, we do not generate sufficient cash from operations, or if we incur additional unanticipated liabilities, we may be required to seek additional financing or sell equity or debt on terms which may not be as favorable as we could have otherwise obtained. No assurance can be given that any refinancing, additional borrowing or sale of equity or debt will be possible when needed or that we will be able to negotiate acceptable terms. In addition, our access to capital is affected by prevailing conditions in the financial and equity capital markets, as well as its own financial condition. While management believes that we will be able to meet our liquidity needs for at least the next 12 months, no assurance can be given that we will be able to do so.

Contractual Obligations

The following table represents our contractual obligations and commercial commitments, excluding interest expense, as of December 31, 2008.

<u>Contractual Obligations</u>	<u>Payments Due by Period</u>				
	<u>Total</u>	<u>Less than 1 Year</u>	<u>1-3 Years</u>	<u>4-5 Years</u>	<u>More than 5 Years</u>
Domestic credit facility	\$ 3,000,000	\$ --	\$ --	\$ 3,000,000	\$ --
Domestic term loan	2,756,250	731,250	2,025,000	--	--
Foreign overdraft and letter of credit facility	605,423	557,777	47,646	--	--
Amecon acquisition payments	259,360	259,360	--	--	--
Partnership payable	1,020,000	260,000	520,000	240,000	--
Dynamic Hearing license payments	1,000,000	475,000	525,000	--	--
Pension other post retirement benefit obligations	1,574,652	184,760	780,470	364,520	244,902
Capital leases	1,330,012	214,735	387,418	412,324	315,535
Operating leases	<u>5,606,566</u>	<u>1,587,816</u>	<u>2,079,981</u>	<u>883,240</u>	<u>1,055,530</u>
Total contractual cash obligations	<u>\$ 17,152,263</u>	<u>\$ 4,270,698</u>	<u>\$ 6,365,515</u>	<u>\$ 4,900,084</u>	<u>\$ 1,615,967</u>

There are certain provisions in the underlying contracts that could accelerate our contractual obligations as noted above.

Foreign Currency Fluctuation

Generally, the effect of changes in foreign currencies on our results of operations is partially or wholly offset by our ability to make corresponding price changes in the local currency. From time to time, the impact of fluctuations in foreign currencies may have a material effect on the financial results of the Company. Foreign currency transaction amounts included in the statements of operation include losses of \$77,000, \$112,000 and \$100,000 in 2008, 2007 and 2006, respectively. See Note 11 to the Company's consolidated financial statements included herein.

Off-Balance Sheet Obligations

We had no material off-balance sheet obligations as of December 31, 2008.

Related Party Transactions

For a discussion of related party transactions, see Note 16 to the Company's consolidated financial statements included herein.

Litigation

For a discussion of litigation, see “Item 3. Legal Proceedings” and Note 15 to the Company’s consolidated financial statements included herein.

New Accounting Pronouncements

See “New Accounting Pronouncements” set forth in Note 1 of the Notes to the Consolidated Financial Statements under Item 8 of this Annual Report on Form 10-K, for information pertaining to recently adopted accounting standards or accounting standards to be adopted in the future.

Critical Accounting Policies and Estimates

The significant accounting policies of the Company are described in Note 1 to the consolidated financial statements and have been reviewed with the audit committee of our Board of Directors. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period.

Certain accounting estimates and assumptions are particularly sensitive because of their importance to the consolidated financial statements and possibility that future events affecting them may differ markedly. The accounting policies of the Company with significant estimates and assumptions are described below.

Revenue Recognition

Our continuing operations recognize revenue when products are shipped and the customer takes ownership and assumes risk of loss, collection of the relevant receivable is probable, persuasive evidence of an arrangement exists and the sales price is fixed or determinable. Under contractual terms, shipments are generally FOB shipment point.

Customers have 30 days to notify the Company if the product is damaged or defective. Beyond that, there are no significant obligations that remain after shipping other than warranty obligations. Contracts with customers do not include product return rights; however, we may elect in certain circumstances to accept returns for product. We record revenue for product sales net of returns. Net sales also include amounts billed to customers for shipping and handling, if applicable. The corresponding shipping and handling costs are included in the cost of sales.

In general, we warrant our products to be free from defects in material and workmanship and will fully conform to and perform to specifications for a period of one year. While our warranty costs have historically been within our expectations, we cannot guarantee that we will continue to experience the same warranty return rates or repair costs that we have experienced in the past.

Accounts Receivable Reserves

This reserve is an estimate of the amount of accounts receivable that are uncollectible. The reserve is based on a combination of specific customer knowledge, general economic conditions and historical trends. Management believes the results could be materially different if economic conditions change for our customers.

Inventory Valuation

Inventory is recorded at the lower of our cost or market value. Market value is an estimate of the future net realizable value of our inventory. It is based on historical trends, product life cycles, forecast of future inventory needs and on-hand inventory levels. Management believes reserve levels could be materially affected by changes in technology, our customer base, customer needs, general economic conditions and the success of certain Company sales programs.

Discontinued Operations

We continuously assess the return on our business segments. When management with the appropriate level of authority determines that a plan is in place to restructure the operations of a business or discontinue an operation, contractual commitments and obligations are recorded. See the discussion in Note 2 to the consolidated financial statements.

Goodwill

We perform an annual assessment of the carrying value of goodwill. As part of this assessment, we estimate future cash flows, as well as making a risk assessment of investing in our company versus other investment opportunities. Changes in either the risk assessment or estimated future cash flows could have a material adverse impact on the carrying value of goodwill.

Long-lived Assets

The carrying value of long-lived assets is periodically assessed to insure their carrying value does not exceed their estimated net realizable future value. This assessment includes certain assumptions related to future needs for the asset to help generate future cash flow. Changes in those assessments, future economic conditions or technological changes could have a material adverse impact on the carrying value of these assets.

Deferred Taxes

The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities and projected future taxable income in making this assessment. Actual future operating results, as well as changes in our future performance, could have a material adverse impact on the valuation reserves.

Employee Benefit Obligations

We provide retirement and health care insurance for certain domestic retirees and employees. We measure the costs of our obligation based on our best estimate. The net periodic costs are recognized as employees render the services necessary to earn the post-retirement benefit. Several assumptions and statistical variables are used in the models to calculate the expense and liability related to the plans. We determine assumptions about the discount rate, the expected rate of return on plan assets and the future rate of compensation increases. The actuarial models also use assumptions on demographic factors such as retirement, mortality and turnover. Changes in actuarial assumptions could vary materially from actual results due to economic events and different rates of retirement, mortality and withdrawal.

ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk

Our consolidated cash flows and earnings are subject to fluctuations due to changes in foreign currency exchange rates and interest rates.

Foreign Currency Risk

We attempt to limit our exposure to changing foreign currency exchange rates through operational and financial market actions. We do not hold derivatives for trading purposes.

We manufacture and sell our products in a number of locations around the world, resulting in a diversified revenue and cost base that is exposed to fluctuations in European and Asian currencies. This diverse base of foreign currency revenues and costs serves to create a hedge that limits our net exposure to fluctuations in these foreign currencies.

Short-term exposures to changing foreign currency exchange rates are occasionally managed by financial market transactions, principally through the purchase of forward foreign exchange contracts (with maturities of six months or less) to offset the earnings and cash flow impact of the nonfunctional currency denominated receivables and payables relating to select contracts. The decision by management to hedge any such transaction is made on a case-by-case basis. Foreign exchange forward contracts are denominated in the same currency as the receivable or payable being covered, and the term and amount of the forward foreign exchange contract substantially mirrors the term and amount of the underlying receivable or payable. The receivables and payables being covered arise from bank debt, trade and intercompany transactions of and among our foreign subsidiaries. At December 31, 2008, we did not have any forward foreign exchange contracts outstanding. We cannot assure you that foreign currency fluctuations will not have a material adverse impact on our financial condition and results of operations.

All assets and liabilities of foreign operations with foreign functional currency are translated into U.S. dollars at prevailing rates of exchange in effect at the balance sheet date. Revenues and expenses are translated using average rates of exchange for the year. The functional currency of the Company's German operations is the European Euro. As of January 1, 2006, the functional currency of the Company's Singapore operations changed from the Singapore dollar to the U.S. dollar. Adjustments resulting from the process of translating the financial statements of foreign subsidiaries into U.S. dollars are reported as a separate component of shareholders' equity, net of tax, where appropriate. Foreign currency transaction amounts included in the statements of operation include losses of \$77,000, \$112,000 and \$100,000 in 2008, 2007 and 2006, respectively. Based on our 2008 results of operations, if foreign currency exchange rates were to strengthen/weaken by 25% against the U.S. dollar, we would expect a resulting pre-tax loss/gain of approximately \$1.6 million.

For more information regarding foreign currency risks, see "Foreign Currency Fluctuation – Item 7 on page 32 of this Annual Report on Form 10-K.

Interest Rate Risk

At December 31, 2008, we had \$6.4 million in outstanding variable rate borrowings. A material change in interest rates could adversely affect our operating results and cash flows. A 100 basis-point increase in interest rates would increase our annual interest expense by \$10,000 for each \$1.0 million of variable debt outstanding for the entire year. Based on our average variable rate borrowings outstanding in 2008, a 100 basis-point increase in interest rates would have resulted in additional interest expense of \$83,000.

The Company uses derivative financial instruments in the form of interest rate swaps in managing its interest rate exposure. The Company does not hold or issue derivative financial instruments for trading purposes. When entered into, the Company formally designates the derivative financial instrument as a hedge of a specific underlying exposure if such criteria are met, and documents both the risk management objectives and strategies for undertaking the hedge. The Company formally assesses, both at inception and at least quarterly thereafter, whether the derivative financial instruments that are used in hedging transactions are effective at offsetting changes in either the fair value or cash flows of the related underlying exposure. Because of the high correlation between the derivative financial instrument and the underlying exposure being hedged, fluctuations in the value of the derivative financial instruments are generally offset by changes in the fair values or cash flows of the underlying exposures being

hedged. Any ineffective portion of a derivative financial instrument's change in fair value would be immediately recognized in earnings.

The swaps are designated as cash flow hedges with the changes in fair value recorded in accumulated other comprehensive loss and as a derivative hedge asset or liability, as applicable. The swaps settle periodically in arrears with the related amounts for the current settlement period payable to, or receivable from, the counter-parties included in accrued liabilities or accounts receivable and recognized in earnings as an adjustment to interest expense from the underlying debt to which the swap is designated. During 2008, approximately \$40,000 of additional expense was recorded as a result of said adjustments. During 2008, ineffectiveness from such hedges was \$0.

At December 31, 2008, the Company had a United States Dollar ("USD") denominated interest rate swap outstanding which effectively fixed the interest rate on floating rate debt, exclusive of lender spreads, at 5.36% for a notional principal amount of \$2,000,000 through September 2010. The derivative net loss on this contract recorded in accumulated other comprehensive loss at December 31, 2008 was \$136,248, which is expected to be reclassified from Accumulated other comprehensive loss into earnings over the next 21 months, the life of the agreement.

ITEM 8. Financial Statements and Supplementary Data

Management's Report on Internal Control over Financial Reporting

Management of IntriCon Corporation and its subsidiaries ("the Company") is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) of the Securities Exchange Act of 1934. The Company's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company's internal control over financial reporting includes those policies and procedures that (1) pertain to maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness of internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The Company's management assessed the effectiveness of the Company's internal control over financial reporting as of December 31, 2008, using criteria set forth in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, the Company's management believes that, as of December 31, 2008, the Company's internal control over financial reporting was effective based on those criteria.

This annual report does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management's report in this annual report.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders, Audit Committee and Board of Directors
IntriCon Corporation and Subsidiaries
Minneapolis, Minnesota

We have audited the accompanying consolidated balance sheets of IntriCon Corporation and Subsidiaries as of December 31, 2008 and 2007, and the related consolidated statements of operations, shareholders' equity and comprehensive income and cash flows for each of the years in the three-year period ended December 31, 2008. These consolidated financial statements are the responsibility of the company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of its internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management as well as evaluating the overall consolidated financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of IntriCon Corporation and Subsidiaries as of December 31, 2008 and 2007 and the results of their operations and their cash flows for each of the years in the three-year period ended December 31, 2008, in conformity with U.S. generally accepted accounting principles.

/s/ Virchow, Krause & Company, LLP

Minneapolis, Minnesota
March 3, 2009

IntriCon Corporation
Consolidated Statements of Operations
Years ended December 31

	<u>2008</u>	<u>2007</u>	<u>2006</u>
Sales, net	\$ 65,555,056	\$ 68,983,380	\$ 51,725,952
Costs of sales	<u>49,509,290</u>	<u>51,738,573</u>	<u>39,304,003</u>
Gross profit	16,045,766	17,244,807	12,421,949
Operating expenses:			
Selling expense	3,958,758	4,034,135	3,410,226
General and administrative expense	6,795,607	6,858,582	4,921,818
Research and development expense	<u>3,247,767</u>	<u>3,088,770</u>	<u>2,122,594</u>
Total operating expenses	14,002,132	13,981,487	10,454,638
Operating income	2,043,634	3,263,320	1,967,311
Interest expense	702,217	978,145	498,521
Interest income	(19,889)	(84,524)	(48,003)
Equity in earnings of partnerships	3,652	157,500	--
Other expense, net	<u>55,986</u>	<u>164,288</u>	<u>101,831</u>
Income from continuing operations before income taxes and discontinued operations ..	1,301,668	2,047,911	1,414,962
Income tax expense	<u>264,067</u>	<u>180,673</u>	<u>174,460</u>
Income before discontinued operations	1,037,601	1,867,238	1,240,502
Loss from discontinued operations, net of income taxes (Note 2)	--	--	(77,990)
Net income	<u>\$ 1,037,601</u>	<u>\$ 1,867,238</u>	<u>\$ 1,162,512</u>
Basic income (loss) per share:			
Continuing operations	\$.20	\$.36	\$.24
Discontinued operations	--	--	(.01)
Net income	<u>\$.20</u>	<u>\$.36</u>	<u>\$.23</u>
Diluted income (loss) per share:			
Continuing operations	\$.19	\$.34	\$.23
Discontinued operations	--	--	(.01)
Net income	<u>\$.19</u>	<u>\$.34</u>	<u>\$.22</u>

See accompanying notes to the consolidated financial statements.

Consolidated Balance Sheets

At December 31,

Assets	<u>2008</u>	<u>2007</u>
Current assets		
Cash.....	\$ 249,396	\$ 381,247
Restricted cash.....	385,916	398,514
Accounts receivable, less allowance for doubtful accounts of \$389,000 at December 31, 2008 and \$259,000 at December 31, 2007.....	9,524,743	8,408,149
Inventories.....	8,852,028	9,835,060
Refundable income taxes.....	27,645	28,297
Note receivable from sale of discontinued operations, less allowance of \$0 and \$225,000 at December 31, 2008 and 2007, respectively.....	225,000	75,000
Other current assets.....	<u>758,193</u>	<u>775,206</u>
Total current assets.....	20,022,921	19,901,473
Property, plant and equipment.....		
Machinery and equipment.....	38,016,681	36,959,184
Less: accumulated depreciation and amortization.....	<u>30,103,771</u>	<u>28,500,318</u>
Net property, plant and equipment.....	7,912,910	8,458,866
Goodwill.....	8,266,438	8,238,020
Investment in partnerships.....	1,386,774	1,590,426
Other assets, net.....	<u>1,872,774</u>	<u>1,543,127</u>
	<u>\$ 39,461,817</u>	<u>\$ 39,731,912</u>

See accompanying notes to the consolidated financial statements.

At December 31,

Liabilities and Shareholders' Equity	<u>2008</u>	<u>2007</u>
Current liabilities		
Checks written in excess of cash	\$ 95,082	\$ 266,027
Current maturities of long-term debt	1,503,762	1,476,665
Accounts payable	3,149,671	3,965,914
Income tax payable	39,997	74,549
Deferred gains	120,478	110,084
Partnership payable	260,000	260,000
Other accrued liabilities	<u>4,251,707</u>	<u>4,382,755</u>
Total current liabilities	9,420,697	10,535,994
Long-term debt, less current maturities	6,187,923	6,963,410
Other post-retirement benefit obligations	760,608	816,532
Partnership payable	760,000	1,020,000
Dynamic Hearing license agreement payable	525,000	--
Note payable, net of current portion (Amecon)	--	259,360
Deferred income taxes	155,273	89,273
Accrued pension liability	578,388	624,517
Deferred gains	761,456	825,631
Total liabilities	<u>19,149,345</u>	<u>21,134,717</u>
Commitments and contingencies (notes 7 and 15)		
Shareholders' equity		
Common shares, \$1.00 par value per share; 20,000,000 and 10,000,000 shares authorized; 5,858,006 and 5,813,491 shares issued; 5,342,252 and 5,297,737 outstanding at December 31, 2008 and 2007, respectively	5,858,006	5,813,491
Additional paid-in capital	14,121,772	13,391,449
Retained earnings	1,915,334	877,733
Accumulated other comprehensive loss	<u>(317,562)</u>	<u>(220,400)</u>
	21,577,550	19,862,273
Less: 515,754 common shares held in treasury, at cost	<u>(1,265,078)</u>	<u>(1,265,078)</u>
Total shareholders' equity	<u>20,312,472</u>	<u>18,597,195</u>
	<u>\$39,461,817</u>	<u>\$39,731,912</u>

See accompanying notes to the consolidated financial statements.

Consolidated Statements of Cash Flows

Years ended December 31,	<u>2008</u>	<u>2007</u>	<u>2006</u>
Cash flows from operating activities:			
Net income	\$ 1,037,601	\$ 1,867,238	\$ 1,162,512
Adjustments to reconcile net income to net cash provided (used) by operating activities:			
Loss from discontinued operations	--	--	77,990
Depreciation and amortization	2,425,704	2,127,568	1,849,354
Stock-based compensation	525,972	280,376	213,531
Gains on sale of property and equipment	(1,900)	(3,858)	(334)
Deferred taxes	66,000	10,000	41,548
Change in deferred gain	(110,084)	(110,084)	(55,033)
Allowance for doubtful accounts	130,134	(11,670)	(124,651)
Allowance for note receivable	(225,000)	--	78,923
Equity in earnings of partnerships including impact of amortization expense	3,652	157,500	--
Changes in operating assets and liabilities:			
Accounts receivable	(1,247,981)	1,242,457	(1,379,448)
Inventories	949,367	(4,607)	(2,119,322)
Other assets	507,371	(476,464)	210,846
Accounts payable	(822,795)	(1,966,327)	2,024,771
Accrued expenses	(553,654)	445,585	(123,553)
Customers advance payments on contracts	(190,062)	10,229	--
Other liabilities	(42,498)	(34,631)	(200,745)
Net cash provided by continuing operations	2,451,827	3,533,313	1,656,389
Net cash used by discontinued operations	--	--	(77,990)
Net cash provided by operating activities	2,451,827	3,533,313	1,578,399
Cash flows from investing activities:			
Purchases of property, plant and equipment	(1,473,563)	(2,763,217)	(3,180,322)
Cash paid for acquisition of assets of Amecon, Inc	--	--	(3,141)
Cash paid for acquisitions, net of cash received	--	(4,606,251)	--
Proceeds from dividend received from joint venture	200,000	--	--
Proceeds from sales of property, plant and equipment	1,100,091	9,169	2,568,363
Proceeds from note receivable	75,000	300,000	50,000
Net cash used by investing activities	(98,472)	(7,060,299)	(565,100)
Cash flows from financing activities:			
Proceeds from short-term borrowings	--	--	425,513
Proceeds from stock purchases and exercise of stock options	236,633	872,221	113,534
Repayments of short-term borrowings	(370,760)	--	(142,382)
Proceeds from long term borrowings	14,752,253	9,483,583	2,654,034
Repayments of long-term debt	(16,664,066)	(6,093,137)	(4,622,893)
Payments of partnership payable	(260,000)	(260,000)	(260,000)
Change in restricted cash	(2,710)	(4,983)	--
Change in checks written in excess of cash	(170,945)	(257,842)	523,869
Net cash provided (used) by financing activities	(2,479,595)	3,739,842	(1,308,325)
Effect of exchange rate changes on cash	(5,611)	8,461	14,314
Increase (decrease) in cash	(131,851)	221,317	(280,712)
Cash beginning of year	381,247	159,930	440,642
Cash end of year	\$ 249,396	\$ 381,247	\$ 159,930

See accompanying notes to the consolidated financial statements.

Consolidated Statements of Shareholders' Equity and Comprehensive Income
Years ended December 31, 2008, 2007 and 2006

	Common Stock Number of Shares	Common Stock \$ Amount	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive Loss	Comprehensive Income	Treasury Stock	Total Shareholders' Equity
Balance December 31, 2005	5,665,568	\$5,665,568	\$12,053,590	\$(2,152,017)	\$(212,552)		\$(1,265,078)	\$14,089,511
Exercise of stock options	40,667	40,667	72,867					113,534
Stock option expense			213,531					213,531
Net income				1,162,512		\$ 1,162,512		1,162,512
Translation gain, net of income taxes of \$0					27,878	27,878		27,878
Comprehensive income						<u>\$ 1,190,390</u>		
Balance December 31, 2006	5,706,235	5,706,235	12,339,988	(989,505)	(184,674)		(1,265,078)	15,606,966
Exercise of stock options	106,502	106,502	765,719					872,220
Shares issued in lieu of cash for services	754	754	5,366					6,120
Stock option expense			280,376					280,376
Net income				1,867,238		\$ 1,867,238		1,867,238
Change in fair value of interest rate swap, net of income taxes of \$0					(79,215)	(79,215)		(79,215)
Translation gain, net of income taxes of \$0					43,489	43,489		43,489
Comprehensive income						<u>\$ 1,831,512</u>		
Balance December 31, 2007	5,813,491	5,813,491	13,391,449	877,733	(220,400)		(1,265,078)	18,597,195
Exercise of stock options	3,400	3,400	4,900					8,300
Shares issued under the Employee Stock Purchase Plan	34,213	34,213	172,870					207,083
Shares issued in lieu of cash for services	1,902	1,902	10,331					12,233
Shares issued under the Non-employee Director and Exec. Officer Stock Purchase Program	5,000	5,000	16,250					21,250
Stock option expense			525,972					525,972
Net income				1,037,601		\$ 1,037,601		1,037,601
Change in fair value of interest rate swap, net of income taxes of \$0					(57,033)	(57,033)		(57,033)
Translation gain, net of income taxes of \$0					(40,129)	(40,129)		(40,129)
Comprehensive income						<u>\$ 940,439</u>		
Balance December 31, 2008	<u>5,858,006</u>	<u>\$ 5,858,006</u>	<u>\$ 14,121,772</u>	<u>\$ 1,915,334</u>	<u>\$ (317,562)</u>		<u>\$(1,265,078)</u>	<u>\$20,312,472</u>

See accompanying notes to the consolidated financial statements.

Notes to Consolidated Financial Statements

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Headquartered in Arden Hills, Minnesota, IntriCon Corporation (formerly Selas Corporation of America) (referred to as the Company, we, us or our) is an international firm engaged in designing, developing, engineering and manufacturing body-worn devices and electronic products. The Company serves the body-worn device market by designing, developing, engineering and manufacturing micro-miniature injection-molded plastics, microelectronics, micro-mechanical assemblies and complete assemblies, primarily for bio-telemetry devices, medical equipment, hearing instruments, electronics, professional audio and telecommunications devices and computers. In addition to its operations in Minnesota, the Company has facilities in California, Maine, Singapore, and Germany.

Basis of Presentation – A portion of the Company’s former Heat Technology segment, operating through a wholly-owned subsidiary located in France, filed insolvency in 2003. The Company has reclassified the historical financial data related to this operation into discontinued operations. In the fourth quarter of 2003, the Company initiated its plan to dispose of the remaining Heat Technology segment. This segment consisted of the operating assets of Selas Corporation of America in Dresher, Pa., and subsidiaries located in Tokyo, Japan and Ratingen, Germany. The Company has accounted for the plan to dispose of the subsidiaries as a discontinued operation and, accordingly, has reclassified the historical financial data. Consequently, the financial statements reflect in continuing operations the body-worn device and electronics products segments. See further information in Note 2.

Reclassification - Certain prior balances have been reclassified to be consistent with the December 31, 2008 presentation including; \$326,000, \$302,000 and \$271,000 of restricted cash previously included in cash on the balance sheet as of December 31, 2007, 2006 and 2005, respectively, and \$944,000, \$138,000 and \$398,000, of cash previously included in checks written in excess of cash on the balance sheet as of December 31, 2007, 2006 and 2005, respectively. The reclassifications did not impact previously reported net income or shareholders’ equity.

Discontinued operations - The Company sold substantially all of the assets and liabilities of its Heat Technology segment in the first quarter of 2005. The divestiture is treated as a discontinued operation for the Company. All references to the business are based on results of operations from continuing operations. See Note 2.

Consolidation – The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The Company owns 90 percent of its Germany subsidiary, with the remaining 10 percent owned by the general manager. All material intercompany transactions and balances have been eliminated in consolidation.

Segment Disclosures – The Company has reviewed the Statement of Financial Accounting Standards No. 131 (SFAS No. 131), “Disclosures about Segments of an Enterprise and Related Information,” and has determined that the Company operates in two segments, our body-worn device segment and our electronics products segment, as further described in Note 4.

Use of Estimates – Management of the Company has made a number of estimates and assumptions relating to the reporting of assets and liabilities, the recording of reported amounts of revenues and expenses and the disclosure of contingent assets and liabilities to prepare these financial statements. Actual results could differ from those estimates.

Revenue Recognition – The Company’s continuing operations recognize revenue when products are shipped and the customer takes ownership and assumes risk of loss, collection of the relevant receivable is probable, persuasive evidence of an arrangement exists and the sales price is fixed or determinable. Under contractual terms shipments are generally FOB shipment point.

Customers have 30 days to notify the Company if the product is damaged or defective. Beyond that, there are no significant obligations that remain after shipping other than warranty obligations. Contracts with customers do not include product return rights, however, the Company may elect in certain circumstances to accept returns for product. The Company records revenue for product sales net of returns.

In general, the Company warrants its products to be free from defects in material and workmanship and will fully conform to and perform to specifications for a period of one year. While the Company's warranty costs have historically been within its expectations, the Company cannot guarantee that it will continue to experience the same warranty return rates or repair costs that it has experienced in the past.

Shipping and Handling Costs – In accordance with Emerging Issues Task Force (ETIF) Issue 00-10, "Accounting for Shipping and Handling Fees and Costs," the Company is including shipping and handling revenues in sales and shipping and handling costs in cost of sales.

Fair Value of Financial Instruments – The carrying value of cash, short-term accounts and notes receivable, notes payable, trade accounts payables, and other accrued expenses approximate fair value because of the short maturity of those instruments. The fair values of the Company's long-term debt and interest rate swap agreement approximate their carrying values based upon current market rates of interest.

Concentration of Cash – The Company deposits its cash in what management believes are high credit quality financial institutions. The balance, at times, may exceed federally insured limits.

Restricted Cash – Restricted cash consists of deposits required to secure a credit facility at our Singapore location and deposits required to fund retirement related benefits for certain employees of foreign subsidiaries.

Accounts Receivable – The Company reviews customers' credit history before extending unsecured credit and establishes an allowance for uncollectible accounts based upon factors surrounding the credit risk of specific customers and other information. Invoices are generally due 30 days after presentation. Accounts receivable over 30 days are considered past due. The Company does not accrue interest on past due accounts receivables. Receivables are written off once all collection attempts have failed and are based on individual credit evaluation and specific circumstances of the customer. Accounts receivable are shown net of allowance for uncollectible accounts of \$389,000 and \$259,000 at December 31, 2008 and 2007, respectively.

Inventories – Inventories are stated at the lower of cost or market. The cost of the inventories was determined by the average cost and first-in, first-out methods.

Property, Plant and Equipment – Property, plant and equipment are carried at cost. Depreciation is computed by straight-line and accelerated methods using estimated useful lives of 5 to 40 years for buildings and improvements, and 3 to 12 years for machinery and equipment. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the asset. Improvements are capitalized and expenditures for maintenance, repairs and minor renewals are charged to expense when incurred. At the time assets are retired or sold, the costs and accumulated depreciation are eliminated and the resulting gain or loss, if any, is reflected in the consolidated statement of operations. Depreciation expense was \$2,297,000, \$2,128,000, and \$1,849,000 for the years ended December 31, 2008, 2007, and 2006, respectively.

Impairment of Long-lived Assets and Long-lived Assets to be Disposed Of – The Company reviews its long-lived assets, certain identifiable intangibles, and goodwill for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to future net cash flows expected to be generated by the asset group. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, in accordance with SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets." The Company will record impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amount. The amount of impairment loss recorded will be measured as the amount by which the carrying value of the assets exceeds the fair value of the assets. To date, the Company has determined that no impairment of long-lived assets exists.

The test for goodwill impairment is a two-step process, and is performed at least annually. The first step is a comparison of the fair value of the reporting unit with its carrying amount, including goodwill. If this step reflects impairment, then the loss would be measured as the excess of recorded goodwill over its implied fair value. Implied fair value is the excess of fair value of the reporting unit over the fair value of all identified assets and liabilities.

Other amortizable intangible assets are otherwise expensed over the expected life of the asset. Amortization expense was \$128,000 and \$65,000 for the years ended December 31, 2008 and 2007, respectively. Remaining amortization expense related to other amortizable intangible assets is expected as follows: 2009 - \$183,000, 2010 - \$183,000, 2011 - \$183,000, 2012 - \$137,000, 2013 - \$74,000.

Investment in Equity Instruments – On December 27, 2006, the Company purchased a membership interest in the Hearing Instrument Manufacturers Patent Partnership (HIMPP). Members of the partnership include the largest six hearing aid manufacturers as well as several other smaller manufacturers. The purchase price of \$1,800,000 included a 9% equity interest in K/S HIMPP as well as a license agreement that will grant the Company access to over 45 US registered patents. The Company accounted for the K/S HIMPP investment using the equity method of accounting for common stock, as the equity interest is deemed to be “more than minor” as defined in AICPA Statement of Position 78-9 “Accounting for Investments in Real Estate Ventures”. The investment required a \$260,000 payment made at the time of closing. The unpaid balance of \$1,020,000 at December 31, 2008 will be paid in three annual installments of \$260,000 in 2009 through 2011, with a final installment of \$240,000 in 2012. The unpaid balance is unsecured and bears interest at an annual rate of 4%, which is payable annually with each installment. The investment in the partnership exceeded underlying net assets by approximately \$1,475,000. Based on the final assessment of the partnership, the Company has determined that approximately \$345,000 of the excess of the investment over the underlying partnership assets relates to underlying patents. The remaining \$1,130,000 of the excess of the investment over the underlying partnership assets has been assigned to the non-exclusive patent license agreement and is included in investment in partnerships on the balance sheet. The weighted average life of amortizable assets is 8 years at December 31, 2008. The Company recorded a \$144,900 and \$332,500 decrease in the carrying amount of the investment, reflecting amortization of the patents, patent license agreement and the Company’s portion of the partnership’s operating results for the years ended December 31, 2008 and 2007, respectively. Remaining annual amortization expense related to partnership intangibles is \$147,500 through 2016. Total amortization expense remaining is \$1,180,000. The difference of \$207,000 in the carrying value of the investment at December 31, 2008 is the Company’s remaining investment in partnership net assets.

Income Taxes – Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation reserves are established to the extent the future benefit from the deferred tax assets realization is more likely than not to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes accrued interest and penalties related to uncertain tax positions in income tax expense. At January 1, 2008, the Company had accrued zero for the payment of tax related interest and there was no tax interest or penalties recognized in the statements of operations. The Company’s federal and state tax returns are potentially open to examinations for fiscal years 2005-2008. The Company does not expect any reasonably possible material changes to the estimated amounts associated with its uncertain tax positions and related accruals for interest and penalties through December 31, 2009.

Employee Benefit Obligations – The Company provides pension and health care insurance for certain domestic retirees and employees of its discontinued operations. These obligations have been included in continuing operations as the Company expects to retain these obligations. The Company also provides retirement related benefits for certain foreign employees. The Company measures the costs of its obligation based on actuarial determinations. The net periodic costs are recognized as employees render the services necessary to earn the post-retirement benefit.

Several assumptions and statistical variables are used in the models to calculate the expense and liability related to the plans. Assumptions about the discount rate, the expected rate of return on plan assets and the future rate of compensation increases are determined by the Company. Note 10 includes disclosure of these rates on a weighted-average basis, encompassing the plans. The actuarial models also use assumptions on demographic factors such as

retirement, mortality and turnover. The Company believes the assumptions are within accepted guidelines and ranges. However, these actuarial assumptions could vary materially from actual results due to economic events and different rates of retirement, mortality and withdrawal.

Stock Option Plan – Under the various Company stock-based compensation plans, executives, employees and outside directors receive awards of options to purchase common stock. Under all awards, the terms are fixed at the grant date. Generally, the exercise price equals the market price of the Company’s stock on the date of the grant. Options under the plans generally vest from one to five years, and the option’s maximum term is 10 years. Options issued to directors vest from one to three years. One plan also permits the granting of stock awards, stock appreciation rights, restricted stock units and other equity based awards.

The Company adopted SFAS 123R on January 1, 2006 using the modified prospective approach. SFAS 123R applies to new awards and to awards that were outstanding on January 1, 2006 that are subsequently modified, repurchased, cancelled or unvested. The Company expenses the grant-date fair values of stock options and awards ratably over the vesting period of the related share-based award. Please see Note 12 for additional information.

Product Warranty – The Company offers a warranty on various products and services. The Company estimates the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product is sold. Factors that affect the Company’s warranty liability include the number of units sold, historical and anticipated rates of warranty claims and cost per claim. The Company periodically assessed the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. The amount of the reserve recorded is equal to the costs to repair or otherwise satisfy the claim. The following table presents changes in the Company’s warranty liability as of December 31, 2008, 2007 and 2006:

	<u>2008</u>	<u>2007</u>	<u>2006</u>
Beginning of the year balance	\$ 136,000	\$ 104,500	\$ 124,483
Warranty expense	44,900	79,900	52,558
Closed warranty claims	<u>(80,700)</u>	<u>(48,400)</u>	<u>(72,541)</u>
End of the year balance	\$ 100,200	\$ 136,000	\$ 104,500

Advertising Costs – Advertising costs are charged to expense as incurred. Advertising costs were \$102,000, \$118,000, and \$133,000, for the years ended December 31, 2008, 2007, and 2006, respectively, and are included in selling expense in the consolidated statements of operations.

Research and Development Costs – Research and development costs, net of customer funding amounted to \$3.2 million, \$3.1 million, and \$2.1 million in 2008, 2007 and 2006, respectively, are charged to expense when incurred.

The following table sets forth development costs associated with customer funding:

	<u>Year ended December 31,</u>		
	<u>2008</u>	<u>2007</u>	<u>2006</u>
Total cost incurred	\$679,000	\$362,000	\$876,000
Amount funded by customers	<u>(645,000)</u>	<u>(281,000)</u>	<u>(762,000)</u>
Net expense	\$ 34,000	\$ 81,000	\$114,000

Income Per Share – Basic income per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted income per common share reflects the potential dilution of securities that could share in the earnings. The Company uses the treasury stock method for calculating the dilutive effect of stock options.

Comprehensive Income – Comprehensive income consists of net income, change in fair value of derivative instruments and foreign currency translation adjustments and is presented in the consolidated statements of shareholders’ equity and comprehensive income.

New Accounting Pronouncements

During March 2008, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standard (“SFAS”) No. 161, “Disclosures about Derivative Instruments and Hedging Activities.” SFAS No. 161 is intended to improve financial reporting about derivative instruments and hedging activities by requiring enhanced disclosures to enable investors to better understand their effects on an entity’s financial position, financial performance and cash flows. SFAS No. 161 also improves transparency about the location and amounts of derivative instruments in an entity’s financial statements; how derivative instruments and related hedged items are accounted for under SFAS No. 133; and how derivative instruments and related hedged items affect the entity’s financial position, financial performance, and cash flows. SFAS No. 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early application encouraged. We do not believe the adoption of SFAS No. 161 will have a material effect on our results of operations or financial position.

On December 4, 2007, the FASB issued SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements - an Amendment of ARB No. 51”. SFAS 160 establishes new accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. Specifically, this statement requires the recognition of a noncontrolling interest (minority interest) as equity in the consolidated financial statements and separate from the parent’s equity. The amount of net income attributable to the noncontrolling interest will be included in consolidated net income on the face of the income statement. SFAS No. 160 clarifies that changes in a parent’s ownership interest in a subsidiary that do not result in deconsolidation are equity transactions if the parent retains its controlling financial interest. In addition, this statement requires that a parent recognize a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss will be measured using the fair value of the noncontrolling equity investment on the deconsolidation date. SFAS No. 160 also includes expanded disclosure requirements regarding the interests of the parent and its noncontrolling interest. SFAS No. 160 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2008. Earlier adoption is prohibited. We do not believe the adoption of SFAS No. 160 will have a material effect on our results of operations or financial position.

On December 4, 2007, the FASB issued SFAS No. 141 (Revised 2007), “Business Combinations”. SFAS No. 141(R) will significantly change the accounting for business combinations. Under SFAS No. 141(R), an acquiring entity will be required to recognize all the assets acquired and liabilities assumed in a transaction at the acquisition-date fair value with limited exceptions. SFAS No. 141R will change the accounting treatment for certain specific items, including:

- Acquisition costs will be generally expensed as incurred;
- Noncontrolling interests (formerly known as “minority interests” will be valued at fair value at the acquisition date;
- Acquired contingent liabilities will be recorded at fair value at the acquisition date and subsequently measured at either the higher of such amount or the amount determined under existing guidance for non-acquired contingencies;
- In-process research and development will be recorded at fair value as an indefinite-lived intangible asset at the acquisition date;
- Restructuring costs associated with a business combination will be generally expensed subsequent to the acquisition date; and
- Changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date generally will affect income tax expense.

SFAS No. 141(R) also includes a substantial number of new disclosure requirements. The statement applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning after December 15, 2008. Earlier adoption is prohibited. This standard will change our

accounting treatment for business combinations on a prospective basis and will be adopted by the Company in the first quarter of 2009.

In May 2008, the FASB issued SFAS No. 162, "The Hierarchy of Generally Accepted Accounting Principles." SFAS No. 162 is intended to improve financial reporting by identifying a consistent framework, or hierarchy, for selecting accounting principles to be used in preparing financial statements that are presented in conformity with U.S. generally accepted accounting principles (GAAP) for nongovernmental entities.

Prior to the issuance of SFAS No. 162, GAAP hierarchy was defined in the American Institute of Certified Public Accountants (AICPA) Statement on Auditing Standards No. 69 ("SAS No. 69"), "The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles." SAS No. 69 has been criticized because it is directed to the auditor rather than the entity. SFAS No. 162 addresses these issues by establishing that the GAAP hierarchy should be directed to entities because it is the entity (not its auditor) that is responsible for selecting accounting principles for financial statements that are presented in conformity with GAAP.

SFAS No. 162 is effective 60 days following the U.S. Securities and Exchange Commission's approval of the Public Company Accounting Oversight Board Auditing amendments to AU Section 411, "The Meaning of Present Fairly in Conformity with Generally Accepted Accounting Principles." The Company does not expect SFAS 162 to have a material effect on our results of operations or financial position.

In September 2006, the FASB issued Statement No. 157, "Fair Value Measurements" ("SFAS No. 157"). This Statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement applies to accounting pronouncements that require or permit fair value measurements, except for share-based compensation transactions under FASB Statement No. 123 (Revised) "Share Based Payment." This Statement was effective for financial statements issued for fiscal years beginning after November 15, 2007, except for non-financial assets and liabilities for which this Statement will be effective for years beginning after November 15, 2008. The Company is evaluating the effect of implementing the Statement relating to such non-financial assets and liabilities, although the Statement does not require any new fair value measurements or remeasurements of previously reported fair values.

In May 2008, the FASB issued FASB Staff Position (FSP) Financial Accounting Standard (FAS) 142-3, "Determination of the Useful Life of Intangible Assets", which is effective for fiscal years beginning after December 15, 2008 and for interim periods within those years. FSP FAS 142-3 provides guidance on the renewal or extension assumptions used in the determination of the useful life of a recognized intangible asset. The intent of FSP FAS 142-3 is to better match the useful life of the recognized intangible asset to the period of the expected cash flows used to measure its fair value. The Company does not expect FSP FAS 142-3 to have a material effect on our results of operations or financial position.

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities" (SFAS 159). This pronouncement permits entities to choose to measure many financial instruments and certain other items at fair value that were not previously required to be measured at fair value. SFAS 159 becomes effective for the Company at the beginning of fiscal year 2009 and is not expected to have a significant impact on our consolidated financial statements.

In June 2007, the Emerging Issues Task Force (EITF) reached a consensus on EITF Issue No. 07-3, "Accounting for Nonrefundable Advance Payments for Goods or Services Received to Be Used in Future Research and Development Activities" (EITF No. 07-3). EITF No. 07-3 requires companies that are involved in research and development activities to defer nonrefundable advance payments for future research and development activities and to recognize those payments as goods and services are delivered. The Company is required to assess on an ongoing basis whether or not the goods or services will be delivered and to expense the nonrefundable advance payments immediately if it is determined that delivery is unlikely. EITF No. 07-3 was effective for new arrangements entered into subsequent to December 15, 2007. The adoption of EITF No. 07-3 was not material to the consolidated financial statements.

2. DISCONTINUED OPERATIONS

The Company has embarked on a strategy to focus on its Body-Worn Device and Electronics Products segments for future growth.

Consistent with this strategy, in 2003, the Company initiated its plan to sell the remainder of its Heat Technology segment and classified it as a discontinued operation. This segment consisted of the operating assets of Selas Corporation of America located in Dresher, Pennsylvania, Nippon Selas located in Tokyo, Japan and Selas Waermetech in Ratingen, Germany. The Company owned the rights to the Selas name and the technology for the European market. In the first quarter of 2005, the Company sold the remainder of its Heat Technology segment, including the stock of Nippon Selas and Selas Waermetech GmbH. The total purchase price was approximately \$3.5 million, of which approximately \$2.7 million was paid in cash and \$800,000 was paid in the form of a unsecured subordinated promissory note. The note is payable in twelve quarterly installments commencing on April 1, 2006 and bears 8 percent per annum on the outstanding principal balance. The principal balance outstanding on the note was \$225,000 and \$300,000 at December 31, 2008 and 2007, respectively. The Company has set-up an allowance for the note of \$0 and \$225,000 at December 31, 2008 and 2007, respectively.

The following table shows the results of operations of the Company's Heat Technology segment:

	<u>Year Ended</u> <u>December 31, 2006</u>
Sales, net	\$ --
Operating costs and expenses	<u>(78)</u>
Operating loss	(78)
Other expense, net (including loss on abandonment)	<u>--</u>
Loss from operations before income tax benefit	(78)
Income tax expense (benefit)	<u>--</u>
Net loss from discontinued operations	<u>\$ (78)</u>

3. ACQUISITION

On May 22, 2007, the Company completed the acquisition of substantially all of the assets, other than real estate, of Tibbetts Industries, Inc. ("Tibbetts"), a privately held designer and manufacturer of components used in hearing aids and medical devices, based in Camden, Maine. The acquisition expanded the Company's component technology and customer base.

Pursuant to an asset purchase agreement, dated as of April 19, 2007, by and among the Company and Tibbetts and certain of the principal shareholders of Tibbetts, the Company purchased substantially all of the assets of Tibbetts, other than real estate, for cash of \$4,500,000, subject to a closing adjustment, and the assumption of certain liabilities (total purchase price of \$5,569,000 including liabilities assumed of \$841,000 and acquisition costs of \$228,000). All escrow amounts were distributed to the seller at the conclusion of the respective escrow periods. The acquisition was financed with borrowings under the Company's new credit facility, as further described in Note 7.

In addition, the Company entered into a five year lease and a ten year lease, respectively, for Tibbetts' two facilities in Camden, Maine, in each case with an option to renew for two additional periods of five years each.

The Company has accounted for the Tibbetts acquisition, utilizing the generally accepted accounting principles of SFAS Nos. 141, "Business Combinations", and 142, "Goodwill and Other Intangible Assets". Under the purchase method of accounting, the assets and liabilities of Tibbetts were recorded as of the acquisition date at their respective fair values and consolidated with those of the Company. Likewise, the results of operations of the Tibbetts' operations since May 22, 2007 have been included in the accompanying consolidated statements of operations. The allocation of the net purchase price of the acquisition resulted in goodwill of approximately \$2,317,000. The goodwill represents operating and market synergies that the Company expects to be realized as a result of the acquisition and future opportunities and is also deductible for tax purposes based on a 15 year amortization schedule. The purchase price allocation is based on estimates of fair values of assets acquired and liabilities

assumed. The valuation required the use of significant assumptions and estimates. These estimates were based on assumptions the Company believed to be reasonable. However, actual results may differ from these estimates.

The purchase price was as follows (amounts in thousands):

Cash	\$ 4,500
Liabilities assumed	841
Acquisition costs	<u>228</u>
Total purchase price	<u>\$ 5,569</u>

The following table summarizes the purchase price allocation for the Tibbetts acquisition (amounts in thousands):

Cash	\$ 130
Other current assets	1,964
Intangible assets subject to amortization (through 2022)	108
Goodwill	2,317
Other long-term assets	1,050
Current liabilities	<u>(841)</u>
Total purchase price allocation, net of liabilities assumed	<u>\$ 4,728</u>

The following unaudited pro forma information presents a summary of consolidated results of operations of the Company as if the acquisition of Tibbetts had occurred at January 1, 2007. All amounts presented are in thousands. The historical consolidated financial information has been adjusted to give effect to pro forma events that are directly attributable to the acquisition and are factually supportable, including the increase in interest expense related to the borrowings used to fund the acquisition and the increase in depreciation expense of Tibbetts related to the step-up of fixed assets to fair value. The unaudited pro forma condensed consolidated financial information is presented for informational purposes only. The pro forma information is not necessarily indicative of what the financial position or results of operations actually would have been had the acquisition been completed on the dates indicated. In addition, the unaudited pro forma condensed consolidated financial information does not purport to project the future financial position or operating results of the Company after completion of the acquisition.

(amounts in thousands, except per share amounts)	Year ended December 31, 2007 (unaudited)
Net sales	\$ 70,519
Cost of sales	53,071
S, G & A	14,495
Interest expense	1,086
Other expense	242
Income from continuing operations before income taxes	\$ 1,625
Income per share:	
Basic	\$ 0.28
Diluted	\$ 0.26
Weighted average number of shares outstanding:	
Basic	5,210
Diluted	5,520

The pro forma income from continuing operations for the period presented includes the increase in interest expense related to the borrowings used to fund the acquisition and the increase in depreciation expense of Tibbetts related to the step-up of fixed assets to fair value.

4. SEGMENT AND GEOGRAPHIC INFORMATION

The Company currently operates in two reportable segments: body-worn devices and electronic products. Previously, these were combined in the Company's "miniature medical and electronics products segment". The Company determined in 2008 that these segments no longer meet the criteria for aggregation. The nature of the products and services has been deemed separately identifiable, as the Company has further developed technologies and products included in the body-worn device segment. This includes products and technologies developed both internally and externally with our strategic partners like AME and Dynamic Hearing. Furthermore, as the underlying products and technology has changed, the economic characteristics of each business segment are not similar. Our electronics products segment margin is subject to more variability due to component material pricing and we believe our future revenue growth and margin will be different for each segment as a result of the proprietary technology included in our body-worn device products. Therefore, segment reporting has been retroactively applied to all periods present.

Income (loss) from operations is total revenues less cost of sales and operating expenses. Identifiable assets by industry segment include both assets directly identifiable with those operations. General corporate assets consist primarily of cash and cash equivalents, and are included in the body-worn device segment. The accounting policies applied to determine segment information are the same as those described in the summary of significant accounting policies. The Company evaluates the performance of each segment based on income and loss from operations before income taxes. The following table summarizes data by industry segment:

At and for the Year Ended December 31, 2008	Body Worn Devices	Electronic Products	TOTAL
Revenues, net	\$ 57,908,000	\$ 7,647,000	\$65,555,000
Income (loss) from operations	2,298,000	(254,000)	2,044,000
Identifiable assets	36,306,000	3,156,000	39,462,000
Depreciation and amortization	1,965,000	332,000	2,297,000
Capital expenditures	1,445,000	29,000	1,474,000
At and for the Year Ended December 31, 2007			
Revenues	\$ 59,668,000	\$ 9,315,000	\$68,983,000
Income from operations	3,065,000	198,000	3,263,000
Identifiable assets	36,068,000	3,664,000	39,732,000
Depreciation and amortization	1,786,000	342,000	2,128,000
Capital expenditures	2,672,000	91,000	2,763,000
At and for the Year Ended December 31, 2006			
Revenues	\$ 41,436,000	\$ 10,290,000	\$51,726,000
Income from operations	1,681,000	286,000	1,967,000
Identifiable assets	29,723,000	4,421,000	34,144,000
Depreciation and amortization	1,511,000	338,000	1,849,000
Capital expenditures	3,083,000	97,000	3,180,000

The geographical distribution of long-lived assets and net sales to geographical areas as of and for the years ended December 31, 2008, 2007 and 2006 are set forth below:

Long-lived Assets

	<u>2008</u>	<u>2007</u>	<u>2006</u>
United States	\$ 17,980,927	\$ 18,737,623	\$ 14,398,571
Other – primarily Singapore	<u>1,457,969</u>	<u>1,092,816</u>	<u>1,097,221</u>
Consolidated	<u>\$ 19,438,896</u>	<u>\$ 19,830,439</u>	<u>\$ 15,495,792</u>

Long-lived assets consist primarily of property and equipment, investment in partnerships and goodwill. The Company capitalizes long-lived assets pertaining to the production of specialized parts. These assets are periodically reviewed to assure the net realizable value from the estimated future production based on forecasted sales exceeds the carrying value of the assets.

Net Sales to Geographical Areas

	<u>2008</u>	<u>2007</u>	<u>2006</u>
United States	\$ 46,455,847	\$ 49,102,782	\$ 35,429,666
Germany	3,855,740	3,476,768	2,293,875
China	2,776,375	2,488,852	2,232,405
Switzerland	1,860,916	2,200,781	1,653,803
Singapore	1,517,256	1,580,854	1,786,344
France	1,462,391	939,847	405,713
Japan	1,161,595	1,280,774	1,919,659
United Kingdom	1,092,366	698,703	736,670
Turkey	446,362	488,539	194,561
Hong Kong	433,634	409,822	333,049
All other countries	<u>4,492,574</u>	<u>6,315,658</u>	<u>4,740,207</u>
Consolidated	<u>\$ 65,555,056</u>	<u>\$ 68,983,380</u>	<u>\$ 51,725,952</u>

Geographic net sales are allocated based on the location of the customer. All other countries include net sales primarily to various countries in Europe and in the Asian Pacific.

One customer accounted for 13 percent and 11 percent of the Company's consolidated net sales in 2008 and 2007, respectively. In 2006 no one customer accounted for more than 10 percent of the Company's consolidated net sales. During 2008, the top five customers accounted for approximately \$23 million or 35 percent of the Company's consolidated net sales. During 2007, the top five customers accounted for approximately \$26 million or 38 percent of the Company's consolidated net sales. During 2006, the top five customers accounted for approximately \$16 million or 30 percent of the Company's consolidated net sales.

At December 31, 2008 two customers accounted for 11 percent and 10 percent of the Company's consolidated accounts receivable, respectively. One customer accounted for 14 percent of the Company's consolidated accounts receivable at December 31, 2007.

5. GOODWILL

The Company applies SFAS No. 142, "Goodwill and Other Intangible Assets," which sets forth financial and reporting standards for the acquisition of intangible assets, other than those acquired in a business combination, and for goodwill and other intangible assets subsequent to their acquisition. This accounting standard requires that goodwill no longer be amortized but tested for impairment on a periodic basis. In conjunction with the acquisitions of Tibbetts on May 22, 2007, approximately \$2,317,000 of goodwill was recognized (see Note 3).

The Company performed the required goodwill impairment test during the years ended December 31, 2008, 2007, and 2006. As part of compliance with this standard, the Company completed or obtained an analysis to assess the fair value of its business units to determine whether goodwill carried on its books was impaired and the extent of

such impairment, if any for the years ended December 31, 2008, 2007, and 2006. For each year, the analysis used the discounted cash flow analysis; future benefits over a period of time are estimated and then discounted back to present value. Based upon this analysis, the Company determined that its current goodwill balances were not impaired as of December 31, 2008 and 2007.

The changes in the carrying amount of goodwill for the years presented are as follows:

	Body-Worn Device Segment	Electronic Products Segment	Total
Carrying amount at December 31, 2006	\$ 5,264,585	\$ 662,596	\$ 5,927,181
Goodwill acquired during the year	<u>2,288,104</u>	<u>22,735</u>	<u>2,310,839</u>
Carrying amount at December 31, 2007	7,552,689	685,331	8,238,020
Revision to prior year purchase price allocation	<u>28,418</u>	<u>--</u>	<u>28,418</u>
Carrying amount at December 31, 2008	<u>\$ 7,581,107</u>	<u>\$ 685,331</u>	<u>\$ 8,266,438</u>

6. INVENTORIES

Inventories consisted of the following:

December 31,	<u>Raw materials</u>	<u>Work-in process</u>	<u>Finished products and components</u>	<u>Total</u>
2008				
Domestic	\$ 3,709,213	\$ 1,644,408	\$ 1,281,771	\$ 6,635,392
Foreign	<u>1,609,392</u>	<u>326,874</u>	<u>280,370</u>	<u>2,216,636</u>
Total	<u>\$ 5,318,605</u>	<u>\$ 1,971,282</u>	<u>\$ 1,562,141</u>	<u>\$ 8,852,028</u>
2007				
Domestic	\$ 3,710,360	\$ 1,779,539	\$ 1,598,241	\$ 7,088,140
Foreign	<u>1,226,589</u>	<u>1,043,245</u>	<u>477,086</u>	<u>2,746,920</u>
Total	<u>\$ 4,936,949</u>	<u>\$ 2,822,784</u>	<u>\$ 2,075,327</u>	<u>\$ 9,835,060</u>

7. SHORT AND LONG-TERM DEBT

Short and long term debt at December 31, 2008 and 2007 were as follows:

	<u>2008</u>	<u>2007</u>
Domestic Asset-Based Revolving Credit Facility	\$ 3,000,000	\$ 3,000,000
Foreign Overdraft and Letter of Credit Facility	605,423	1,071,009
Domestic Term Loan	2,756,250	4,275,000
Domestic Capital Equipment Leases	<u>1,330,012</u>	<u>94,066</u>
Total Debt	7,691,685	8,440,075
Less: Current maturities	<u>(1,503,762)</u>	<u>(1,476,665)</u>
Total Long Term Debt	<u>\$ 6,187,923</u>	<u>\$ 6,963,410</u>

	Payments Due by Period						Total
	2009	2010	2011	2012	2013	Thereafter	
Domestic credit facility	\$ --	\$ --	\$ --	\$3,000,000	\$ --	\$ --	\$3,000,000
Domestic term loan	731,250	1,068,750	956,250	--	--	--	2,756,250
Foreign overdraft and letter of credit facility	557,777	47,646	--	--	--	--	605,423
Capital leases	<u>214,735</u>	<u>194,867</u>	<u>192,551</u>	<u>201,484</u>	<u>210,840</u>	<u>315,535</u>	<u>1,330,012</u>
Total debt	<u>\$1,503,762</u>	<u>\$1,311,263</u>	<u>\$1,148,801</u>	<u>\$3,201,484</u>	<u>\$210,840</u>	<u>\$ 315,535</u>	<u>\$7,691,685</u>

The Company and its subsidiaries, IntriCon, Inc. (formerly known as Resistance Technology, Inc.), RTI Electronics, Inc. and IntriCon Tibbetts Corporation, referred to as the borrowers, entered into a credit facility with LaSalle Bank, National Association (now Bank of America), referred to as the lender, on May 22, 2007 replacing the prior credit facilities with M & I Business Credit (formerly known as Diversified Business Credit, Inc.). The credit facility provides for:

- a \$10,000,000 revolving credit facility, with a \$200,000 subfacility for letters of credit. Under the revolving credit facility, the availability of funds depends on a borrowing base composed of stated percentages of our eligible trade receivables and eligible inventory, less a reserve.
- a \$4,500,000 term loan, which was used to fund the Tibbetts acquisition.

Loans under the new credit facility are secured by a security interest in substantially all of the assets of the borrowers including a pledge of the stock of the subsidiaries. All of the borrowers are jointly and severally liable for all borrowings under the new credit facility.

Proceeds from the new facility were used to repay amounts owed under the prior credit facilities of approximately \$5.0 million and the \$4.5 million purchase price to complete the Tibbetts asset acquisition.

Loans under the new credit facility bear interest, at the option of the Company, at:

- the London InterBank Offered Rate (“LIBOR”) plus 1.90%, in the case of revolving line of credit loans, or LIBOR plus 2.15%, in the case of the term loan, or
- the base rate, which is the higher of (a) the rate publicly announced from time to time by the lender as its “prime rate” and (b) the Federal Funds Rate plus 0.5%.

Interest is payable monthly in arrears, except that interest on LIBOR based loans is payable at the end of the one, two or three month interest periods applicable to LIBOR based loans, or every three months in the case of LIBOR based loans with a six month interest period.

Weighted average interest on the domestic asset-based revolving credit facilities (including the prior credit facility) was 5.51%, 7.82% and 8.17% for 2008, 2007 and 2006, respectively.

The new credit facility will expire and all outstanding loans will become due and payable on June 30, 2012. The term loan requires quarterly principal payments, commencing on September 30, 2007, based on an increasing installment schedule, with any balance due on June 30, 2012. In 2008 we used proceeds of \$1,013,000 from the equipment sale-leaseback described below to pay down the term loan.

The outstanding balance of the revolving credit facility was \$3,000,000 at December 31, 2008 and 2007, respectively. The total remaining availability on the revolving credit facility was approximately \$4,349,000 and \$4,443,000 at December 31, 2008 and 2007, respectively.

The revolving facility carries a non-use fee equal to 0.25% per year of the unused portion of the revolving line of credit facility, payable quarterly in arrears.

The Company is subject to various covenants under the credit facility, including financial covenants relating to tangible net worth, funded debt to Earnings Before Interest, Taxes, Depreciation and Amortization, fixed charge coverage ratio and capital expenditures. Under the credit facility, except as otherwise permitted, the borrowers may not, among other things, incur or permit to exist any indebtedness; grant or permit to exist any liens or security interests on their assets or pledge the stock of any subsidiary; make investments; be a party to any merger or consolidation, or purchase of all or substantially all of the assets or equity of any other entity; sell, transfer, convey or lease all or any substantial part of its assets or capital securities; sell or assign, with or without recourse, any receivables; issue any capital securities; make any distribution or dividend (other than stock dividends), whether in cash or otherwise, to any of its equityholders; purchase or redeem any of its equity interests or any warrants, options or other rights in respect thereof; enter into any transaction with any of its affiliates or with any director, officer or employee of any borrower; be a party to any unconditional purchase obligations; cancel any claim or debt owing to

it; enter into any agreement inconsistent with the provisions of the credit facility or other agreements and documents entered into in connection with the credit facility; engage in any line of business other than the businesses engaged in on the date of the credit facility and businesses reasonably related thereto; or permit its charter, bylaws or other organizational documents to be amended or modified in any way which could reasonably be expected to materially adversely affect the interests of the lender. Effective as of September 30, 2007, the credit facility was amended to change the tangible net worth covenant. Effective as of June 30, 2008, the credit facility was amended to correct an error in the amortization table set forth in the loan agreement. Effective as of December 31, 2008, the credit facility was amended to change the fixed charge coverage covenant to exclude payments made in connection with the June 2008 equipment sale-leaseback described below. As of December 31, 2008, the Company was in compliance with all financial covenants under the credit facility, as amended.

Upon the occurrence and during the continuance of an event of default (as defined in the credit facility), the lender may, among other things: terminate its commitments to the borrowers (including terminating or suspending its obligation to make loans and advances); declare all outstanding loans, interest and fees to be immediately due and payable; take possession of and sell any pledged assets and other collateral; and exercise any and all rights and remedies available to it under the Uniform Commercial Code or other applicable law. In the event of the insolvency or bankruptcy of any borrower, all commitments of the lender will automatically terminate and all outstanding loans, interest and fees will be immediately due and payable. Events of default include, among other things: failure to pay any amounts when due; material misrepresentation; default in the performance of any covenant, condition or agreement to be performed that is not cured within 20 days after notice from the lender; default in the payment of other indebtedness or other obligation with an outstanding principal balance of more than \$50,000, or of any other term, condition or covenant contained in the agreement under which such obligation is created, the effect of which is to allow the other party to accelerate such payment or to terminate the agreements; the insolvency or bankruptcy of any borrower; the entrance of any judgment against any borrower in excess of \$50,000, which is not fully covered by insurance; the occurrence of a change in control (as defined in the credit facility); certain collateral impairments; and a contribution failure with respect to any employee benefit plan that gives rise to a lien under ERISA.

The prior credit facility originally included a real estate loan with an original principal balance of \$1,500,000, which was associated with our Vadnais Heights manufacturing facility. In June 2006, the Company completed a sale-leaseback of the Vadnais Heights manufacturing facility. The transaction generated proceeds of \$2,650,000, of which \$1,388,000 was used to repay the associated real estate loan and the remainder to pay down our domestic revolver. The remaining gain on the sale of \$825,631 is being recognized over the initial 10-year lease term as the renewal options in the lease are not assured and a penalty does not exist if we do not exercise the renewal options.

In addition to its domestic credit facilities, the Company's wholly-owned subsidiary, IntriCon, PTE LTD., entered into an international senior secured credit agreement with Oversea-Chinese Banking Corporation Ltd. that provides for a \$1.8 million line of credit through 2009. Borrowings bear interest at a rate of .75% to 2.5% over the lender's prevailing prime lending rate. Weighted average interest on the international credit facilities was 5.84%, 6.36% and 6.47% for 2008, 2007 and 2006, respectively. The outstanding balance was \$605,000 and \$1,071,000 at December 31, 2008 and 2007, respectively. The total remaining availability on the international senior secured credit agreement was approximately \$1,203,000 and \$740,000 at December 31, 2008 and 2007, respectively.

In June 2008, the Company completed a sale-leaseback of machinery and equipment with Bank of America. The transaction generated proceeds of \$1,098,000, of which \$1,013,000 was used to pay down the domestic term loan. The capital lease agreement expires in June 2014, requires monthly payments of \$15,800 and has a present value of future minimum lease payments of \$1,098,000 with an effective interest rate of 5.14%. The transaction resulted in a gain of \$62,000 which is being recognized over the initial 6-year lease term.

The Company also has entered into several other capital lease agreements to fund the acquisition of machinery and equipment. The total principal amount of all capital leases (including the equipment sale-leaseback described above) was \$1,661,000 with effective interest rates ranging from 5.1% to 8.0%. These agreements range from 3 to 6 years. The outstanding balance under these capital lease agreements at December 31, 2008 and December 31, 2007 was \$1,330,000 and \$94,000, respectively. The accumulated amortization on leased equipment was \$257,000 and \$119,000 at December 31, 2008 and 2007, respectively. The amortization of capital leases is included in depreciation expense for 2008, 2007 and 2006.

8. OTHER ACCRUED LIABILITIES

Other accrued liabilities at December 31, 2008, and 2007 were as follows:

	<u>2008</u>	<u>2007</u>
Salaries, wages and commissions	\$2,020,539	\$2,496,610
Taxes, including payroll withholdings and excluding income taxes	80,202	101,617
Accrued severance benefits	61,639	100,000
Accrued professional fees	361,580	161,736
Current portion of note payable	259,360	256,360
Deferred revenue	--	113,618
Accrued Dynamic Hearing strategic alliance payments	475,000	--
Customers' advance payments on contracts	--	190,062
Other	993,387	962,752
	<u>\$4,251,707</u>	<u>\$4,382,755</u>

Accrued severance benefits recorded at December 31, 2007 were paid in 2008. Severance benefits accrued at December 31, 2008 will be paid in 2009.

9. DOMESTIC AND FOREIGN INCOME TAXES

Domestic and foreign income taxes (benefits) from continuing operations were comprised as follows:

	<u>Years ended December 31,</u>		
	<u>2008</u>	<u>2007</u>	<u>2006</u>
Current			
Federal	\$ -	\$ -	\$ -
State	93,319	(11,978)	21,654
Foreign	<u>104,748</u>	<u>182,651</u>	<u>111,258</u>
	<u>198,067</u>	<u>170,673</u>	<u>132,912</u>
Deferred			
Federal	-	-	-
State	-	-	-
Foreign	<u>66,000</u>	<u>10,000</u>	<u>41,548</u>
	<u>66,000</u>	<u>10,000</u>	<u>41,548</u>
Income taxes	<u>\$ 264,067</u>	<u>\$ 180,673</u>	<u>\$ 174,460</u>
Income (loss) from continuing operations before income taxes is as follows:			
Foreign	597,234	1,088,951	1,492,092
Domestic	<u>704,434</u>	<u>958,960</u>	<u>(77,130)</u>
	<u>\$ 1,301,668</u>	<u>\$ 2,047,911</u>	<u>\$ 1,414,962</u>

The following is a reconciliation of the statutory federal income tax rate to the effective tax rate based on income (loss):

	<u>Years ended December 31,</u>		
	<u>2008</u>	<u>2007</u>	<u>2006</u>
Tax provision at statutory rate	34.0%	34.0%	34.0%
Change in valuation allowance	(29.1)	(20.9)	0.5
Impact of permanent items, including stock based compensation expense	14.6	--	--
Effect of foreign tax rates	(2.4)	(8.7)	(25.1)
State taxes net of federal benefit	3.2	1.4	1.5
Other	<u>0.0</u>	<u>3.1</u>	<u>1.4</u>
Domestic and foreign income tax rate	<u>20.3%</u>	<u>8.8%</u>	<u>12.3%</u>

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2008, and 2007 are presented below:

	<u>2008</u>	<u>2007</u>
Deferred tax assets:		
Net operating loss carry forwards – United States	\$ 4,707,273	\$ 5,299,146
Post-retirement benefit obligations	327,098	475,859
Goodwill amortization	155,937	269,948
State income taxes	--	483,594
Inventory reserves	785,976	901,720
Guarantee obligations and estimated future costs of service accruals	31,568	35,700
Compensated absences, principally due to accrual for financial reporting purposes	225,424	225,041
Other	<u>1,033,860</u>	<u>442,827</u>
Total gross deferred tax assets	7,267,135	8,133,835
Less: valuation allowance	<u>7,267,135</u>	<u>8,133,835</u>
Net deferred tax assets	<u>\$ --</u>	<u>\$ --</u>
Deferred tax liabilities:		
Plant and equipment, due to differences in depreciation and capitalized interest	(155,273)	(89,273)
Total gross deferred tax liabilities	<u>(155,273)</u>	<u>(89,273)</u>
Net deferred tax liabilities	<u>\$ (155,273)</u>	<u>\$ (89,273)</u>

Domestic and foreign deferred taxes were comprised as follows:

December 31, 2008	<u>Federal</u>	<u>State</u>	<u>Foreign</u>	<u>Total</u>
Current deferred asset	\$ --	\$ --	\$ --	\$ --
Non-current deferred liability	<u>--</u>	<u>--</u>	<u>(155,273)</u>	<u>(155,273)</u>
Net deferred tax liability	\$ --	\$ --	\$ (155,273)	\$ (155,273)
December 31, 2007	<u>Federal</u>	<u>State</u>	<u>Foreign</u>	<u>Total</u>
Current deferred asset	\$ --	\$ --	\$ --	\$ --
Non-current deferred liability	<u>--</u>	<u>--</u>	<u>(89,273)</u>	<u>(89,273)</u>
Net deferred tax liability	\$ --	\$ --	\$ (89,273)	\$ (89,273)

The valuation allowance is maintained against deferred tax assets which the Company has determined are not likely to be realized. In addition, the Company has net operating loss carryforwards for Federal tax purposes of approximately \$13.6 million that begin to expire in 2022. Subsequently recognized tax benefits, if any, relating to the valuation allowance for deferred tax assets or realization of net operating loss carryforwards will be reported in the consolidated statements of operations. If substantial changes in the Company's ownership occur, there could be

an annual limitation on the amount of the carryforwards that are available to be utilized. The Company analyzes ownership changes on a consistent basis.

At December 31, 2007, the Company had a valuation allowance against deferred tax assets to reduce the total to an amount our management believed was appropriate. The valuation allowance decreased in the current year primarily as a result of taxable income generated during the year, which was also impacted by an adjustment in the amount of \$167,000 to decrease the valuation allowance to their proper amounts.

The Company has not recognized a deferred tax liability relating to cumulative undistributed earnings of controlled foreign subsidiaries in Germany and Singapore that are essentially permanent in duration. If some or all of the undistributed earnings of the controlled foreign subsidiaries are remitted to the Company in the future, income taxes, if any, after the application of foreign tax credits will be provided at that time. Determination of the amount of unrecognized tax liability related to undistributed earnings in foreign subsidiaries is not currently practical.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company regularly assesses the likelihood that the deferred tax assets will be recovered from future taxable income. The Company considers projected future taxable income and ongoing tax planning strategies, then records a valuation allowance to reduce the carrying value of the net deferred taxes to an amount that is more likely than not to be realized. Based upon the Company's assessment of all available evidence, including the previous three years of United States based taxable income and loss after permanent items, estimates of future profitability, and the Company's overall prospects of future business, the Company determined that it is more likely than not that the Company will not be able to realize a portion of the deferred tax assets in the future. The Company will continue to assess the potential realization of deferred tax assets on an annual basis, or an interim basis if circumstances warrant. If the Company's actual results and updated projections vary significantly from the projections used as a basis for this determination, the Company may need to change the valuation allowance against the gross deferred tax assets.

The following was the income before income taxes for each jurisdiction in which the Company has operations for the years ended December 31, 2008, 2007 and 2006:

	December 31, 2008	December 31, 2007	December 31, 2006
United States	\$ 704,434	\$ 958,960	\$ (77,130)
Singapore	283,455	930,718	1,346,807
Germany	<u>313,779</u>	<u>158,233</u>	<u>145,285</u>
Income before income taxes	<u>\$1,301,668</u>	<u>\$2,047,911</u>	<u>\$1,414,962</u>

The Company adopted the provisions of FASB Interpretation 48, Accounting for Uncertainty in Income Taxes, on January 1, 2007. Previously, the Company had accounted for tax contingencies in accordance with Statement of Financial Accounting Standards 5, Accounting for Contingencies. As required by FASB Interpretation 48, which clarifies Statement 109, Accounting for Income Taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant taxing authority. At the adoption date, the Company applied Interpretation 48 to all tax positions for which the statute of limitations remained open. As a result of the implementation of Interpretation 48, the Company did not record any adjustment to the liability for unrecognized income tax benefits or retained earnings. The Company does not have any unrecognized tax benefits as of December 31, 2008.

The Company is subject to income taxes in the U.S. federal jurisdiction, and various states and foreign jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for the years starting before 2005. There are no other on-going or pending IRS, state, or foreign examinations.

The Company recognizes penalties and interest accrued related to unrecognized tax benefits in income tax expense for all periods presented. During the tax years ended December 31, 2008, 2007, and 2006 the Company has no amounts accrued for the payment of interest and penalties.

10. EMPLOYEE BENEFIT PLANS

The Company has defined contribution plans for most of its domestic employees. Under these plans, eligible employees may contribute amounts through payroll deductions supplemented by employer contributions for investment in various investments specified in the plans. The Company contribution to these plans for 2008, 2007, and 2006 was \$419,000, \$360,000, and \$289,000, respectively.

The Company provides post-retirement medical benefits to certain domestic full-time employees who meet minimum age and service requirements. In 1999, a plan amendment was instituted which limits the liability for post-retirement benefits beginning January 1, 2000 for certain employees who retire after that date. This plan amendment resulted in a \$1.1 million unrecognized prior service cost reduction which will be recognized as employees render the services necessary to earn the post-retirement benefit. The Company's policy is to pay the cost of these post-retirement benefits when required on a cash basis. The Company also has provided certain foreign employees with retirement related benefits.

The following table presents the amounts recognized in the Company's consolidated balance sheet at December 31, 2008 and 2007 for post-retirement medical benefits:

	<u>2008</u>	<u>2007</u>
Change in Projected Benefit Obligation		
Projected benefit obligation at January 1	\$1,001,532	\$1,243,744
Service cost (excluding administrative expenses)	--	629
Interest cost	55,292	69,225
Actuarial loss/(gain)	8,784	(132,066)
Participant contributions	85,000	115,000
Benefits paid	<u>(245,000)</u>	<u>(295,000)</u>
Projected benefit obligation at December 31	<u>905,608</u>	<u>1,001,532</u>
Change in fair value of plan assets		
Employer contributions	160,000	180,000
Participant contributions	85,000	115,000
Benefits paid	<u>(245,000)</u>	<u>(295,000)</u>
Fair value of plan assets at December 31	<u>--</u>	<u>--</u>
Funded status	(905,608)	(1,001,532)
Amount recognized in statement of financial position		
Current liabilities	145,000	185,000
Noncurrent liabilities	<u>760,608</u>	<u>816,532</u>
Net amount	\$ 905,608	\$1,001,532
Amount recognized in other comprehensive income		
Unrecognized net actuarial gain	--	--
Total	<u>\$ --</u>	<u>\$ --</u>

Accrued post-retirement medical benefit costs are classified as other post-retirement benefit obligations as of December 31, 2008 and 2007.

Net periodic post-retirement medical benefit costs for 2008, 2007 and 2006 included the following components:

	<u>2008</u>	<u>2007</u>	<u>2006</u>
Service cost	\$ --	\$ 629	\$ 5,029
Interest cost	55,292	69,225	71,175
Amortization of unrecognized actuarial loss	==	==	(5,908)
Net periodic post-retirement medical benefit cost	<u>\$ 55,292</u>	<u>\$ 69,854</u>	<u>\$ 70,296</u>

For measurement purposes, a 9.0% annual rate of increase in the per capita cost of covered benefits (i.e., health care cost trend rate) was assumed for 2009; the rate was assumed to decrease gradually to 5% by the year 2013 and remain at that level thereafter. The health care cost trend rate assumption may have a significant effect on the amounts reported. For example, increasing the assumed health care cost trend rates by one percentage point in each year would increase the accumulated post-retirement medical benefit obligation as of December 31, 2008 by \$11,707 and the aggregate of the service and interest cost components of net periodic post-retirement medical benefit cost for the year ended December 31, 2008 by \$768. Employer contributions for 2009 are expected to be approximately \$145,000.

The assumptions used years ended December 31 were as follows:

	<u>2008</u>	<u>2007</u>	<u>2006</u>
Annual increase in cost of benefits	9.00%	9.00%	10.00%
Discount rate used to determine year-end obligations	7.00%	6.00%	6.00%
Discount rate used to determine year-end expense	6.00%	6.00%	6.00%

The following employer benefit payments, which reflect expected future service, are expected to be paid:

2009	\$ 145,000
2010	\$ 145,000
2011	\$ 145,000
2012	\$ 145,000
2013	\$ 140,000
Years 2014 – 2018	\$ 685,000

The Company provides retirement related benefits to former executive employees and to certain employees of foreign subsidiaries. The liabilities established for these benefits at December 31, 2008 and 2007 are illustrated below.

	<u>2008</u>	<u>2007</u>
Current portion	\$ 90,656	\$ 90,656
Long term portion	<u>578,388</u>	<u>624,517</u>
Total liability at December 31	<u>\$ 669,044</u>	<u>\$ 715,173</u>

11. CURRENCY TRANSLATION ADJUSTMENTS

All assets and liabilities of foreign operations in which the functional currency is foreign are translated into U.S. dollars at prevailing rates of exchange in effect at the balance sheet date. Revenues and expenses are translated using average rates of exchange for the year. The functional currency of the Company's German operations is the European euro. As of January 1, 2006, the functional currency of the Company's Singapore operations changed from the Singapore dollar to the U.S. dollar. Adjustments resulting from the process of translating the financial statements of foreign subsidiaries into U.S. dollars are reported as a separate component of shareholders' equity, net of tax, where appropriate. Foreign currency transaction amounts included in the statements of operation include a loss of \$77,000 in 2008, a loss of \$112,000 in 2007, and a loss of \$100,000 in 2006.

12. COMMON STOCK AND STOCK OPTIONS

The Company applies the provisions of SFAS No. 123R “Share-Based Payment” (“FAS 123(R)”), which establishes the accounting for stock-based awards.

The Company has a 1994 stock option plan, a 2001 stock option plan, a non-employee directors’ stock option plan and a 2006 equity incentive plan. New grants may not be made under the 1994, the 2001 and the non-employee directors’ stock option plans; however certain option grants under these plans remain exercisable as of December 31, 2008. The aggregate number of shares of common stock for which awards could be granted under the 2006 equity incentive plan as of the date of adoption was 698,500 shares. Additionally, as outstanding options under the 2001 stock option plan and non-employee directors’ stock option plan expire, the shares of the Company’s common stock subject to the expired options will become available for issuance under the 2006 equity incentive plan.

Under the various plans, executives, employees and outside directors receive awards of options to purchase common stock. Under the 2006 equity incentive plan, the Company may also grant stock awards, stock appreciation rights, restricted stock units and other equity-based awards, although no such awards, other than awards under the director program and management purchase program described below, had been granted as of December 31, 2008. Under all awards, the terms are fixed on the grant date. Generally, the exercise price equals the market price of the Company’s stock on the date of the grant. Options under the plans generally vest over three years, and have a maximum term of 10 years.

Additionally, the board has established the non-employee directors stock fee election program, referred to as the director program, as an award under the 2006 equity incentive plan. The director program gives each non-employee director the right under the 2006 equity incentive plan to elect to have some or all of his quarterly director fees paid in common shares rather than cash. There were 1,902 and 754 shares issued in lieu of cash for director fees under the director program for the years ended December 31, 2008 and 2007, respectively.

On July 23, 2008, the Compensation Committee of the Board of Directors approved the non-employee director and executive officer stock purchase program, referred to as the management purchase program, as an award under the 2006 Plan. The purpose of the management purchase program is to permit the Company’s non-employee directors and executive officers to purchase shares of the Company’s Common Stock directly from the Company. Pursuant to the management purchase program, as amended, participants may elect to purchase shares of Common Stock from the Company not exceeding an aggregate of \$100,000 during any fiscal year. Participants may make such election one time during each twenty business day period following the public release of the Company’s earnings announcement, referred to as a window period, and only if such participant is not in possession of material, non-public information concerning the Company and subject to the discretion of the Board to prohibit any transactions in Common Stock by directors and executive officers during a window period. There were 5,000 shares purchased under the management purchase program during the year ended December 31, 2008.

Stock option activity during the periods indicated is as follows:

	<u>Number of Shares</u>	<u>Weighted-average Exercise Price</u>	<u>Aggregate Intrinsic Value</u>
Outstanding at December 31, 2005	729,900	\$3.98	
Options forfeited	(51,500)	1.96	
Options granted	160,000	5.68	
Options exercised	<u>(40,667)</u>	<u>2.79</u>	
Outstanding at December 31, 2006	797,733	\$4.51	
Options forfeited	(2,000)	4.60	
Options granted	165,000	13.72	
Options exercised	<u>(106,502)</u>	<u>8.19</u>	
Outstanding at December 31, 2007	854,231	\$5.83	
Options forfeited	(45,131)	9.82	
Options granted	175,950	7.35	
Options exercised	<u>(3,400)</u>	<u>2.44</u>	

Outstanding at December 31, 2008	981,650	<u>\$5.93</u>	<u>\$ --</u>
Exercisable at December 31, 2007	<u>524,397</u>	<u>\$3.70</u>	\$ --
Exercisable at December 31, 2008	<u>642,866</u>	<u>\$4.23</u>	
Available for future grant at January 1, 2008	<u>425,500</u>		
Available for future grant at December 31, 2008	<u>261,894</u>		

The number of shares available for future grant at December 31, 2008, does not include a total of up to 399,200 shares subject to options outstanding under the 2001 stock option plan and non-employee directors' stock option plan which will become available for grant under the 2006 Equity Incentive Plan in the event of the expiration of said options. Based on the stock price at December 31, 2008, the aggregate intrinsic value of outstanding and exercisable options was \$0.

The weighted-average remaining contractual term of options exercisable at December 31, 2008, was 5.6 years. The total intrinsic value of options exercised during fiscal 2008, 2007, and 2006, was \$19,028, \$475,090, and \$111,874, respectively.

The weighted-average per share fair value of options granted was \$2.85, \$5.13, and \$2.77, in 2008, 2007, and 2006, respectively, using the Black-Scholes option-pricing model.

For disclosure purposes, the fair value of each stock option granted is estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions:

	<u>2008</u>	<u>2007</u>	<u>2006</u>
Dividend yield	0.0%	0.0%	0.0%
Expected volatility	42.3 - 53.5%	43.0%	57.5%
Risk-free interest rate	1.4 - 2.8%	3.5%	4.6%
Expected life (years)	4.0	4.0	4.0

The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option-pricing models require the input of subjective assumptions, including the expected stock price volatility. Because the Company's options have characteristics different from those of traded options, in the opinion of management, the existing models do not necessarily provide a reliable single measure of the fair value of its options.

The Company calculates expected volatility for stock options and awards using both historical volatility as well as the average volatility of our peer competitors. The reason historical volatility was not strictly used is the material changes in the Company's operations as a result of the sales of business segments that occurred in 2004 and 2005 (see Note 2). The expected term for stock options and awards is calculated based on the Company's estimate of future exercise at the time of grant.

The Company currently estimates a nine percent forfeiture rate for stock options but will continue to review this estimate in future periods.

The risk-free rates for the expected terms of the stock options and awards and the employee stock purchase plan is based on the U.S. Treasury yield curve in effect at the time of grant.

The Company recorded \$525,972, \$280,376 and \$213,531 of non-cash stock option expense related to FAS 123(R) for the years ended December 31, 2008, 2007 and 2006, respectively. As of December 31, 2008, there was \$946,492 of total unrecognized compensation costs related to non-vested awards that is expected to be recognized over a weighted-average period of 2.0 years.

At the 2007 annual meeting of shareholders, the shareholders approved the IntriCon Corporation 2007 Employee Stock Purchase Plan (the "Purchase Plan"). A maximum of 100,000 shares may be sold under the Purchase Plan. There were 34,213 shares purchased under the plan for the year ended December 31, 2008. There were no employee stock purchases under the plan as of December 31, 2007.

13. QUARTERLY RESULTS OF OPERATIONS (UNAUDITED)

The following is a tabulation of unaudited quarterly results of operations (in thousands, except for per share data).

	2008				2007			
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
Sales, net	\$16,591	\$17,525	\$16,091	\$15,348	\$14,579	\$16,938	\$18,442	\$19,025
Gross profit	3,845	4,254	3,943	4,004	3,211	4,207	5,126	4,701
Net income	150	410	309	169	28	527	650	662
Income per share (a):								
Basic income per share	\$.03	\$.08	\$.06	\$.03	\$.01	\$.10	\$.13	\$.13
Diluted income per share	\$.03	\$.07	\$.06	\$.03	\$.01	\$.10	\$.12	\$.12

- a) Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not add to the annual amounts because of differences in the average common shares outstanding during each period. Additionally, in regard to diluted per share amounts only, quarterly amounts may not add to the annual amounts.

14. INCOME PER SHARE

The following table sets forth the computation of basic and diluted income per share:

	2008			2007			2006		
	Income Numerator	Shares Denominator	Per Share Amount	Income Numerator	Shares Denominator	Per Share Amount	Loss Numerator	Shares Denominator	Per Share Amount
Basic income per share									
Income available to common shareholders	\$1,037,601	5,314,387	\$.20	\$1,867,238	5,209,567	\$.36	\$1,162,512	5,159,216	\$.23
Effect of dilutive securities									
Stock options	---	225,069		---	310,213		---	160,586	
Diluted income per share	\$1,037,601	5,539,456	\$.19	\$1,867,238	5,519,780	\$.34	\$1,162,512	5,319,802	\$.22

The Company excluded stock options of 231,950, 190,131, and 196,000, in 2008, 2007, and 2006, respectively, from the computation of the diluted income per share as their effect would be anti-dilutive. For additional disclosures regarding the stock options, see Note 12.

15. CONTINGENCIES AND COMMITMENTS

We are a defendant along with a number of other parties in approximately 122 lawsuits as of December 31, 2008, (approximately 122 lawsuits as of December 31, 2007) alleging that plaintiffs have or may have contracted asbestos-related diseases as a result of exposure to asbestos products or equipment containing asbestos sold by one or more named defendants. Due to the noninformative nature of the complaints, we do not know whether any of the complaints state valid claims against us. Certain insurance carriers have informed us that the primary policies for the period August 1, 1970-1973, have been exhausted and that the carriers will no longer provide a defense under those

policies. We have requested that the carriers substantiate this situation. We believe we have additional policies available for other years which have been ignored by the carriers. Because settlement payments are applied to all years a litigant was deemed to have been exposed to asbestos, we believe when settlement payments are applied to these additional policies, we will have availability under the years deemed exhausted. We do not believe that the asserted exhaustion of the primary insurance coverage for this period will have a material adverse effect on our financial condition, liquidity, or results of operations. Management believes that the number of insurance carriers involved in the defense of the suits and the significant number of policy years and policy limits, to which these insurance carriers are insuring us, make the ultimate disposition of these lawsuits not material to our consolidated financial position or results of operations.

The Company's wholly owned French subsidiary, Selas SAS, filed for insolvency in France and is being managed by a court appointed judiciary administrator. The Company may be subject to additional litigation or liabilities as a result of the French insolvency proceeding.

We are also involved in other lawsuits arising in the normal course of business. While it is not possible to predict with certainty the outcome of these matters, management is of the opinion that the disposition of these lawsuits and claims will not materially affect our consolidated financial position, liquidity or results of operations.

Total rent expense for 2008, 2007, and 2006 under leases pertaining primarily to engineering, manufacturing, sales and administrative facilities, with an initial term of one year or more, aggregated \$1,583,000, \$1,440,000, and \$1,082,000, respectively. Remaining rentals payable under such leases, including equipment leases are as follows: 2009 - \$1,588,000; 2010 - \$1,126,000; 2011 - \$954,000; 2012 - \$477,000; 2013 - \$406,000 and thereafter - \$1,056,000, which includes two leased facilities in Minnesota that expire in 2011 and 2016 respectively, one leased facility in California that expires in 2009, two leased facilities in Maine that expire in 2012 and 2017 respectively, one leased facility in Singapore that expires in 2010 and one leased facility in Germany that expires in 2012. Certain leases contain renewal options as defined in the lease agreements.

On October 5, 2007, the Company entered into employment agreements with its executive officers. The agreements call for payments ranging from three months to two years base salary and unpaid bonus, if any, to the executives should there be a change of control as defined in the agreement and the executives are not retained for a period of at least one year following such change of control. Under the agreements, all stock options granted to the executives would vest immediately and be exercisable in accordance with the terms of such stock options. The Company also agreed that if it enters into an agreement to sell substantially all of its assets, it will obligate the buyer to fulfill its obligations pursuant to the agreements. The agreements terminate, except to the extent that any obligation remains unpaid, upon the earlier of termination of the executive's employment prior to a change of control or asset sale for any reason or the termination of the executive after a change of control for any reason other than by involuntary termination as defined in the agreements.

On July 20, 2008, the Company entered into a strategic alliance agreement with Dynamic Hearing Pty Ltd ("Dynamic Hearing"). Effective October 1, 2008, Dynamic Hearing granted a license to the Company to use certain of Dynamic Hearing's technology. The initial term of the agreement is five years from the date of execution and may be extended upon agreement of the parties within two months of the expiration of the initial term; however, either party may terminate the agreement after the second year of the term upon three months notice. The Company agreed to pay Dynamic Hearing: (i) an annual fee for access to the technology licensed pursuant to the agreement and (ii) an additional "second component" fee to maintain exclusive rights granted to the Company with respect to hearing health products. Additionally, IntriCon agreed to make royalty payments on products that incorporate Dynamic Hearing's technology, and Dynamic Hearing has also agreed to provide the Company with engineering and other services in connection with the licensed technology. The Company has recorded \$1,000,000 payable to Dynamic Hearing for the first two years of exclusive license fees described above. The Company has \$331,000 and \$691,000 of short-term and long-term assets, respectively, remaining at December 31, 2008 which will be amortized through September 2010 as it pertains to exclusive rights and engineering and other services. The technology access fee will be amortized through September 2013, the life of the agreement.

16. RELATED-PARTY TRANSACTIONS

One of the Company's subsidiaries leases office and factory space from a partnership consisting of three present or former officers of the subsidiary, including Mark Gorder, a member of the Company's Board of Directors and the President and Chief Executive Officer of the Company. The subsidiary is required to pay all real estate taxes and operating expenses. In the opinion of management, the terms of the lease agreement are comparable to those which could be obtained from unaffiliated third parties. The total base rent expense, real estate taxes and other charges incurred under the lease was approximately \$477,000 in 2008 and \$481,000 for each of 2007 and 2006. Annual lease commitments, which include base rent expense, real estate taxes and other charges approximate \$475,000 through October 2011.

The Company uses the law firm of Blank Rome LLP for legal services. A partner of that firm is the son-in-law of the Chairman of our Board of Directors. We paid that firm approximately \$235,000, \$466,000, and \$282,000 for legal services and costs in 2008, 2007, and 2006, respectively. The Chairman of our Board of Directors is considered independent under applicable Nasdaq and SEC rules because (i) no payments were made to the Chairman or the partner directly in exchange for the services provided by the law firm and (ii) the amounts paid to the law firm did not exceed the thresholds contained in the Nasdaq standards. Furthermore, the aforementioned partner does not provide any legal services to the Company and is not involved in billing matters.

17. STATEMENTS OF CASH FLOWS

Supplemental disclosures of cash flow information:

	Years ended December 31,		
	<u>2008</u>	<u>2007</u>	<u>2006</u>
Interest received	\$ 30,692	\$ 78,896	\$ 33,674
Interest paid	599,856	741,930	380,159
Income taxes paid	222,224	194,502	205,565
Deferred gain recorded on sale of manufacturing facility	--	--	1,045,799
Acquisition of assets of Amecon, Inc:			
Goodwill	--	--	172,962
Property and equipment	--	--	53,522
Equipment purchased through capital lease obligation	1,277,823	--	--
Shares issued for services	12,233	6,120	--
License agreement financed through licensor	1,000,000	--	--

The 2006 adjustments to the assets of Amecon, Inc., which were acquired in October 2005, was due to the final adjustment to the working capital requirement pursuant to the asset purchase agreement.

18. DERIVATIVE FINANCIAL INSTRUMENTS

Derivative financial instruments in the form of interest rate swaps are used by the Company in managing its interest rate exposure. The Company does not hold or issue derivative financial instruments for trading purposes. When entered into, the Company formally designates the derivative financial instrument as a hedge of a specific underlying exposure if such criteria are met, and documents both the risk management objectives and strategies for undertaking the hedge. The Company formally assesses, both at inception and at least quarterly thereafter, whether the derivative financial instruments that are used in hedging transactions are effective at offsetting changes in either the fair value or cash flows of the related underlying exposure. Because of the high correlation between the derivative financial instrument and the underlying exposure being hedged, fluctuations in the value of the derivative financial instruments are generally offset by changes in the fair values or cash flows of the underlying exposures being hedged. Any ineffective portion of a derivative financial instrument's change in fair value would be immediately recognized in earnings.

The swaps are designated as cash flow hedges with the changes in fair value recorded in accumulated other comprehensive loss and as a derivative hedge asset or liability, as applicable. The swaps settle periodically in arrears

with the related amounts for the current settlement period payable to, or receivable from, the counter-parties included in accrued liabilities or accounts receivable and recognized in earnings as an adjustment to interest expense from the underlying debt to which the swap is designated. Approximately \$40,000 and \$2,000 of additional expense were recorded to interest expense as a result of said adjustments for the years ended December 31, 2008 and 2007, respectively. During 2008 and 2007, ineffectiveness from such hedges was \$0.

At December 31, 2008 and 2007, the Company had a United States Dollar (“USD”) denominated interest rate swap outstanding which effectively fixed the interest rate on floating rate debt, exclusive of lender spreads, at 5.36% for a notional principal amount of \$2,000,000 through September 2010. The derivative net loss on this contract recorded in accumulated other comprehensive loss at December 31, 2008 and 2007 was \$136,248 and \$79,215, respectively. The accumulated other comprehensive loss at December 31, 2008 is expected to be reclassified into earnings over the next 21 months, the life of the agreement.

19. INVESTMENT IN EQUITY INSTRUMENTS

On December 27, 2006, the Company joined the Hearing Instrument Manufacturers Patent Partnership (HIMPP). Members of the partnership include the largest six hearing aid manufacturers as well as several other smaller manufacturers. The purchase price of \$1,800,000 included a 9% equity interest in K/S HIMPP as well as a license agreement that will grant the Company access to over 45 US registered patents. The Company accounted for the K/S HIMPP investment using the equity method of accounting for common stock, as the equity interest is deemed to be “more than minor” as defined in AICPA Statement of Position 78-9 “Accounting for Investments in Real Estate Ventures”. The investment required a \$260,000 payment made at the time of closing. The unpaid balance of \$1,020,000 at December 31, 2008 will be paid in three annual installments of \$260,000 in 2009 through 2011, with a final installment of \$240,000 in 2012. The unpaid balance is unsecured and bears interest at an annual rate of 4%, which is payable annually with each installment. The investment in the partnership exceeded underlying net assets by approximately \$1,475,000. Based on the final assessment of the partnership, the Company has determined that approximately \$345,000 of the excess of the investment over the underlying partnership net assets relates to underlying patents. The remaining \$1,130,000 of the excess of the investment over the underlying partnership net assets has been assigned to the non-exclusive patent license agreement. The Company has recorded a \$144,900 and \$332,500 decrease in the carrying amount of the investment, reflecting amortization of the patents, patent license agreement and the Company’s portion of the partnership’s operating results for the years ended December 31, 2008 and 2007, respectively. Total amortization expense remaining is \$1,180,000. The difference of \$207,000 in the carrying value of the investment at December 31, 2008 is the Company’s remaining investment in partnership net assets.

The Company’s subsidiary, IntriCon Tibbetts Corporation, owns a 50% interest in a joint venture with a Swiss company to market, design, manufacture, and sell audio coils to the hearing health industry. The Company has recorded a total decrease of approximately \$59,000 in the carrying amount of the investment for the year ended December 31, 2008, consisting of an approximately \$141,000 increase for the Company’s portion of the joint venture’s operating results for the year ended December 31, 2008 offset by a decrease of \$200,000 for dividends received from the joint venture during the year ended December 31, 2008. The Company recorded a \$175,000 increase in the carrying amount of the investment, reflecting the Company’s portion of the joint venture’s operating results for the period ended December 31, 2007. The carrying amount of the investment was \$64,000 and \$123,000 at December 31, 2008 and 2007, respectively.

Condensed financial information of the joint venture at and for the years ended December 31, 2008 and 2007 are as follows (in thousands):

	<u>2008</u>	<u>2007</u>
Balance Sheet:		
Current assets	\$ 642	\$1,013
Non-current assets	196	273
Total assets	<u>\$ 838</u>	<u>\$1,286</u>
Current liabilities	312	889
Non-current liabilities	--	353
Stockholders' equity	<u>526</u>	44
Total liabilities and stockholders' equity	<u>\$ 838</u>	<u>\$1,286</u>
Income Statement:		
Net revenues	<u>\$2,750</u>	<u>\$2,820</u>
Net income	<u>\$ 282</u>	<u>\$ 400</u>

20. REVENUE BY MARKET

The following tables set forth, for the periods indicated, net revenue by market:

	<u>December 31,</u> <u>2008</u>	<u>Years Ended</u> <u>December 31,</u> <u>2007</u>	<u>December 31,</u> <u>2006</u>
<u>Body-Worn Device Segment</u>			
Hearing Health	\$23,768,000	\$29,297,000	\$24,956,000
Medical	20,133,000	18,765,000	8,439,000
Professional Audio Communications	14,007,000	11,606,000	8,041,000
<u>Electronic Products Segment</u>			
Electronics	<u>7,647,000</u>	<u>9,315,000</u>	<u>10,290,000</u>
Total Revenue	<u>\$65,555,000</u>	<u>\$68,983,000</u>	<u>\$51,726,000</u>

ITEM 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

None.

ITEM 9A(T). Controls and Procedures

Evaluation of Disclosure Controls and Procedures. As of the end of the period covered by this report (the “Evaluation Date”), the Company carried out an evaluation, under the supervision and with the participation of management, including the Chief Executive Officer (principal executive officer) and the Chief Financial Officer (principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Exchange Act). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the Evaluation Date, our disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in applicable rules and forms, and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Management’s Annual Report on Internal Control Over Financial Reporting. The report of management required under this Item 9A is contained in Item 8 of this Annual Report on Form 10-K under the caption “Management’s Report on Internal Control Over Financial Reporting.”

Changes in Internal Controls over Financial Reporting. There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the most recent fiscal quarter covered by this report that would have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

ITEM 9B. Other Information

In December 2008, the Compensation Committee of the Board of Directors made determinations with respect to the bonuses and stock options to be awarded to the executive officers for services in 2008 and salaries to be paid in 2009. For further information, see Exhibit 10.13 which is incorporated herein by reference.

In February 2009, the Compensation Committee of the Board of Directors adopted the 2009 Annual Incentive Plan for Executives and Key Employees for Fiscal Year 2009. For further information, see Exhibit 10.13 which is incorporated herein by reference.

The disclosure of the foregoing information is voluntary and shall not be deemed an admission that such information is material or required to be disclosed on a Current Report on Form 8-K.

PART III

ITEM 10. Directors, Executive Officers and Corporate Governance

The information called for by Item 10 is incorporated by reference from the Company's definitive proxy statement relating to its 2009 annual meeting of shareholders, including but not necessarily limited to the sections of the 2009 proxy statement entitled "Proposal 1 – Election of Directors" and "Section 16(a) Beneficial Ownership Reporting Compliance."

The information concerning executive officers contained in Item 4A hereof is incorporated by reference into this Item 10.

Code of Ethics

The Company has adopted a code of ethics that applies to its directors, officers and employees, including its principal executive officer, principal financial and accounting officer, controller and persons performing similar functions. Copies of the Company's code of ethics are available without charge upon written request directed to Cari Sather, Director of Human Resources, IntriCon Corporation, 1260 Red Fox Road, Arden Hills, MN 55112. The Company intends to satisfy the disclosure requirement under Item 10 of Form 8-K regarding any future amendments to a provision of its code of ethics by posting such information on the Company's website: www.intricon.com.

ITEM 11. Executive Compensation

The information called for by Item 11 is incorporated by reference from the Company's definitive proxy statement relating to its 2009 annual meeting of shareholders, including but not necessarily limited to the sections of the 2009 proxy statement entitled "Director Compensation for 2008," and "Executive Compensation".

ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information called for by Item 12 is incorporated by reference from the Company's definitive proxy statement relating to its 2009 annual meeting of shareholders, including but not necessarily limited to the section of the 2009 proxy statement entitled "Share Ownership of Certain Beneficial Owners, Directors and Certain Officers."

Equity Compensation Plan Information

The following table details information regarding the Company's existing equity compensation plans as of December 31, 2008:

<u>Plan Category</u>	<u>(a) Number of securities to be issued upon exercise of outstanding options, warrants and rights</u>	<u>(b) Weighted-average exercise price of outstanding options, warrants and rights</u>	<u>(c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</u>	
Equity compensation plans approved by security holders	799,150	\$6.68	261,894	(1)
Equity compensation plans not approved by security holders(2) ..	<u>182,500</u>	\$3.02	---	
Total.....	981,650	\$5.93	261,894	

(1) The amount shown in column (c) represents shares issuable under the Company's 2006 Equity Incentive Plan (the "2006 Plan"). Under the terms of the 2006 Plan, as outstanding options under the Company's 2001 Stock Option Plan and Non-Employee Directors' Stock Option Plan expire, the shares of common stock subject to the expired options will become available for issuance under the 2006 Plan. As of December 31, 2008, 399,200 shares of common stock were subject to outstanding options under the 2001 Stock Option Plan and Non-Employee Directors' Stock Option Plan. Accordingly, if any of these options expire, the shares of common stock subject to expired options also will be available for issuance under the 2006 Plan.

(2) Represents shares issuable under the Non-Employee Directors Stock Option Plan, the ("Non-Employee Directors Plan"), pursuant to which directors who are not employees of the Company or any of its subsidiaries were eligible to receive options. The exercise price of the option was the fair market value of the stock on the date of grant. Options become exercisable in equal one-third annual installments beginning one year from the date of grant, except that the vesting schedule for discretionary grants is determined by the Compensation Committee. As a result of the approval of the 2006 Plan by the shareholders at the 2006 annual meeting of shareholders, no further grants will be made pursuant to the Non-Employee Directors Plan.

ITEM 13. Certain Relationships and Related Transactions, and Director Independence

The information called for by Item 13 is incorporated by reference from the Company's definitive proxy statement relating to its 2009 annual meeting of shareholders, including but not necessarily limited to the sections of the 2009 proxy statement entitled "Certain Relationships and Related Party Transactions" and "Independence of the Board of Directors."

ITEM 14. Principal Accountant Fees and Services

The information called for by Item 14 is incorporated by reference from the Company's definitive proxy statement relating to its 2009 annual meeting of shareholders, including but not necessarily limited to the sections of the 2009 proxy statement entitled "Independent Registered Public Accounting Fee Information."

PART IV

ITEM 15. Exhibits, Financial Statement Schedules

(a) The following documents are filed as a part of this report:

- 1) Financial Statements – The consolidated financial statements of the Registrant are set forth in Item 8 of Part II of this report.

Consolidated Statements of Operations for the years ended December 31, 2008, 2007 and 2006.

Consolidated Balance Sheets at December 31, 2008 and 2007.

Consolidated Statements of Cash Flows for the years ended December 31, 2008, 2007 and 2006.

Consolidated Statements of Shareholders' Equity and Comprehensive Income for the years ended December 31, 2008, 2007 and 2006.

Notes to Consolidated Financial Statements.

- 2) Financial Statement Schedules

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ON SUPPLEMENTARY INFORMATION

To the Shareholders, Audit Committee and Board of Directors

IntriCon Corporation and Subsidiaries
 Minneapolis, Minnesota

Our audits were made for the purpose of forming an opinion on the basic 2008, 2007, and 2006 consolidated financial statements of IntriCon Corporation and Subsidiaries taken as a whole. The consolidated supplemental schedule II is presented for purposes of complying the Securities Exchange Commission's rules and is not a part of the basic consolidated financial statements. This schedule has been subjected to the auditing procedures applied in our audits of the 2008, 2007 and 2006 basic consolidated financial statements and, in our opinion, is fairly stated in all materials respects in relation to the basic consolidated financial statements taken as a whole.

VIRCHOW, KRAUSE & COMPANY, LLP
 Minneapolis, Minnesota
 March 3, 2009

Schedule II - Valuation and Qualifying Accounts

INTRICON CORPORATION AND SUBSIDIARY COMPANIES

**Valuation and Qualifying Accounts
 December 31, 2008, 2007 and 2006**

<u>Description</u>	<u>Balance at beginning of Year</u>	<u>"Addition" charged to costs and expense</u>	<u>"Less" deductions</u>	<u>Balance at end of year</u>
<u>Year ended December 31,2008</u>				
Allowance for doubtful accounts	\$ 258,873	\$ 131,090	\$ 956 (a)	\$ 389,007
Allowance for note receivable	\$ 225,000	\$ --	\$ 225,000	\$ --
Deferred tax asset valuation allowance	\$8,133,835	\$ --	\$ 866,700	\$7,267,135
<u>Year ended December 31,2007</u>				
Allowance for doubtful accounts	\$ 245,543	\$ 91,236	\$ 77,906 (a)	\$ 258,873
Allowance for note receivable	\$ 225,000	\$ --	\$ --	\$ 225,000
Deferred tax asset valuation allowance	\$8,562,449	\$ --	\$ 428,614	\$8,133,835
<u>Year ended December 31,2006</u>				
Allowance for doubtful accounts	\$ 370,195	\$ 19,036	\$ 143,688 (a)	\$ 245,543
Allowance for note receivable	\$ 296,077	\$ --	\$ 71,077	\$ 225,000
Deferred tax asset valuation allowance	\$8,593,829	\$ --	\$ 31,380	\$8,562,449

- a) Uncollectible accounts written off.
- b) Continuing operations net operating loss utilized to offset tax impact of operating income from discontinued operations.

All other schedules are omitted because they are not applicable, or because the required information is included in the consolidated financial statements or notes thereto.

3) Exhibits –

- 2.1 Asset and Share Purchase Agreement dated as of October 11, 2002 among the Company, Selas S.A.S., Andritz A.G. and Andritz Acquisition S.A.S. Schedules and attachments are listed under section 1.2 of the agreement and will be provided to the Commission upon request. (Incorporated

by reference from the Company's current report on Form 8-K filed with the Commission on December 17, 2002.)

- 2.2 Stock purchase Agreement dated July 21, 2003 between the Company and Ventra Ohio Corp, and VTA USA, INC. Schedules and attachments are listed beginning on page 38 of the agreement and will be provided to the Commission upon request. (Incorporated by reference from the Company's current report on Form 8-K/A filed with the Commission on July 23, 2003.)
- 2.3 Agreement of Sales between the Company and BET Investments, Inc. dated December 31, 2002, as amended. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission on June 29, 2004.)
- 2.4 Asset purchase agreement dated March 31, 2005 among the Company and Selas Heat Technology, LLP (Schedules and exhibits are omitted pursuant to Regulation S-K, Item 601(b)(2); IntriCon Corporation agrees to furnish a copy of such schedules and/or exhibits to the Securities and Exchange Commission upon request) (Incorporated by reference from the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2005.)
- 2.5 Asset Purchase Agreement by and among IntriCon Corporation, TI Acquisition Corporation, Tibbetts Industries, Inc. and certain shareholders of Tibbetts Industries, Inc. dated April 19, 2007. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission on April 23, 2007.)
- 3.1 The Company's Amended and Restated Articles of Incorporation, as amended. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission on April 24, 2008.)
- 3.2 The Company's Amended and Restated By-Laws. (Incorporated by reference from the Company's annual report on Form 8-K filed with the Commission October 12, 2007.)
- + 10.1.1 Amended and Restated 1994 Stock Option Plan. (Incorporated by reference from the Company's annual report on Form 10-K for the year ended December 31, 1997.)
- + 10.1.2 Form of Stock Option Agreements granted under the Amended and Restated 1994 Stock Option Plan. (Incorporated by reference from the Company's annual report on Form 10-K for the year ended December 31, 1995.)
- + 10.2.1 2001 Stock Option Plan. (Incorporated by reference from the Company's annual report on Form 10-K for the year ended December 31, 2000.)
- 10.2.2 Form of Stock Option Agreement issued to executive officers pursuant to the 2001 Stock Option Plan. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission on April 26, 2005.)
- + 10.3 Supplemental Retirement Plan (amended and restated effective January 1, 1995). (Incorporated by reference from the Company's annual report on Form 10-K for the year ended December 31, 1995.)
- 10.4 Amended and Restated Office/Warehouse Lease, between Resistance Technology, Inc. and Arden Partners I. L.L.P. (of which Mark S. Gorder is one of the principal owners) dated November 1, 1996. (Incorporated by reference from the Company's annual report on Form 10-K for the year ended December 31, 1996.)
- + 10.5.1 Amended and Restated Non-Employee Directors' Stock Option Plan. (Incorporated by reference from the Company's annual report on Form 10-K for the year ended December 31, 2001.)

- 10.5.2 Form of Non-employee director Option Agreement for options issued pursuant to the Amended and Restated Non-Employee Directors Stock Option Plan. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission on October 3, 2005.)
- + 10.6 Retirement Agreement, Consulting Agreement and General Release, dated August 30, 2000, between the Company and Stephen F. Ryan. (Incorporated by reference from the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2000.)
- 10.7 Separation Agreement dated November 30, 2001 between the Company and Robert W. Ross. (Incorporated by reference from the Company's annual report on Form 10-K for the year ended December 31, 2001.)
- 10.8 Settlement agreement dated September 12, 2003 between the Company and Andritz AG, Andritz Acquisition S.A.A. (Incorporated by reference from the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2003.)
- + 10.9 Termination agreement following change of control or asset sale between the Company and Mark S. Gorder dated December 14, 2004. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission on December 20, 2004.)
- + 10.10.1* Summary sheet for director fees.
- + 10.10.2* Summary sheet for executive officer compensation.
- 10.11.1 Credit and Security Agreement dated August 31, 2005 by Resistance Technology, Inc. and RTI Electronics, Inc. and Diversified Business Credit, Inc. (Incorporated by reference from the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2005.)
- 10.11.2 Security Agreement dated August 31, 2005 between IntriCon Corporation and Diversified Business Credit, Inc. (Incorporated by reference from the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2005.)
- 10.11.3 First Amendment to Credit and Security Agreement between Resistance Technology, Inc., RTI Electronics, Inc. and M&I Business Credit f/k/a Diversified Business Credit, Inc. dated June 30, 2006. (Incorporated by reference from the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2006.)
- 10.11.4 Guaranty by Corporation dated August 31, 2005 between IntriCon Corporation and Diversified Business Credit, Inc. (Incorporated by reference from the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2005.)
- 10.11.5 Term Loan Supplement (Real Estate) to Credit Agreement dated August 31, 2005, by Resistance Technology, Inc. and RTI Electronics, Inc. for the benefit of Diversified Business Credit, Inc. (Incorporated by reference from the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2005.)
- 10.11.6 Term Loan Supplement (Equipment) to Credit Agreement dated August 31, 2005, by Resistance Technology, Inc. and RTI Electronics, Inc. for the benefit of Diversified Business Credit, Inc. (Incorporated by reference from the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2005.)
- 10.11.7 Mortgage, Security Agreement, Fixture Financing Statement and Assignment of Leases and Rents by Resistance Technology, Inc. to Diversified Business Credit, Inc. (Incorporated by reference from the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2005.)

- 10.12 Promissory note from Selas Heat Technology, LLP dated March 31, 2005. (Incorporated by reference from the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2005.)
- 10.13.1 Employment agreement between the Company and William J. Kullback dated April 25, 2005. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission on April 26, 2005.)
- 10.13.2 Termination agreement following change of control or asset sale between the Company and William J. Kullback dated April 25, 2005. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission on April 26, 2005.)
- + 10.14.1 2006 Equity Incentive Plan. (Incorporated by reference from the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2006.)
- + 10.14.2 Form of Stock Option Agreement issued to executive officers pursuant to the 2006 Equity Incentive Plan. (Incorporated by reference from the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2006.)
- + 10.14.3 Form of Stock Option Agreement issued to directors pursuant to the 2006 Equity Incentive Plan. (Incorporated by reference from the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2006.)
- + 10.14.4 Non-Employee Directors Stock Fee Election Program. (Incorporated by reference from the Company's annual report on Form 10-K for the year ended December 31, 2006.)
- +10.14.5 Non-Employee Director and Executive Officer Stock Purchase Program, as amended. (Incorporated by reference from the Company's quarterly report on Form 10-Q filed with the Commission on November 14, 2008.)
- + 10.15 Deferred Compensation Plan. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission on May 17, 2006.)
- 10.16 Purchase Agreement between Resistance Technology, Inc. and MDSC Partners, LLP dated May 5, 2006. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission on June 21, 2006.)
- 10.17 Land and Building Lease Agreement between Resistance Technology, Inc. and MDSC Partners, LLP dated June 15, 2006. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission on June 21, 2006.)
- 10.18 Agreement by and between K/S HIMPP and IntriCon Corporation dated December 1, 2006 and the schedules thereto. (Incorporated by reference from the Company's annual report on Form 10-K for the year ended December 31, 2006.)
- + 10.19 Employment Agreement with Mark S. Gorder. (Incorporated by reference from the Company's annual report on Form 8-K filed with the Commission October 12, 2007.)
- + 10.20 Form of Employment Agreement with executive officers. (Incorporated by reference from the Company's annual report on Form 8-K filed with the Commission October 12, 2007.)
- 10.21.1 Loan and Security Agreement dated as of May 22, 2007, by and among IntriCon, Resistance Technology, Inc., RTI Electronics, Inc. and IntriCon Tibbetts Corporation and LaSalle Bank National Association. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission on May 25, 2007.)

- 10.21.2 First Amendment to Loan and Security Agreement dated as of September 30, 2007, by and among IntriCon, Resistance Technology, Inc., RTI Electronics, Inc. and IntriCon Tibbetts Corporation and LaSalle Bank National Association. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission October 12, 2007.)
- 10.21.3 Second Amendment to Loan and Security Agreement dated as of June 30, 2008, by and among IntriCon, Resistance Technology, Inc., RTI Electronics, Inc., IntriCon Tibbetts Corporation and LaSalle Bank National Association. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission July 7, 2008.)
- 10.21.4* Third Amendment to Loan and Security Agreement dated as of December 31, 2008, by and among IntriCon, IntriCon, Inc., RTI Electronics, Inc., IntriCon Tibbetts Corporation and LaSalle Bank National Association.
- 10.21.5 Trademark Security Agreement dated as of May 22, 2007, by IntriCon in favor of LaSalle Bank National Association. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission on May 25, 2007.)
- 10.21.6 Trademark Security Agreement dated as of May 22, 2007, by Resistance Technology, Inc. in favor of LaSalle Bank National Association. (Incorporated by reference from the Company's current report on Form 8-K filed with the Commission on May 25, 2007.)
- 10.22* Strategic Alliance Agreement among IntriCon Corporation and Dynamic Hearing Pty Ltd effective as of October 1, 2008.
- 21* List of significant subsidiaries of the Company.
- 23.1* Consent of Independent Registered Public Accounting Firm (Virchow, Krause & Company, LLP).
- 31.1* Certification of principal executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 31.2* Certification of principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1* Certification of principal executive officer pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 32.2* Certification of principal financial officer pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

* Filed herewith.

+ Denotes management contract, compensatory plan or arrangement.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INTRICON CORPORATION
(Registrant)

By: /s/ Scott Longval
Scott Longval
Chief Financial Officer,
Treasurer and Secretary

Dated: March 3, 2009

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

/s/ Mark S. Gorder

Mark S. Gorder
President and Chief Executive
Officer and Director (principal executive officer)
March 3, 2009

/s/ Scott Longval

Scott Longval
Chief Financial Officer
Treasurer and Secretary
(principal accounting and financial officer)
March 3, 2009

/s/Nicholas A. Giordano

Nicholas A. Giordano
Director
March 3, 2009

/s/Robert N. Masucci

Robert N. Masucci
Director
March 3, 2009

/s/ Michael J. McKenna

Michael J. McKenna
Director
March 3, 2009

/s/ Philip N. Seamon

Philip N. Seamon
Director
March 3, 2009

Management

Mark S. Gorder

President & Chief Executive Officer

J. Scott Longvai

Chief Financial Officer, Secretary & Treasurer

Chris D. Conger

Vice President, Research & Development

Michael P. Geraci

Vice President, Sales & Marketing

Greg Gruenhagen

Vice President, Quality & Regulatory Affairs

Dennis L. Gonsior

Vice President, Global Operations

Steve M. Binnix

Vice President & General Manager,
RTI Electronics, Inc.

Colman Lau

General Manager, IntriCon PTE LTD

Directors

Michael J. McKenna

Chairman of the Board of IntriCon Corporation,
Retired Vice Chairman,
President & Director,
Crown Cork & Seal Company, Inc.

Nicholas A. Giordano

Business Consultant,
Former President & CEO
Philadelphia Stock Exchange

Mark S. Gorder

President & Chief Executive Officer
IntriCon Corporation

Robert N. Masucci

Chairman of Barclay Brand Ferndon, Inc.
Chairman, Montgomery Capital Advisors, Inc.

Philip N. Seamon

President, Philip N. Seamon, Inc.
Retired Senior Managing Director,
Corporate Finance,
FTI Consulting, Inc.

Legal Counsel

Blank Rome LLP

Philadelphia, Pennsylvania

Auditors

Virchow Krause & Company

Minneapolis, Minnesota

Transfer Agent and Registrar

Stock Trans

44 West Lancaster Avenue
Ardmore, Pennsylvania 19003
www.stocktrans.com
1.800.733.1121

Locations

IntriCon Corporation Headquarters

1260 Red Fox Road
Arden Hills, Minnesota 55112
Phone: 651.636.9770
Fax: 651.636.8944
www.intricon.com

IntriCon, Inc.

1260 Red Fox Road
Arden Hills, Minnesota 55112

IntriCon Tibbetts Corporation

5 Colcord Avenue
Camden, Maine 04843

RTI Electronics, Inc.

1800 Via Burton Street
Anaheim, California 92806

IntriCon PTE LTD

26 Ayer Rajah Crescent
#04-04
Singapore 139944

IntriCon GmbH

Kesselschmiedstr. 10
D-75354 Freising, Germany



1260 Red Fox Road • Arden Hills Minnesota 55112 • 651.636.9770 • fax 651.636.8944



END

intricon.com